fluorouracil has been researched along with Diarrhea in 518 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180 mg/m(2) IV over 90 min, day 1), 5-fluorouracil (400mg/m(2) IV bolus and 2400 mg/m(2) by 46-hour infusion from day 1) and folinic acid (20mg/m(2) IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350 mg/m(2) IV over 90 min), 3-weekly." | 10.25 | Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. ( Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J, 2011) |
| "The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen." | 9.19 | Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014) |
| "This report describes the results of an analysis of patient-reported outcomes from EMILIA (TDM4370g/BO21977), a randomized phase 3 study of the antibody-drug conjugate trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer." | 9.19 | Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. ( Althaus, B; Diéras, V; Fang, L; Guardino, E; Hurvitz, SA; Lalla, D; Miles, D; Sohn, JH; Welslau, M, 2014) |
| "Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC)." | 9.19 | Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. ( Dranitsaris, G; Lacouture, ME, 2014) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 9.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 9.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| "Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib." | 9.19 | Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014) |
| "This randomized phase II trial investigated the efficacy and safety of capecitabine/oxaliplatin (CapOx) plus bevacizumab and dose-modified capecitabine/irinotecan (mCapIri) plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer (mCRC)." | 9.17 | Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. ( Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A, 2013) |
| "Capecitabine/taxane combinations are highly active in metastatic breast cancer (MBC)." | 9.17 | Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. ( Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K, 2013) |
| "The safety and efficacy of neratinib monotherapy were compared with that of lapatinib plus capecitabine in patients with human epidermal growth factor receptor-2-positive (HER2+), locally advanced/metastatic breast cancer and prior trastuzumab treatment." | 9.17 | A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. ( Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K, 2013) |
| "To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy." | 9.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 9.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
| "This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)." | 9.17 | Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013) |
| " The primary objectives of this study were to determine the maximum tolerated dose of vandetanib with capecitabine and oxaliplatin, without and with bevacizumab, for the first line treatment of metastatic colorectal cancer (mCRC), and to define the dose limiting toxicities." | 9.16 | A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. ( Cabebe, EC; Fisher, GA; Sikic, BI, 2012) |
| "To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTD) of oral metronomic vinorelbine with capecitabine in patients with metastatic breast cancer (MBC)." | 9.16 | A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. ( Androulakis, N; Ardavanis, A; Georgoulias, V; Kalbakis, K; Kourakos, P; Malamos, N; Mavroudis, D; Polyzos, A; Saridaki, Z; Vamvakas, L, 2012) |
| "This study was intended to ascertain the feasibility of a combination therapy with irinotecan by 24-h intravenous infusion (24-h CPT-11) and 5-fluorouracil (5-FU) for patients with metastatic colorectal cancer, to estimate the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD), to determine the recommended dose (RD) for the Phase II study, and to evaluate the efficacy of the combination therapy." | 9.16 | Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ( Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 9.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)." | 9.16 | Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012) |
| "Irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) is accepted as a reference treatment for the first-line treatment of patients with metastatic colorectal cancer (MCRC)." | 9.14 | Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the ( Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M, 2009) |
| "Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 9.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 9.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 9.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 9.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 9.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| "The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer." | 9.13 | Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008) |
| "Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU) +/- folinic acid (FA) has changed the treatment standards for metastatic colorectal cancer (CRC)." | 9.12 | Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. ( Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E, 2006) |
| "The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity." | 9.12 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006) |
| "To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy." | 9.12 | Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. ( Abdi, E; Cesano, A; Chen, MG; Clarke, S; Davis, ID; Gayko, U; Gutheil, J; Rosen, LS; Schnell, FM; Zalcberg, J, 2006) |
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 9.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "Forty-two rectal carcinoma (T(3-4)N(0-2)M(0)) patients with grade 2 or 3 diarrhea refractory to loperamide were enrolled to receive octreotide." | 9.12 | Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. ( Karaoglu, A; Topkan, E, 2006) |
| "The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed." | 9.11 | A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 9.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 9.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)." | 9.11 | A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004) |
| "This study evaluated the toxicity and efficacy of docetaxel/capecitabine as neoadjuvant treatment for stage 2/3 breast cancer." | 9.11 | A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. ( Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J, 2004) |
| "The addition of capecitabine to docetaxel on a 3-week schedule resulted in superior response rate, increased time to progression (TTP), and improved overall survival in patients with anthracycline-pretreated metastatic breast cancer (MBC)." | 9.11 | Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. ( Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS, 2004) |
| "Capecitabine and irinotecan are commonly used in the treatment of metastatic colorectal cancer (CRC)." | 9.11 | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. ( Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H, 2005) |
| " Glutamine may decrease chemotherapy-associated diarrhea." | 9.11 | A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. ( Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 9.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "Overall results of this study indicate that the administration of clinically relevant single-agent doses of both capecitabine and oxaliplatin is feasible and seems to result in promising therapeutic activity in patients with advanced colorectal cancer." | 9.10 | Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. ( Huber, H; Kornek, GV; Längle, F; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B, 2002) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 9.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| "We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting." | 9.10 | Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002) |
| "This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer." | 9.10 | Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 9.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer." | 9.10 | Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. ( Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M, 2002) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)." | 9.10 | Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. ( Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N, 2002) |
| "This multicenter, open-label study evaluated a 28-day oral regimen of 5-FU (1 mg/m2 twice daily) plus the dihydropyrimidine dehydrogenase inhibitor, eniluracil (10 mg/m2 twice daily), in patients with chemotherapy-naive or anthracycline-refractory inoperable hepatocellular carcinoma." | 9.10 | Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002) |
| "To determine the maximum-tolerated dose (MTD) of a weekly schedule of irinotecan (CPT-11), leucovorin (LV), and a 24-hour infusion of fluorouracil (5-FU24h) as first-line chemotherapy in advanced colorectal cancer and to assess preliminary data on the antitumor activity." | 9.09 | Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. ( Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H, 1999) |
| "Fourteen patients with CPT-11- and seven patients with 5-FU-induced grade 3-4 (NCI/WHO) diarrhea and loperamide failure were enrolled in this study." | 9.09 | Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. ( Droege, CM; Hausamen, TU; Lenfers, BH; Loeffler, TM, 1999) |
| "Thirty-seven colorectal cancer patients with grade 1-4 diarrhea (NCICTC) caused by chemotherapy with 5-FU-containing regimens, received oral loperamide at the initial dose of 4 mg followed by 4 mg every 8 h (total dose 16 mg/24 h)." | 9.09 | High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. ( Agostinelli, R; Amadori, D; Bichisao, E; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Luppi, G; Sansoni, E; Silingardi, V, 2000) |
| " One hundred thirty-six patients with metastatic colorectal cancer who failed to respond to a 5-fluorouracil-based treatment received 714 cycles of irinotecan." | 9.09 | Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. ( Adenis, A; Burki, F; Douillard, JY; Dufour, P; Marty, M; Mignard, D; Mousseau, M; Rougier, P; Wendling, JL; Ychou, M, 2000) |
| "In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen." | 9.09 | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000) |
| "The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer." | 9.09 | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 9.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 9.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| "To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum." | 9.09 | Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. ( Bell, A; Burmeister, BH; Fisher, R; Goldstein, D; Joseph, D; Kneebone, A; MacKay, JR; Ngan, SY; Rischin, D; Schache, DJ, 2001) |
| "To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)." | 9.09 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001) |
| "Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer." | 9.09 | Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. ( Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 9.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC)." | 9.09 | Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. ( Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M, 2001) |
| "A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer." | 9.08 | [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995) |
| "No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 9.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 9.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV." | 9.08 | A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996) |
| "Diarrhea is one of the dose-limiting toxicities for administration of fluorouracil (5FU) in patients with colorectal cancer and can result in severe morbidity and mortality." | 9.08 | Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. ( Ardizzoia, A; Barni, S; Cascinu, S; Catalano, G; Cazzaniga, M; Del Ferro, E; Ghiandoni, G; Labianca, R; Ligi, M; Luporini, G; Pessi, MA; Rocchi, MB; Ugolini, G; Zamparelli, G, 1997) |
| "A total of 50 patients were treated weekly with 5-fluorouracil (FU), leucovorin (LV), and 4'-O-tetrahydropyranyl-doxorubicin (THP) as first-line chemotherapy for advanced breast cancer (ABC)." | 9.07 | A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients. ( Bauernhofer, T; Derstvenscheg, E; Kuss, I; Moser, R; Ploner, F; Samonigg, H; Schmid, M; Steindorfer, P; Stöger, H; Wilders-Truschnig, M, 1994) |
| "Diarrhea is a prominent feature of fluorouracil (5FU) gastrointestinal toxicity, especially when 5FU is combined with leucovorin (LV) or interferon (IFN)." | 9.07 | Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. ( Cascinu, S; Catalano, G; Fedeli, A; Fedeli, SL, 1993) |
| "We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer." | 9.07 | Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 9.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 8.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| " A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia." | 8.83 | Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006) |
| "But fluorouracil (5-FU) and irinotecan (CPT-11 [Camptosar]) have shown activity in metastatic colorectal cancer and are approved for its treatment in the United States." | 8.80 | Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. ( Erlichman, C; Goldberg, RM, 1998) |
| "5-fluorouracil (5-FU) is an antineoplastic drug used to treat colorectal cancer, but it causes, among other adverse effects, diarrhea and mucositis, as well as enteric neuropathy, as shown in experimental animals." | 8.31 | Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat. ( Abalo, R; Girón, R; López-Gómez, L; Martín-Fontelles, MI; Nurgali, K; Uranga, JA; Vera, G, 2023) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 8.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| " polysaccharides (PCCL) on 5-fluorouracil-(5-FU)-induced intestinal mucositis (IM) in mice." | 8.12 | Protective effect of polysaccharides isolated from the seeds of Cuscuta chinensis Lam. on 5-fluorouracil-induced intestinal mucositis in mice. ( Chen, Z; Ji, Y; Lu, H; Luo, R; Tan, W; Tian, C; You, Y; Zhao, X; Zhou, L; Zhou, W; Zhou, X, 2022) |
| " We evaluated the effect of WMP on CIM by observing the general conditions of the mice (body weight, food intake, spleen weight, diarrhea score, and hematoxylin and eosin stained tissues)." | 8.12 | Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation. ( Chen, BY; Liu, F; Liu, HX; Lu, DX; Lu, Y; Sun, ZG; Wu, H; Yan, J, 2022) |
| " Reactive oxygen species (ROS) have been reported to be involved in the induction of intestinal mucositis and diarrhea, which are common side effects of treatment with fluoropyrimidine 5-fluorouracil (5-FU)." | 8.02 | Oral administration of cystine and theanine attenuates 5-fluorouracil-induced intestinal mucositis and diarrhea by suppressing both glutathione level decrease and ROS production in the small intestine of mucositis mouse model. ( Kurihara, S; Nishikawa, S; Yoneda, J, 2021) |
| "Female patients and patients aged sixty-five or older had an increased risk of developing severe diarrhea during preoperative chemoradiation therapy with capecitabine." | 8.02 | Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study. ( Hartman, W; Nuyttens, JJME; Oomen-de Hoop, E; Rothbarth, J; van Meerten, E; van Rees, JM; van Vugt, JLA; Verhoef, C, 2021) |
| "The study aimed to explore the efficacy of pharmacokinetic-based 5-fluorouracil dose management by plasma concentration test in advanced colorectal cancer treatment." | 7.96 | Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment. ( Deng, R; Guan, X; Shen, B; Shi, L; Wang, M; Yang, D; Zhu, W, 2020) |
| "oil in treating 5-fluorouracil (5-FU)-induced intestinal mucositis have not yet been reported." | 7.96 | Patchouli oil ameliorates 5-fluorouracil-induced intestinal mucositis in rats via protecting intestinal barrier and regulating water transport. ( Ai, G; Chen, L; Gan, Y; Huang, Q; Huang, X; Li, M; Liu, Y; Luo, H; Su, Z; Wu, J; Wu, X; Xu, N, 2020) |
| "Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients." | 7.96 | Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020) |
| "5-Fluorouracil (5-FU)-induced intestinal mucositis (IM) is one of the most common oncological problem." | 7.91 | Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. ( Ali, H; Ali, J; Islam, SU; Khan, AU; Khan, S; Kim, YS; Shah, FA, 2019) |
| "To investigate therapeutic effects and mechanism of Atractylodes macrocephala essential oil (AMO) and Panax ginseng total saponins (PGS) alone and in combination (AP) on 5-fluorouracil (5-FU) chemotherapy induced diarrhea in mice." | 7.91 | Ameliorative effect of Atractylodes macrocephala essential oil combined with Panax ginseng total saponins on 5-fluorouracil induced diarrhea is associated with gut microbial modulation. ( Ao, H; Chen, L; Feng, W; He, J; Peng, C; Sheng, Y; Tang, F; Wang, J; Xu, X; Zhang, S, 2019) |
| "Cholinergic syndrome is an acute adverse reaction associated with irinotecan." | 7.88 | Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. ( Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T, 2018) |
| "The chemotherapeutic agent 5-fluorouracil (5-FU) causes intestinal mucositis with severe diarrhoea, but the pathogenesis is not fully understood." | 7.85 | Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Amagase, K; Hamouda, N; Higuchi, K; Kato, S; Matsumoto, K; Oikawa, Y; Ozaki, T; Sano, T; Shimakawa, M, 2017) |
| " 5-Fluorouracil (5-FU), widely used for cancer chemotherapy, is known to frequently induce intestinal mucositis accompanied by severe diarrhoea." | 7.85 | Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. ( Amagase, K; Hamouda, N; Kano, Y; Kato, S; Matsumoto, K; Oikawa, Y; Shimakawa, M; Tanaka, Y, 2017) |
| "5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents." | 7.85 | Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017) |
| "5-Fluorouracil (5-FU) is widely used as an anti cancer drug and is known to cause severe diarrhea." | 7.85 | Active Ingredients of Hange-shashin-to, Baicalelin and 6-Gingerol, Inhibit 5-Fluorouracil-Induced Upregulation of CXCL1 in the Colon to Attenuate Diarrhea Development. ( Isa, Y; Kai, Y; Kimura, M; Miyano, K; Narita, M; Sakai, H; Sato, F; Tabata, S; Uezono, Y; Yabe, S; Yumoto, T, 2017) |
| "Wei-Chang-An pill (WCA pill), a traditional Chinese pharmaceutical preparation, possessed potential anti-inflammatory advantages and noteworthy gastrointestinal regulations in digestive diseases, which might represent a promising candidate for the treatment of intestinal mucositis (IM) induced by 5-fluorouracil (5-FU)." | 7.83 | Protective effect and potential mechanisms of Wei-Chang-An pill on high-dose 5-fluorouracil-induced intestinal mucositis in mice. ( Chen, Y; Gao, W; Jin, Z; Wang, L; Zhang, J; Zheng, H, 2016) |
| " This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer." | 7.81 | Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015) |
| "Diarrhea is a common side effect experienced by cancer patients undergoing clinical chemotherapy, such as with 5-fluorouracil (5-FU)." | 7.80 | Neutrophil recruitment is critical for 5-fluorouracil-induced diarrhea and the decrease in aquaporins in the colon. ( Hirosaki, A; Horie, S; Ikegami, D; Jo, A; Matoba, M; Matsumoto, K; Narita, M; Sagara, A; Sakai, H; Sato, K; Sugiyama, R; Takase, K, 2014) |
| "This study is aimed to identify clinical predictors, other than HER2 overexpression, for the response to lapatinib plus capecitabine (LAPCAP) in patients with HER2-positive advanced breast cancer (HER2ABC)." | 7.80 | Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. ( Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S, 2014) |
| "Chemotherapeutic agents, including 5-fluorouracil (5-FU), frequently cause intestinal mucositis resulting in severe diarrhoea and morphological mucosal damage." | 7.79 | 5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. ( Amagase, K; Horie, S; Iimori, M; Kato, S; Kitahara, Y; Matsumoto, K; Takeuchi, K; Utsumi, D; Yamanaka, N; Yasuda, M, 2013) |
| "Although the mechanisms of 5-fluorouracil (5-FU)-induced diarrhea remain unclear, accumulating evidence has indicated that changes in the mucosal immune system and aquaporins (AQPs) may play a role in its pathogenesis." | 7.79 | 5-Fluorouracil induces diarrhea with changes in the expression of inflammatory cytokines and aquaporins in mouse intestines. ( Hasegawa, S; Horie, S; Matsumoto, K; Nakagawa, T; Narita, M; Nishizaki, M; Sagara, A; Sakai, H; Sato, K; Shoji, T; Tokuyama, S, 2013) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 7.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| "To evaluate retrospectively the efficacy and toxicity of capecitabine-based chemotherapy in the treatment of advanced breast cancer." | 7.77 | [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer]. ( Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 7.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "This study demonstrates that CR3294 acts on key molecular targets to reduce the signs of mucositis and the occurrence of diarrhea in mice exposed to the chemotherapy drug 5-fluorouracil." | 7.76 | Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. ( Bonazzi, A; Booth, C; Caselli, G; Garofalo, P; Letari, O; Makovec, F; Rovati, LC, 2010) |
| "Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 7.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
| "To characterize diarrhea events in patients with cancer treated with lapatinib as monotherapy or in combination with capecitabine or taxanes." | 7.74 | Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. ( Boyle, F; Burris, HA; Byrne, J; Chan, S; Crown, JP; Jones, S; Koehler, M; Newstat, BO; Oliva, C; Parikh, R; Preston, A, 2008) |
| "70 patients with advanced colorectal cancer were treated with irinotecan and 5-fluorouracil." | 7.74 | [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. ( Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS, 2007) |
| "Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m(2)." | 7.72 | Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. ( Kosmas, C; Koufos, C; Margaris, H; Papalambros, E; Papantoniou, N; Retalis, G; Rokana, S; Tsavaris, N; Vadiaka, M; Zografos, G; Zonios, D, 2003) |
| "5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer." | 7.70 | Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998) |
| "The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 7.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
| "In 16 advanced colorectal cancer patients with 5-fluorouracil-associated diarrhea, we evaluated the role of bacterial pathogens in the development of this adverse effect." | 7.69 | Have enteric infections a role in 5-fluorouracil-associated diarrhea? ( Cascinu, S; Catalano, G, 1995) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 7.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| " In a literature review of all published data of folinic acid and 5-fluorouracil intravenous bolus therapy in colorectal cancer with comparable dose intensity, an attempt was made to characterize the possible differences of the variations of schedules used." | 7.68 | The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. ( Bokemeyer, C; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992) |
| "After perioperative adjuvant chemotherapy of a sigma-adenocarcinoma with 400 mg peptichemio and 500 mg 5-fluorouracil a 61-year-old woman developed a severe intoxication: myelosuppression with pancytopenia, gastroenteritis and ulcerative proctitis, toxic hepato- and myocardiopathy, impaired renal function and alopecia." | 7.66 | [Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)]. ( Gasser, RW; Schmalzl, F, 1982) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 6.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| "Sixty breast cancer patients undergoing an FEC60 regimen were enrolled, 37 patients completed the study." | 6.78 | The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. ( Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F, 2013) |
| " Patients exhibited high compliance in dosing administration." | 6.74 | Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009) |
| "Capecitabine was administered at a dose of 1,250 mg/m(2) bid for 14 consecutive days in 3-week cycles, with dose modifications if necessary." | 6.73 | Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. ( Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC, 2007) |
| "Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection." | 6.73 | Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008) |
| "Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever." | 6.71 | A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005) |
| "Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay." | 6.69 | Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998) |
| "To determine the most effective dose of leucovorin (folinic acid [FA]) within a weekly bolus fluorouracil (FU) schedule, we conducted a randomized multicenter trial to compare therapeutic effects and toxicity of high-dose FA versus low-dose FA combined with FU at equal doses in both treatment groups." | 6.68 | Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. ( Bernhard, G; Bernhard, H; Heike, M; Jäger, E; Klein, O; Knuth, A; Lautz, D; Meyer zum Büschenfelde, KH; Michaelis, J, 1996) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 6.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| "Therapy for metastatic breast cancer has not improved significantly in recent years." | 6.68 | Metastatic breast cancer: treatment with fluorouracil-based combinations. ( Klaassen, U; Seeber, S, 1997) |
| "To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings." | 6.53 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016) |
| "Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination." | 6.50 | Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. ( Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M, 2014) |
| "Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration." | 6.46 | Update on capecitabine alone and in combination regimens in colorectal cancer patients. ( Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S, 2010) |
| "Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2." | 6.45 | [Lapatinib treatment-option in trastuzumab-resistant breast cancer]. ( Pikó, B, 2009) |
| "Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells." | 6.41 | Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002) |
| "In DaVINCI, a randomised phase II trial, patients with advanced colorectal cancer were randomly allocated to: Combination therapy (FOLFIRI), irinotecan (180 mg/m(2) IV over 90 min, day 1), 5-fluorouracil (400mg/m(2) IV bolus and 2400 mg/m(2) by 46-hour infusion from day 1) and folinic acid (20mg/m(2) IV bolus, day 1), 2-weekly; or Single-agent, irinotecan (350 mg/m(2) IV over 90 min), 3-weekly." | 6.25 | Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. ( Boland, A; Brown, C; Buck, M; Clarke, SJ; Gebski, V; Goldstein, D; Jeffrey, GM; Lowenthal, RM; Ransom, DT; Simes, RJ; Tebbutt, NC; van Hazel, GA; Yip, S; Zalcberg, J, 2011) |
| "17 patients with metastasizing colorectal cancer were treated in a phase II-study with systemic intravenous chemotherapy (Petrelli N, Proc ASCO 286, 1987) consisting of leucovorin 500 mg/m2 in a 2 hr infusion and 5-fluorouracil (5-FU) 600 mg/m2 bolus one hour after the commencement of the leucovorin infusion." | 6.16 | [5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma]. ( Baur, M; Dittrich, C; Havelec, L; Mader, R; Marosi, C; Scheithauer, W; Schlappack, O, 1991) |
| "Mucositis was induced through a single injection with 2 mg/kg idarubicin (with saline as control), followed by daily treatments of anakinra (100 mg/kg/day), dexamethasone (10 mg/kg/day) or both for 3 days." | 5.91 | Anakinra and dexamethasone treatment of idarubicin-induced mucositis and diarrhoea in rats. ( Dahlgren, D; Heindryckx, F; Kullenberg, F; Lennernäs, H; Peters, K; Sjöblom, M, 2023) |
| "Capecitabine is a widely-used antineoplastic drug, a prodrug to 5-fluorouracil which commonly induces gastrointestinal toxicity." | 5.72 | Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile. ( Chen, J; Liu, J; Shao, T; Shou, L; Shu, Q; Zhang, Y, 2022) |
| "Intestinal mucositis is a common side effect of chemotherapy and radiotherapy." | 5.62 | TBHQ attenuates ferroptosis against 5-fluorouracil-induced intestinal epithelial cell injury and intestinal mucositis via activation of Nrf2. ( Deng, S; Li, J; Li, L; Wu, D; Xu, Y, 2021) |
| "5-Fluorouracil (5-FU) is a chemotherapy agent that is widely used in clinical oncologic practice." | 5.62 | Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice. ( Chang, CW; Chen, YJ; Hsieh, CH; Liu, CY; Liu, JH; Tsai, TH, 2021) |
| "Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the consequent impact on the prognosis of survival." | 5.51 | Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| " On the 7th day, the mice were euthanized, and intestinal samples were collected for histopathology and morphometric analysis, as well as for the determination of myeloperoxidase activity and cytokine dosage (TNF-α and IL-6)." | 5.43 | A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice. ( Almeida, PR; Assis-Júnior, EM; Brito, GA; Lima-Júnior, RC; Melo, AT; Pereira, VB; Ribeiro, RA; Wong, DV, 2016) |
| "Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients." | 5.41 | A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab. ( Chang, TK; Chen, PJ; Chen, YC; Cheng, TL; Chuang, KH; Huang, CW; Li, CC; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yin, TC, 2021) |
| "5-Fluorouracil was given every 3 weeks by 5-day continuous chronomodulated venous infusion (CMVI) with peak 5-FU delivery at 4 a." | 5.29 | Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Itzhaki, M; Lévi, F; Misset, JL; Soussan, S, 1993) |
| "Aflibercept combined with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) as second-line treatment of metastatic colorectal cancer (mCRC) significantly improved survival compared with FOLFIRI alone in the pivotal VELOUR (aflibercept vs." | 5.27 | Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. ( Antoniotti, C; Aprile, G; Bordonaro, R; Ciuffreda, L; Di Bartolomeo, M; Di Costanzo, F; Fasola, G; Frassineti, GL; Iaffaioli, V; Leone, F; Maiello, E; Marchetti, P; Pastorino, A; Sobrero, A; Zaniboni, A; Zilocchi, C, 2018) |
| "Irinotecan (CPT-11) in combination with 5-fluorouracil (5FU) is widely used in the treatment of colorectal cancer." | 5.27 | Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. ( Bosman, F; Brauchli, P; Delorenzi, M; Dietrich, D; Fiocca, R; Klingbiel, D; Piessevaux, H; Roth, AD; Tejpar, S; Yan, P, 2018) |
| "The hepatic artery infusion (HAI) of irinotecan, oxaliplatin and 5-fluorouracil with intravenous cetuximab achieved outstanding efficacy in previously treated patients with initially unresectable liver metastases from colorectal cancer." | 5.24 | Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). ( Adam, R; Boige, V; Bouchahda, M; Carvalho, C; Desterke, C; Ducreux, M; Focan, C; Guimbaud, R; Hebbar, M; Innominato, P; Karaboué, A; Lemoine, A; Lévi, F; Milano, G; Saffroy, R; Smith, D; Taieb, J, 2017) |
| "The aim of this multicenter, open-label, randomized phase II trial was to evaluate the efficacy of a dose-dense capecitabine and oxaliplatin (XELOX) regimen in patients with metastatic colorectal cancer (mCRC) for whom reintroduction of oxaliplatin had been planned as a third- or later-line regimen." | 5.22 | Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study). ( Bando, H; Fujii, A; Fukunaga, M; Hata, T; Honda, M; Ishibashi, K; Kobayashi, M; Matsuda, C; Mishima, H; Munemoto, Y; Nagata, N; Oba, K; Oshiro, M; Tanaka, C; Tokunaga, Y, 2016) |
| "The antiangiogenic agent aflibercept (ziv-aflibercept in the United States) in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) significantly improved survival in a phase III study of patients with metastatic colorectal cancer (mCRC) previously treated with an oxaliplatin-based regimen." | 5.19 | Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. ( Allegra, CJ; Chevalier, S; Ferry, DR; Lakomý, R; McKendrick, JJ; Moiseyenko, VM; Prausová, J; Ruff, P; Soussan-Lazard, K; Tabernero, J; Van Cutsem, E; van Hazel, GA, 2014) |
| "This report describes the results of an analysis of patient-reported outcomes from EMILIA (TDM4370g/BO21977), a randomized phase 3 study of the antibody-drug conjugate trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer." | 5.19 | Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. ( Althaus, B; Diéras, V; Fang, L; Guardino, E; Hurvitz, SA; Lalla, D; Miles, D; Sohn, JH; Welslau, M, 2014) |
| "Patients with colorectal cancer starting adjuvant or first-line treatment with a chemotherapy combination containing fluorouracil, capecitabine, and/or irinotecan were randomly assigned to receive octreotide LAR 30 mg intramuscularly every 4 weeks (experimental arm) or the physician's treatment of choice in case of diarrhea (control arm)." | 5.19 | Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. ( Andrade, AC; Barrios, CH; Chinen, RN; Correa, M; Coutinho, AK; del Giglio, A; Dutra, C; Forones, NM; Hoff, PM; Passos, VQ; Portella, Mdo S; Saragiotto, DF; van Eyll, B, 2014) |
| "The purpose of this phase I study was to determine the safety, toxicity, maximum tolerated dose, and pharmacokinetics of capecitabine when administered concurrently with radiotherapy in patients with localised, inoperable pancreatic adenocarcinoma." | 5.19 | A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. ( Crellin, A; Evans, TR; Harden, S; James, A; Lumsden, GR; McDonald, AC; Morrison, R; Paul, J; Roxburgh, P; Sweeting, L, 2014) |
| "Lapatinib and capecitabine (L-CAP) is effective in HER-2 positive patients with metastatic breast cancer (MBC)." | 5.19 | Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine. ( Dranitsaris, G; Lacouture, ME, 2014) |
| "To determine the maximum tolerated dose (MTD) and preliminary efficacy of concurrent hepatic arterial infusion (HAI) of floxuridine (FUDR) and systemic modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable hepatic metastases from colorectal cancer." | 5.19 | Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. ( Chen, C; Chen, G; Ding, P; Gu, Y; He, Y; Li, C; Li, W; Li, Y; Lu, Z; Luo, H; Pan, Z; Wan, D; Wang, F; Wang, Z; Wu, X; Xu, R; Yuan, Y; Zhao, M, 2014) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 5.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| " The incidence of adverse events frequently associated with irinotecan and capecitabine were neutropenia (any grade, 55." | 5.19 | A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). ( Goto, A; Hamamoto, Y; Morita, S; Nakajima, T; Nakayama, N; Nishina, T; Sakamoto, J; Shimada, K; Ura, T; Yamada, Y; Yamaguchi, T; Yamazaki, K, 2014) |
| "Neratinib in combination with capecitabine had a manageable toxicity profile and showed promising antitumor activity in patients with HER2-positive metastatic breast cancer pretreated with trastuzumab and lapatinib." | 5.19 | Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. ( Baselga, J; Cortés, J; Garcia-Saenz, JA; Germa, C; Harb, W; Kiger, C; Kim, SB; Martin, M; Moroose, R; Pluard, T; Saura, C; Wang, K; Xu, B, 2014) |
| "The incidence of diarrhea during chemotherapy was significantly lower in the S-1 plus lafutidine group than in the group treated with S-1 alone (10% vs." | 5.19 | Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. ( Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Namikawa, T, 2014) |
| "This randomized phase II trial investigated the efficacy and safety of capecitabine/oxaliplatin (CapOx) plus bevacizumab and dose-modified capecitabine/irinotecan (mCapIri) plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer (mCRC)." | 5.17 | Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. ( Arnold, D; Dietrich, G; Freier, W; Geißler, M; Graeven, U; Hegewisch-Becker, S; Hinke, A; Kubicka, S; Pohl, M; Reinacher-Schick, A; Schmiegel, W; Schmoll, HJ; Tannapfel, A, 2013) |
| "Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment of anal cancer." | 5.17 | Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. ( Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Dewit, L; Schellens, JH, 2013) |
| "Capecitabine/taxane combinations are highly active in metastatic breast cancer (MBC)." | 5.17 | Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group. ( Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K, 2013) |
| "The safety and efficacy of neratinib monotherapy were compared with that of lapatinib plus capecitabine in patients with human epidermal growth factor receptor-2-positive (HER2+), locally advanced/metastatic breast cancer and prior trastuzumab treatment." | 5.17 | A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. ( Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K, 2013) |
| "To investigate the association of colonic methane, formed by methanogenic achaea, and pH with gastrointestinal symptoms during colorectal cancer chemotherapy." | 5.17 | Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer. ( Blom, M; Holma, R; Korpela, R; Osterlund, P; Poussa, T; Rautio, M; Sairanen, U; Saxelin, M, 2013) |
| "The combination of bevacizumab and bolus 5-fluorouracil, leucovorin and irinotecan is highly effective in patients with metastatic colorectal cancer (mCRC)." | 5.17 | Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu ( Adenis, A; Boucher, E; Chauffert, B; Conroy, T; Ducreux, M; François, E; Ichanté, JL; Montoto-Grillot, C; Pierga, JY; Pignon, JP; Ychou, M, 2013) |
| "This double-blind, phase III study aimed to demonstrate that sunitinib plus FOLFIRI (fluorouracil, leucovorin, and irinotecan) was superior to placebo plus FOLFIRI in previously untreated metastatic colorectal cancer (mCRC)." | 5.17 | Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial. ( Bondarenko, I; Carrato, A; Christensen, JG; De la Cruz, JA; Jonker, DJ; Korytowsky, B; Lechuga, MJ; Lim, R; Lin, X; Roman, L; Shparyk, Y; Staszewska-Skurczynska, M; Sun, Y; Swieboda-Sadlej, A; Tursi, JM; Van Cutsem, E; Williams, JA, 2013) |
| " The primary objectives of this study were to determine the maximum tolerated dose of vandetanib with capecitabine and oxaliplatin, without and with bevacizumab, for the first line treatment of metastatic colorectal cancer (mCRC), and to define the dose limiting toxicities." | 5.16 | A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer. ( Cabebe, EC; Fisher, GA; Sikic, BI, 2012) |
| "To determine the dose-limiting toxicities (DLTs) and the maximum tolerated doses (MTD) of oral metronomic vinorelbine with capecitabine in patients with metastatic breast cancer (MBC)." | 5.16 | A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. ( Androulakis, N; Ardavanis, A; Georgoulias, V; Kalbakis, K; Kourakos, P; Malamos, N; Mavroudis, D; Polyzos, A; Saridaki, Z; Vamvakas, L, 2012) |
| "This study was intended to ascertain the feasibility of a combination therapy with irinotecan by 24-h intravenous infusion (24-h CPT-11) and 5-fluorouracil (5-FU) for patients with metastatic colorectal cancer, to estimate the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD), to determine the recommended dose (RD) for the Phase II study, and to evaluate the efficacy of the combination therapy." | 5.16 | Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer. ( Gamo, M; Kambe, M; Kanamaru, R; Kikuchi, H; Ohashi, Y; Yoshioka, T, 2012) |
| "We previously reported a 35% overall response rate (ORR) with biweekly 5-fluorouracil (5-FU) continuous infusion (TTD [Spanish Cooperative Group for Digestive Tumour Therapy] schedule) plus irinotecan as first-line therapy in elderly patients with metastatic colorectal cancer (mCRC)." | 5.16 | Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. ( Alfaro, J; Aparicio, J; Aranda, E; Benavides, M; Cabrera, E; Campos, JM; Carrato, A; Dueñas, R; Etxeberría, A; Gil-Calle, S; Gómez, A; Gómez, MJ; González-Flores, E; Guasch, I; Marcuello, E; Massutí, B; Pericay, C; Queralt, B; Reina, JJ; Valladares-Ayerbes, M, 2012) |
| "To evaluate the maximum tolerated dose (MTD) and pharmacokinetic profile of a chronomodulated, dose-intensified regimen of capecitabine in combination with oxaliplatin (XELOX) in metastatic colorectal cancer (mCRC)." | 5.16 | Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. ( Chen, X; Choo, SP; Chowbay, B; Farid, M; Koo, WH; Ong, SY; Ramasamy, S; Tan, SH; Toh, HC, 2012) |
| "The efficacy and safety of bevacizumab with modified irinotecan, leucovorin bolus, and 5-fluorouracil intravenous infusion (mIFL) in the first-line treatment of metastatic colorectal cancer (mCRC) has not been well evaluated in randomized clinical trials in Chinese patients." | 5.15 | Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. ( Ba, Y; Feng, FY; Guan, ZZ; He, J; Liang, J; Luo, RC; Qi, C; Qin, SK; Shen, L; Wang, D; Wang, JJ; Wang, LW; Xu, JM; Xu, RH; Yu, SY, 2011) |
| "Irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) is accepted as a reference treatment for the first-line treatment of patients with metastatic colorectal cancer (MCRC)." | 5.14 | Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the ( Aranda, E; Benavides, M; Cámara, JC; Carrato, A; Constenla, M; Díaz-Rubio, E; Dueñas, R; Gomez, A; Marcuello, E; Martinez-Villacampa, M; Massutti, B; Navarro, M; Reboredo, M; Valladares, M, 2009) |
| "Oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (LV) are standard first-line treatments for patients with metastatic colorectal cancer (mCRC)." | 5.14 | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. ( Bridgewater, J; Cassidy, J; Chan, RT; Clingan, P; Cunningham, D; Glynne-Jones, R; Koralewski, P; Mainwaring, P; Pluzanska, A; Sirohi, B; Szczylik, C; Tabah-Fisch, I; Utracka-Hutka, B; Wang, JY; Wasan, H; Zaluski, J, 2009) |
| "This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer." | 5.14 | Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. ( Brezault, C; Cals, L; Husseini, F; Loos, AH; Nippgen, J; Peeters, M; Raoul, JL; Rougier, P; Van Laethem, JL, 2009) |
| "Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 5.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
| "To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial." | 5.14 | Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. ( Ackland, SP; Broad, A; Chua, Y; Cummins, MM; Cunningham, D; Forgeson, G; Ganju, V; Gebski, VJ; Price, TJ; Robinson, B; Saunders, MP; Simes, RJ; Stockler, MR; Tebbutt, NC; van Hazel, GA; Wilson, K; Zalcberg, JR; Zannino, D, 2010) |
| "Consenting operable patients with stage II or III adenocarcinoma of the rectum received capecitabine (825 mg/m2 PO BID, 5 days/wk x 5 weeks) and SIB-IMRT delivering 55 Gy (2." | 5.13 | Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. ( Ballonoff, A; Kane, M; Kavanagh, B; McCarter, M; Nash, R; Pearlman, N; Raben, D; Schefter, TE; Shah, RJ, 2008) |
| "The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)." | 5.13 | Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008) |
| "The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer." | 5.13 | Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008) |
| "To assess the predictive value of polymorphisms in dihydropyrimidine dehydrogenase (DPYD ), thymidylate synthase (TYMS ), and methylene tetrahydrofolate reductase (MTHFR ) and of nongenetic factors for severe leukopenia, diarrhea, and mucositis related to fluorouracil (FU) treatment." | 5.13 | Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. ( Blievernicht, J; Bokemeyer, C; Dippon, J; Eichelbaum, M; Fischer, J; Hofmann, U; Kerb, R; Klein, K; Marx, C; Schaeffeler, E; Schwab, M; Zanger, UM, 2008) |
| "Irinotecan or oxaliplatin combined with 5-fluorouracil (5-FU) +/- folinic acid (FA) has changed the treatment standards for metastatic colorectal cancer (CRC)." | 5.12 | Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients. ( Bas, C; Bella, S; Chacon, M; Coppola, F; Escobar, E; Hidalgo, J; Korbenfeld, E; Martin, C; Martinez, J; Reale, M; Richardet, E; Senna, S; Smilovich, AM; Wasserman, E, 2006) |
| "The purpose of this study was to evaluate the safety and activity of fixed-dose capecitabine in patients with advanced colorectal cancer and to correlate pretreatment plasma concentrations of homocysteine and serum and red cell folate with toxicity." | 5.12 | A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. ( Beale, P; Clarke, SJ; Horvath, L; Ong, S; Rivory, L; Sharma, R, 2006) |
| "To characterize the efficacy and safety of palifermin in reducing the incidence of oral mucositis (OM) and diarrhea when administered to patients with metastatic colorectal cancer (CRC) receiving fluorouracil/leucovorin (FU/LV) chemotherapy." | 5.12 | Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. ( Abdi, E; Cesano, A; Chen, MG; Clarke, S; Davis, ID; Gayko, U; Gutheil, J; Rosen, LS; Schnell, FM; Zalcberg, J, 2006) |
| "Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as second-line treatment for advanced colorectal cancer (CRC)." | 5.12 | First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. ( Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L, 2007) |
| "To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide." | 5.12 | [A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007) |
| "Forty-two rectal carcinoma (T(3-4)N(0-2)M(0)) patients with grade 2 or 3 diarrhea refractory to loperamide were enrolled to receive octreotide." | 5.12 | Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. ( Karaoglu, A; Topkan, E, 2006) |
| "Tegafur is an oral fluorouracil prodrug used in the treatment of colorectal cancer." | 5.12 | A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule. ( Bennouna, J; Cardot, JM; Château, Y; Douillard, JY; Etienne-Grimaldi, MC; François, E; Gamelin, E; Milano, G; Renée, N, 2007) |
| "The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed." | 5.11 | A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 5.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 5.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "To evaluate the safety and efficacy of irinotecan (CPT-11) alternated with a weekly treatment for 4 weeks of oxaliplatin (L-OHP), high-dose leucovorin (LV) and a 48-hour 5-fluorouracil infusion (5-FU 48 h) as first-line chemotherapy for patients with advanced colorectal cancer (ACC)." | 5.11 | A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer. ( Colarusso, D; Manzione, L; Pizza, C; Reggiardo, G; Rinaldi, A; Rosati, G; Tucci, A, 2004) |
| "This study evaluated the toxicity and efficacy of docetaxel/capecitabine as neoadjuvant treatment for stage 2/3 breast cancer." | 5.11 | A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. ( Berman, A; Chow, CK; Danforth, D; Eng-Wong, J; Lebowitz, PF; Liu, E; Merino, MJ; Swain, SM; Venzon, D; Zia, F; Zujewski, J, 2004) |
| "The addition of capecitabine to docetaxel on a 3-week schedule resulted in superior response rate, increased time to progression (TTP), and improved overall survival in patients with anthracycline-pretreated metastatic breast cancer (MBC)." | 5.11 | Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. ( Au, HJ; Bodnar, DM; Joy, AA; Koski, SL; Mackey, JR; Scarfe, AG; Smith, SW; Smylie, MG; Soulieres, D; Tonkin, KS, 2004) |
| "Capecitabine and irinotecan are commonly used in the treatment of metastatic colorectal cancer (CRC)." | 5.11 | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. ( Andria, ML; Bever, J; Blanchard, RL; Carlini, LE; Gold, P; Hill, T; Meropol, NJ; Rogatko, A; Wang, H, 2005) |
| " Glutamine may decrease chemotherapy-associated diarrhea." | 5.11 | A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. ( Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 5.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "Recently, high-dose FEC (fluorouracil, epirubicin, and cyclophosphamide) has been increasingly used in adjuvant chemotherapy for breast cancer in Japan." | 5.11 | [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients]. ( Kim, SJ; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanji, Y, 2005) |
| "During adjuvant radiotherapy (RT) for rectal cancer, patients receiving 5-fluorouracil (5-FU) by protracted venous infusion have a higher risk of diarrhea than have patients receiving bolus 5-FU." | 5.10 | Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. ( Cha, SS; Gunderson, LL; Haller, D; Macdonald, JS; Martenson, JA; Mayer, RJ; Miller, RC; O'Connell, MJ; Rich, TA; Sargent, DJ, 2002) |
| "Overall results of this study indicate that the administration of clinically relevant single-agent doses of both capecitabine and oxaliplatin is feasible and seems to result in promising therapeutic activity in patients with advanced colorectal cancer." | 5.10 | Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer. ( Huber, H; Kornek, GV; Längle, F; Raderer, M; Scheithauer, W; Schmid, K; Schüll, B, 2002) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 5.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| "We investigated the activity of irinotecan given with a more convenient modified bimonthly de Gramont regimen of bolus and infusional 5-fluorouracil [IrMdG] in advanced or metastatic colorectal cancer in the first and second line setting." | 5.10 | Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. ( Hochhauser, D; James, R; Ledermann, JA; Leonard, P; Seymour, MT, 2002) |
| "This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer." | 5.10 | Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003) |
| " once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment." | 5.10 | Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003) |
| "To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer." | 5.10 | Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. ( Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M, 2002) |
| "To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (L-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC)." | 5.10 | Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. ( Agelaki, S; Androulakis, N; Athanasiadis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, Ch; Mavroudis, D; Samonis, G; Souglakos, J; Tsetis, D; Vardakis, N, 2002) |
| "This multicenter, open-label study evaluated a 28-day oral regimen of 5-FU (1 mg/m2 twice daily) plus the dihydropyrimidine dehydrogenase inhibitor, eniluracil (10 mg/m2 twice daily), in patients with chemotherapy-naive or anthracycline-refractory inoperable hepatocellular carcinoma." | 5.10 | Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002) |
| "To determine the maximum-tolerated dose (MTD) of a weekly schedule of irinotecan (CPT-11), leucovorin (LV), and a 24-hour infusion of fluorouracil (5-FU24h) as first-line chemotherapy in advanced colorectal cancer and to assess preliminary data on the antitumor activity." | 5.09 | Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. ( Achterrath, W; Harstrick, A; Köhne, CH; Rustum, YM; Seeber, S; Vanhoefer, U; Wilke, H, 1999) |
| " Other toxicities included hand-foot syndrome, diarrhea, hyperbilirubinemia, skin rash, myalgia, and arthralgia." | 5.09 | Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. ( Burger, HU; Burris, HA; Drengler, RL; Eckhardt, SG; Griffin, T; Kraynak, M; Moczygemba, J; Reigner, B; Rodrigues, G; Rowinsky, EK; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR, 1999) |
| "Fourteen patients with CPT-11- and seven patients with 5-FU-induced grade 3-4 (NCI/WHO) diarrhea and loperamide failure were enrolled in this study." | 5.09 | Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment. ( Droege, CM; Hausamen, TU; Lenfers, BH; Loeffler, TM, 1999) |
| "Thirty-seven colorectal cancer patients with grade 1-4 diarrhea (NCICTC) caused by chemotherapy with 5-FU-containing regimens, received oral loperamide at the initial dose of 4 mg followed by 4 mg every 8 h (total dose 16 mg/24 h)." | 5.09 | High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. ( Agostinelli, R; Amadori, D; Bichisao, E; Cascinu, S; Catalano, G; Catalano, V; Giordani, P; Luppi, G; Sansoni, E; Silingardi, V, 2000) |
| " Diarrhea was the principal dose-limiting toxicity of oral 5-FU and eniluracil given on this chronic schedule." | 5.09 | Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. ( Baker, SD; Diasio, RB; Donehower, RC; Grochow, LB; Hohneker, JA; Khor, SP; Lucas, VS; O'Reilly, S; Rowinsky, EK; Sartorius, SE; Spector, T, 2000) |
| " One hundred thirty-six patients with metastatic colorectal cancer who failed to respond to a 5-fluorouracil-based treatment received 714 cycles of irinotecan." | 5.09 | Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study. ( Adenis, A; Burki, F; Douillard, JY; Dufour, P; Marty, M; Mignard, D; Mousseau, M; Rougier, P; Wendling, JL; Ychou, M, 2000) |
| " A regimen of sequential TMTX, FA and 5-fluorouracil (5-FU) has shown efficacy in patients with colorectal cancer." | 5.09 | Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO. ( Berdel, WE; Haboubi, N; Hohenberger, P; Kreuser, ED; Lochs, H; Szelényi, H; Thiel, E, 2000) |
| "In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen." | 5.09 | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000) |
| "Diarrhea is dose-limiting with weekly 5-fluorouracil (5-FU) plus high-dose leucovorin (LV)." | 5.09 | Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant. ( Blumenson, LE; Creaven, PJ; Frank, C; Meropol, NJ; Rustum, YM, 1999) |
| "The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectal cancer." | 5.09 | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. ( Ackland, SP; Blanke, C; Cox, JV; Elfring, GL; Fehrenbacher, L; Locker, PK; Maroun, JA; Miller, LL; Moore, MJ; Pirotta, N; Rosen, LS; Saltz, LB, 2000) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 5.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 5.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| "To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum." | 5.09 | Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. ( Bell, A; Burmeister, BH; Fisher, R; Goldstein, D; Joseph, D; Kneebone, A; MacKay, JR; Ngan, SY; Rischin, D; Schache, DJ, 2001) |
| "To identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of oxaliplatin (L-OHP) given on a weekly schedule including fixed doses of leucovorin (LV) and infusional 5-fluorouracil (5-FU), to define the toxicity profile of this regimen and to find preliminary evidence of its activity in pretreated patients with metastatic colorectal cancer (MCRC)." | 5.09 | Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer. ( Manzione, L; Pizza, C; Rosati, G; Rossi, A; Tucci, A, 2001) |
| "Oral capecitabine was evaluated in terms of overall response rate, safety, and tolerability as first-line therapy in women aged > or = 55 years with advanced/metastatic breast cancer." | 5.09 | Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. ( Bell, D; Blum, J; Burger, HU; Jones, SE; Laws, S; Mauriac, L; Miles, D; Moiseyenko, V; Oshaughnessy, JA; Osterwalder, B; Rosso, R, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 5.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC)." | 5.09 | Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. ( Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M, 2001) |
| "A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer." | 5.08 | [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995) |
| "Diarrhea is one of the dose-limiting toxicities for administration of fluorouracil (5FU) in patients with gastrointestinal malignancies and can result in severe morbidities or mortality." | 5.08 | Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. ( Haynes, H; Wadler, S; Wiernik, PH, 1995) |
| "No effective systemic salvage therapy exists for patients with advanced colorectal cancer who progress after receiving bolus fluorouracil (FU) and leucovorin (LV) chemotherapy." | 5.08 | Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. ( André, AM; Bertino, JR; Conti, JA; Grossano, DD; Kemeny, NE; Saltz, LB, 1995) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 5.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "A phase I trial of 5-fluorouracil (5-FU), leucovorin (LV) and interferon (IFN) was conducted in 15 advanced colorectal cancer patients refractory to a bolus regimen of 5-FU/LV." | 5.08 | A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma. ( Cascinu, S; Catalano, G; Del Ferro, E; Ligi, M, 1996) |
| "The combination of radiation therapy with fluorouracil (5-FU)-based chemotherapy is generally accepted as appropriate postoperative therapy for patients with adenocarcinomas of the rectum that extend through the bowel wall or with lymph nodes positive for tumor." | 5.08 | Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. ( Benson, AB; Cooke, E; Cummings, B; Gunderson, LL; Hollis, D; Macdonald, JS; Martenson, JA; O'Connell, MJ; Petroni, GR; Tepper, JE, 1997) |
| "Diarrhea is one of the dose-limiting toxicities for administration of fluorouracil (5FU) in patients with colorectal cancer and can result in severe morbidity and mortality." | 5.08 | Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study. ( Ardizzoia, A; Barni, S; Cascinu, S; Catalano, G; Cazzaniga, M; Del Ferro, E; Ghiandoni, G; Labianca, R; Ligi, M; Luporini, G; Pessi, MA; Rocchi, MB; Ugolini, G; Zamparelli, G, 1997) |
| "The combination of pelvic radiotherapy and 5-fluorouracil-based chemotherapy is associated with an increase in acute gastrointestinal toxicity during rectal adjuvant therapy, most notably an increased incidence of diarrhea." | 5.08 | Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. ( Kahn, MJ; Krook, JE; Martenson, JA; Miller, RC; Sargent, DJ, 1998) |
| "A total of 50 patients were treated weekly with 5-fluorouracil (FU), leucovorin (LV), and 4'-O-tetrahydropyranyl-doxorubicin (THP) as first-line chemotherapy for advanced breast cancer (ABC)." | 5.07 | A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients. ( Bauernhofer, T; Derstvenscheg, E; Kuss, I; Moser, R; Ploner, F; Samonigg, H; Schmid, M; Steindorfer, P; Stöger, H; Wilders-Truschnig, M, 1994) |
| "We have reported that 5-fluorouracil (5-FU) and folinic acid increased response rate and survival in patients with metastatic colorectal cancer." | 5.07 | Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. ( Erlichman, C; Fine, S; Gadalla, T; Steinberg, J; Wong, A, 1992) |
| "148 patients with advanced untreated colorectal cancer were randomised to receive a weekly bolus of 5-fluorouracil (5-FU) 600 mg/m2 alone, with or without leucovorin (LV) 500 mg/m2." | 5.07 | Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma. ( Canobbio, L; Fassio, T; Gallo, L; Guglielmi, A; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Venturini, M; Vidili, MG, 1992) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 5.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "One hundred twenty-one patients with advanced measurable adenocarcinoma of the colon were randomized for treatment with intravenous 5-fluorouracil (IV 5-FU) alone, 15 mg/kg/week vs." | 5.05 | Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count. ( Bateman, JR; Chlebowski, RT; Kardinal, C; Pajak, T; Silverberg, I; Weiner, J, 1980) |
| "The aim of this study was to evaluate systematically the efficacy and safety of oral uracil-tegafur (UFT) plus leucovorin (LV) compared with infusional fluorouracil (5-FU) plus LV for advanced colorectal cancer." | 4.87 | Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials. ( Bin, Q; Cao, Y; Gao, F; Li, J; Liao, C, 2011) |
| "We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy." | 4.87 | Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. ( Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM, 2011) |
| " A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia." | 4.83 | Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006) |
| "But fluorouracil (5-FU) and irinotecan (CPT-11 [Camptosar]) have shown activity in metastatic colorectal cancer and are approved for its treatment in the United States." | 4.80 | Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. ( Erlichman, C; Goldberg, RM, 1998) |
| " The model describes stem and progenitor cell dynamics in the small intestinal epithelium and integrates heterogeneous epithelial-related processes, such as transcriptional profiles, citrulline kinetics, and probability of diarrhea." | 4.31 | A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug-induced toxicity. ( Beattie, KA; Chung, SW; Coyle, L; de Kok, TM; Duckworth, CA; Ferreira, S; Gall, L; Jardi, F; Jennen, DGJ; Jo, H; Kelly, C; Lammens, L; Pin, C; Piñero, J; Pritchard, DM; Rodrigues, D; Souza, TM, 2023) |
| "5-fluorouracil (5-FU) is an antineoplastic drug used to treat colorectal cancer, but it causes, among other adverse effects, diarrhea and mucositis, as well as enteric neuropathy, as shown in experimental animals." | 4.31 | Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat. ( Abalo, R; Girón, R; López-Gómez, L; Martín-Fontelles, MI; Nurgali, K; Uranga, JA; Vera, G, 2023) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 4.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| " polysaccharides (PCCL) on 5-fluorouracil-(5-FU)-induced intestinal mucositis (IM) in mice." | 4.12 | Protective effect of polysaccharides isolated from the seeds of Cuscuta chinensis Lam. on 5-fluorouracil-induced intestinal mucositis in mice. ( Chen, Z; Ji, Y; Lu, H; Luo, R; Tan, W; Tian, C; You, Y; Zhao, X; Zhou, L; Zhou, W; Zhou, X, 2022) |
| " We evaluated the effect of WMP on CIM by observing the general conditions of the mice (body weight, food intake, spleen weight, diarrhea score, and hematoxylin and eosin stained tissues)." | 4.12 | Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation. ( Chen, BY; Liu, F; Liu, HX; Lu, DX; Lu, Y; Sun, ZG; Wu, H; Yan, J, 2022) |
| " Reactive oxygen species (ROS) have been reported to be involved in the induction of intestinal mucositis and diarrhea, which are common side effects of treatment with fluoropyrimidine 5-fluorouracil (5-FU)." | 4.02 | Oral administration of cystine and theanine attenuates 5-fluorouracil-induced intestinal mucositis and diarrhea by suppressing both glutathione level decrease and ROS production in the small intestine of mucositis mouse model. ( Kurihara, S; Nishikawa, S; Yoneda, J, 2021) |
| "6-μm laser moxibustion and electroacupuncture in 5-fluorouracil (5-Fu)-induced diarrhea model rats." | 4.02 | Effects of 10.6-μm laser moxibustion and electroacupuncture at ST36 in a 5-Fu-induced diarrhea rat model. ( Cheng, H; Ju, Z; Mao, H; Qin, M; Shen, X; Wang, F; Zhao, L, 2021) |
| "Female patients and patients aged sixty-five or older had an increased risk of developing severe diarrhea during preoperative chemoradiation therapy with capecitabine." | 4.02 | Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study. ( Hartman, W; Nuyttens, JJME; Oomen-de Hoop, E; Rothbarth, J; van Meerten, E; van Rees, JM; van Vugt, JLA; Verhoef, C, 2021) |
| "The study aimed to explore the efficacy of pharmacokinetic-based 5-fluorouracil dose management by plasma concentration test in advanced colorectal cancer treatment." | 3.96 | Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment. ( Deng, R; Guan, X; Shen, B; Shi, L; Wang, M; Yang, D; Zhu, W, 2020) |
| " Normal adjacent gut epithelium tissue was collected during resection surgery from a cohort of 35 patients with stage II-III colorectal cancer (CRC) who were subsequently treated with capecitabine, XELOX or FOLFOX." | 3.96 | Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea. ( Bacon, O; Burke, JP; Carberry, S; Choudhry, A; Cremona, M; Doherty, G; Hennessy, BT; Lee, CS; Lindner, AU; McNamara, D; Oficjalska, K; Prehn, JHM; Resler, AJ; Ryan, EJ; Sheahan, K, 2020) |
| "oil in treating 5-fluorouracil (5-FU)-induced intestinal mucositis have not yet been reported." | 3.96 | Patchouli oil ameliorates 5-fluorouracil-induced intestinal mucositis in rats via protecting intestinal barrier and regulating water transport. ( Ai, G; Chen, L; Gan, Y; Huang, Q; Huang, X; Li, M; Liu, Y; Luo, H; Su, Z; Wu, J; Wu, X; Xu, N, 2020) |
| "Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients." | 3.96 | Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020) |
| "5-Fluorouracil (5-FU)-induced intestinal mucositis (IM) is one of the most common oncological problem." | 3.91 | Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model. ( Ali, H; Ali, J; Islam, SU; Khan, AU; Khan, S; Kim, YS; Shah, FA, 2019) |
| "To investigate therapeutic effects and mechanism of Atractylodes macrocephala essential oil (AMO) and Panax ginseng total saponins (PGS) alone and in combination (AP) on 5-fluorouracil (5-FU) chemotherapy induced diarrhea in mice." | 3.91 | Ameliorative effect of Atractylodes macrocephala essential oil combined with Panax ginseng total saponins on 5-fluorouracil induced diarrhea is associated with gut microbial modulation. ( Ao, H; Chen, L; Feng, W; He, J; Peng, C; Sheng, Y; Tang, F; Wang, J; Xu, X; Zhang, S, 2019) |
| "5-Fluorouracil (5-FU)-based chemotherapy often causes several drawbacks including weight loss, diarrhea, myelosuppression, and the intestinal mucositis." | 3.91 | Qingjie Fuzheng Granule attenuates 5-fluorouracil-induced intestinal mucosal damage. ( Chen, W; Jin, Y; Lin, J; Lisha, L; Peng, J; Zhang, L, 2019) |
| "Cholinergic syndrome is an acute adverse reaction associated with irinotecan." | 3.88 | Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis. ( Hosokawa, T; Ishikawa, T; Kanazawa, M; Kanbayashi, Y; Kawano, R; Nakajima, Y; Tabuchi, Y; Taguchi, T; Takayama, K; Yoshida, N; Yoshioka, T, 2018) |
| "The chemotherapeutic agent 5-fluorouracil (5-FU) causes intestinal mucositis with severe diarrhoea, but the pathogenesis is not fully understood." | 3.85 | Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Amagase, K; Hamouda, N; Higuchi, K; Kato, S; Matsumoto, K; Oikawa, Y; Ozaki, T; Sano, T; Shimakawa, M, 2017) |
| " 5-Fluorouracil (5-FU), widely used for cancer chemotherapy, is known to frequently induce intestinal mucositis accompanied by severe diarrhoea." | 3.85 | Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. ( Amagase, K; Hamouda, N; Kano, Y; Kato, S; Matsumoto, K; Oikawa, Y; Shimakawa, M; Tanaka, Y, 2017) |
| "5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents." | 3.85 | Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017) |
| "5-Fluorouracil (5-FU) is widely used as an anti cancer drug and is known to cause severe diarrhea." | 3.85 | Active Ingredients of Hange-shashin-to, Baicalelin and 6-Gingerol, Inhibit 5-Fluorouracil-Induced Upregulation of CXCL1 in the Colon to Attenuate Diarrhea Development. ( Isa, Y; Kai, Y; Kimura, M; Miyano, K; Narita, M; Sakai, H; Sato, F; Tabata, S; Uezono, Y; Yabe, S; Yumoto, T, 2017) |
| "Wei-Chang-An pill (WCA pill), a traditional Chinese pharmaceutical preparation, possessed potential anti-inflammatory advantages and noteworthy gastrointestinal regulations in digestive diseases, which might represent a promising candidate for the treatment of intestinal mucositis (IM) induced by 5-fluorouracil (5-FU)." | 3.83 | Protective effect and potential mechanisms of Wei-Chang-An pill on high-dose 5-fluorouracil-induced intestinal mucositis in mice. ( Chen, Y; Gao, W; Jin, Z; Wang, L; Zhang, J; Zheng, H, 2016) |
| " This gene codifies for the target enzyme of 5-fluorouracil (5-FU), the basic treatment in colorectal cancer." | 3.81 | Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS. ( Balboa-Beltrán, E; Barros, F; Carracedo, A; Duran, G; Lamas, MJ, 2015) |
| "Chemotherapy-induced mucositis (CIM) is a major does limiting side-effect of chemoagents such as 5-fluorouracil (5-FU)." | 3.80 | Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil. ( Gao, J; Han, W; Qian, L; Wang, X; Wu, M; Ye, H; Yu, Y; Zhang, Y; Zhu, S, 2014) |
| "Diarrhea is a common side effect experienced by cancer patients undergoing clinical chemotherapy, such as with 5-fluorouracil (5-FU)." | 3.80 | Neutrophil recruitment is critical for 5-fluorouracil-induced diarrhea and the decrease in aquaporins in the colon. ( Hirosaki, A; Horie, S; Ikegami, D; Jo, A; Matoba, M; Matsumoto, K; Narita, M; Sagara, A; Sakai, H; Sato, K; Sugiyama, R; Takase, K, 2014) |
| "This study is aimed to identify clinical predictors, other than HER2 overexpression, for the response to lapatinib plus capecitabine (LAPCAP) in patients with HER2-positive advanced breast cancer (HER2ABC)." | 3.80 | Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. ( Akiyama, F; Araki, K; Fukada, I; Horii, R; Ito, Y; Iwase, T; Takahashi, S, 2014) |
| "Hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and cisplatin for intractable advanced hepatocellular carcinoma (HCC) may have survival benefits." | 3.79 | Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. ( Lee, HJ; Lee, SH; Oh, MJ, 2013) |
| "Chemotherapeutic agents, including 5-fluorouracil (5-FU), frequently cause intestinal mucositis resulting in severe diarrhoea and morphological mucosal damage." | 3.79 | 5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells. ( Amagase, K; Horie, S; Iimori, M; Kato, S; Kitahara, Y; Matsumoto, K; Takeuchi, K; Utsumi, D; Yamanaka, N; Yasuda, M, 2013) |
| "Although the mechanisms of 5-fluorouracil (5-FU)-induced diarrhea remain unclear, accumulating evidence has indicated that changes in the mucosal immune system and aquaporins (AQPs) may play a role in its pathogenesis." | 3.79 | 5-Fluorouracil induces diarrhea with changes in the expression of inflammatory cytokines and aquaporins in mouse intestines. ( Hasegawa, S; Horie, S; Matsumoto, K; Nakagawa, T; Narita, M; Nishizaki, M; Sagara, A; Sakai, H; Sato, K; Shoji, T; Tokuyama, S, 2013) |
| "In Nordic countries, the standard treatment of colorectal cancer (CRC) in the adjuvant setting is bolus 5-fluorouracil (5-FU) plus leucovorin alone or in combination with oxaliplatin." | 3.78 | Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy. ( Carlsson, G; Gustavsson, B; Odin, E; Wettergren, Y, 2012) |
| ", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, it was suggested that leukopenia, neutropenia, and thrombocytopenia were more frequently accompanied by the use of 5-FU than capecitabine, whereas diarrhea, nausea, vomiting, and hand-foot syndrome were more frequently associated with capecitabine." | 3.78 | Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. ( Brown, JB; Kadoyama, K; Miki, I; Okuno, Y; Sakaeda, T; Tamura, T, 2012) |
| "The patients with local advanced and metastatic colorectal cancer, receiving fluorouracil-based chemotherapy, and with an average plasma concentration of fluorouracil between 25 - 35 mg/L have a better prognosis, and lower incidence of adverse reactions such as bone marrow suppression, mucositis and diarrhea." | 3.78 | [Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ( Cai, X; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2012) |
| "We examined the feasibility of regimen selection for first-line irinotecan, 5-fluorouracil and leucovorin or oxaliplatin, 5-fluorouracil and leucovorin in Japanese patients with advanced colorectal cancer based on UDP-glucuronosyltransferase 1A1 genotype as well as physical status of patients related to diarrhea." | 3.77 | Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer. ( Akiyama, Y; Ando, Y; Fujita, K; Ichikawa, W; Ishida, H; Kawara, K; Miwa, K; Mizuno, K; Saji, S; Sasaki, Y; Sunakawa, Y; Yamashita, K, 2011) |
| "Diarrhea is a side effect of a 5-fluorouracil (5-FU) anti-cancer drug-induced intestinal mucosal disorder, which sometimes becomes more severe." | 3.77 | [Diamine oxidase as blood biomarker in rats and humans to GI tract toxicity of fluorouracil anti-cancer drugs]. ( Goto, T; Kouchi, Y; Matsubara, T; Moriyama, K; Nemoto, H; Sanada, Y; Sasaya, S; Yoshizawa, Y, 2011) |
| " The aim of the present report was to evaluate real-life drug adherence in a prospective cohort analysis of patients with gastrointestinal or breast cancer treated with capecitabine-based chemotherapy." | 3.77 | Self-reported compliance with capecitabine: findings from a prospective cohort analysis. ( Bressoud, A; Delmore, G; Hermann, F; Hoesli, P; Pederiva, S; von Moos, R; Winterhalder, R, 2011) |
| "To evaluate retrospectively the efficacy and toxicity of capecitabine-based chemotherapy in the treatment of advanced breast cancer." | 3.77 | [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer]. ( Bian, L; Cao, Y; Huang, HY; Jiang, ZF; Song, ST; Wang, T; Wu, SK; Zhang, SH, 2011) |
| " Toxicity (primarily gastrointestinal) necessitated dosage modification in 10 patients (29%)." | 3.77 | Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review. ( Balaban, EP; Bull, J; Frenkel, EP; Graham, M; Periman, P; Perkins, S; Pruitt, B; Ross, M; Ruud, C; Sheehan, RG, 1994) |
| "This study demonstrates that CR3294 acts on key molecular targets to reduce the signs of mucositis and the occurrence of diarrhea in mice exposed to the chemotherapy drug 5-fluorouracil." | 3.76 | Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. ( Bonazzi, A; Booth, C; Caselli, G; Garofalo, P; Letari, O; Makovec, F; Rovati, LC, 2010) |
| "Accurate description of current practice within advanced colorectal cancer (CRC) specialties were needed to inform an economic evaluation of the UGT1A1 pharmacogenetic test for irinotecan in the United Kingdom." | 3.76 | Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. ( Elliott, RA; Newman, WG; Payne, K; Shabaruddin, FH; Valle, JW, 2010) |
| "FOLFOX (oxaliplatin/leucovorin/5-fluorouracil) and FOLFIRI (irinotecan/leucovorin/5-fluorouracil) are important regimens for the treatment of advanced-stage colorectal cancer (CRC)." | 3.74 | Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool. ( Dranitsaris, G; Shah, A; Spirovski, B; Vincent, M, 2007) |
| "Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 3.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
| "To characterize diarrhea events in patients with cancer treated with lapatinib as monotherapy or in combination with capecitabine or taxanes." | 3.74 | Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. ( Boyle, F; Burris, HA; Byrne, J; Chan, S; Crown, JP; Jones, S; Koehler, M; Newstat, BO; Oliva, C; Parikh, R; Preston, A, 2008) |
| "70 patients with advanced colorectal cancer were treated with irinotecan and 5-fluorouracil." | 3.74 | [Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients]. ( Bao, HY; Jiao, SC; Li, F; Li, J; Shen, L; Song, ST; Wang, JW; Wang, Y; Xu, JM; Xu, N; Yang, L; Zhang, JS, 2007) |
| "Hepatic arterial infusion chemotherapy with levofolinate (l-leucovorin) and fluorouracil regimen was performed using an implanted port system on unresectable hepatic metastasis patients with colorectal cancer." | 3.73 | [Method of levofolinate.5-FU administration by hepatic arterial infusion therapy for hepatic metastasis from colorectal cancer]. ( Fujino, H; Hata, K; Kitamura, N; Kobuchi, T; Maruhashi, K; Nakamura, T; Shimomatsuya, T; Shiraishi, S, 2006) |
| "Fifty-two consecutive patients with advanced colorectal cancer who developed persistent diarrhea following chemotherapy with 5-fluorouracil despite dose reduction were treated with amifostine 800, 500 or 150 mg/m(2)." | 3.72 | Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study. ( Kosmas, C; Koufos, C; Margaris, H; Papalambros, E; Papantoniou, N; Retalis, G; Rokana, S; Tsavaris, N; Vadiaka, M; Zografos, G; Zonios, D, 2003) |
| "Chemotherapy-induced diarrhea (CID) became first apparent during clinical studies on the combination of 5-FU with leucovorin and, furthermore, with irinotecan in the treatment of metastatic colorectal carcinoma." | 3.72 | [Management of chemotherapy induced diarrhea]. ( Kullmann, F; Schölmerich, J; Schultz, M, 2004) |
| "To retrospectively analyze a clinical experience with a fixed-unit daily dose of capecitabine employed continuously (open ended without cycling) as a single agent, in combination with other agents, or combined with radiation to determine the drug tolerability with regard to stomatitis, diarrhea, and hand/foot syndrome, compared with the "standard" dose schedule." | 3.72 | Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule. ( Lokich, J, 2004) |
| "One hundred and three patients with recurrent adenocarcinoma of the rectum underwent reirradiation with concurrent 5-fluorouracil-based chemotherapy." | 3.71 | Long-term results of reirradiation for patients with recurrent rectal carcinoma. ( Marks, G; Marks, J; Mohiuddin, M, 2002) |
| "5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer." | 3.70 | Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998) |
| " It is the first drug since fluorouracil to possess consistent antitumour activity against metastatic colorectal cancer." | 3.70 | A risk-benefit assessment of irinotecan in solid tumours. ( Rowinsky, EK; Siu, LL, 1998) |
| "The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 3.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
| "For almost 40 years, 5-fluorouracil (5-FU) has been the only useful drug with clinically meaningful activity in metastatic colorectal carcinoma." | 3.70 | Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer. ( Au, E; Khoo, KS; Koo, WH; Lim, WT, 1999) |
| "Diarrhea and oral mucositis are the most frequently reported gastrointestinal side effects caused by 5-fluorouracil (5-FU)." | 3.70 | 5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. ( Fata, F; Kelsen, DP; Kemeny, N; Klimstra, D; O'Reilly, E; Ron, IG, 1999) |
| "In 16 advanced colorectal cancer patients with 5-fluorouracil-associated diarrhea, we evaluated the role of bacterial pathogens in the development of this adverse effect." | 3.69 | Have enteric infections a role in 5-fluorouracil-associated diarrhea? ( Cascinu, S; Catalano, G, 1995) |
| "A total of 44 women with advanced breast cancer who had failed first- and second-line chemotherapy were given combination chemotherapy consisting of folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC)." | 3.68 | Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C. ( Aquino, A; Francini, G; Gonnelli, S; Petrioli, R, 1993) |
| "A prospective trial was conducted involving 16 patients with colorectal adenocarcinoma using a regimen of continuous-infusion octreotide acetate (Sandostatin [octreotide acetate], Sandoz, East Hanover, NJ for the treatment of severe diarrhea induced by the weekly schedule of 5-fluorouracil (5-FU) in combination with leucovorin who were refractory to opiate therapy." | 3.68 | Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. ( Creaven, P; Herrera, L; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, Y, 1993) |
| "In a previous trial in which methotrexate and N-phosphonacetyl-L-aspartate (PALA) were used to modulate 5-fluorouracil (5-FU), four of six patients could not tolerate treatment at the 600 mg/m2 5-FU dose level because of mucositis, diarrhea, and a decrease in performance status." | 3.68 | Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin. ( Colofiore, J; Kemeny, N; Martin, D; Sawyer, R; Schneider, A; Seiter, K; Williams, L, 1993) |
| " In a literature review of all published data of folinic acid and 5-fluorouracil intravenous bolus therapy in colorectal cancer with comparable dose intensity, an attempt was made to characterize the possible differences of the variations of schedules used." | 3.68 | The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer. ( Bokemeyer, C; Poliwoda, H; Schmoll, HJ; Schöber, C; Stahl, M; Wilke, HJ, 1992) |
| "The watery diarrhea-hypokalemia-achlorhydria syndrome associated with ectopic secretion of vasoactive intestinal peptide has only been conclusively documented with tumors originating in the pancreas or sympathetic chain." | 3.67 | Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus. ( Douglas, MC; Hurley, R; Kalnins, R; Moran, L; Shulkes, A; Smallwood, RA; Watson, KJ, 1985) |
| "After perioperative adjuvant chemotherapy of a sigma-adenocarcinoma with 400 mg peptichemio and 500 mg 5-fluorouracil a 61-year-old woman developed a severe intoxication: myelosuppression with pancytopenia, gastroenteritis and ulcerative proctitis, toxic hepato- and myocardiopathy, impaired renal function and alopecia." | 3.66 | [Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)]. ( Gasser, RW; Schmalzl, F, 1982) |
| "We analyzed the incidence, time to first onset, and time to resolution for adverse events that require special attention and other selected toxicities in the nal-IRI combination group (n = 46)." | 3.30 | Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. ( Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M, 2023) |
| " Treatment-emergent adverse events (TEAEs) were evaluated, and HRQL was assessed at baseline, cycle 3, and every other cycle using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-CR29, and EuroQol 5-Dimensions 3-Levels questionnaires (NCT01571284)." | 2.90 | Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). ( Aparicio, J; Bordonaro, R; Bury, D; Chau, I; Cicin, I; Di Bartolomeo, M; Drea, E; Fedyanin, MY; García-Alfonso, P; Heinemann, V; Karthaus, M; Kavan, P; Ko, YJ; Maiello, E; Martos, CF; Peeters, M; Picard, P; Riechelmann, RP; Sobrero, A; Srimuninnimit, V; Ter-Ovanesov, M; Yalcin, S, 2019) |
| "vomiting, anorexia and infection) were recorded, and short-term effect of chemotherapy was evaluated regularly." | 2.84 | Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms. ( Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L, 2017) |
| " The objective of this systematic review/meta-analysis was to evaluate treatment outcomes between Pharmacogenetics Guided Dosing (PGD) versus non-PGD and within PGD (DPYD variant allele carriers versus wild type)." | 2.82 | A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. ( Alexander, M; Brennan, A; Glewis, S; Khabib, MNH; Lazarakis, S; Lingaratnam, S; Martin, J; Michael, M; Tie, J, 2022) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 2.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| " Toxicities are described per treatment arm according to the Common Toxicity Criteria for Adverse Events version 4." | 2.82 | Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. ( Dezentjé, VO; Honkoop, AH; Kemper, I; Linn, SC; Mandjes, IA; Oving, IM; Smorenburg, CH; Sonke, GS; Stouthard, JM; van Ramshorst, MS; van Werkhoven, E, 2016) |
| "Stage II and III rectal cancer patients received, after total mesorectal excision, 2 cycles of XELOX regimen (oxaliplatin 130 mg/m(2) on day 1; capecitabine 1000 mg/m(2) bid on day 1 to 14, q21), followed by capecitabine (800 mg/m(2) bid daily; 20% dose at 12:00 AM and 80% dose at 12:00 PM) administered continuously during pelvic radiation (total 50." | 2.79 | Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. ( Bajetta, E; Biondani, P; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Formisano, B; Gevorgyan, A; Grassi, P; Mariani, L; Pietrantonio, F; Valvo, F, 2014) |
| "Twenty-one Japanese colorectal cancer patients received intravenous FOLFIRI (bolus irinotecan, folinic acid, and fluorouracil followed by 46-hour fluorouracil infusion) followed by bevacizumab (5 mg/kg) in Cycle 1." | 2.79 | Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ( Doi, T; Fuse, N; Hamamoto, Y; Hatake, K; Iwasaki, J; Matsumoto, H; Mizunuma, N; Motomura, S; Ohtsu, A; Suenaga, M; Yamaguchi, T; Yamanaka, Y, 2014) |
| "In 2594 patients with complete adverse event (AE) data, the incidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88." | 2.79 | DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). ( Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA, 2014) |
| "The purpose of this study was to investigate the association between single nucleotide polymorphism (SNP) of CCND1 A870G and acute adverse events (AEs) in postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT)." | 2.78 | [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy]. ( DU, ZL; Huang, Y; Jin, J; Li, YX; Lin, DX; Qiao, Y; Ren, H; Tan, W; Yu, DK, 2013) |
| "Capecitabine was administered orally twice a day at a dose of 1, 250 mg/m(2) for 14-day followed by 7-day rest and oral thalidomide 100 mg was given daily without interruption until disease progression or occurrence of unacceptable toxicity." | 2.78 | [Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer]. ( Li, CH; Ma, TH; Shi, SB; Tang, XY, 2013) |
| "Sixty breast cancer patients undergoing an FEC60 regimen were enrolled, 37 patients completed the study." | 2.78 | The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. ( Campanella, G; Clemente, C; D'Attoma, B; Giotta, F; Linsalata, M; Orlando, A; Riezzo, G; Russo, F, 2013) |
| "Patients with T3 to T4 and/or N+ rectal cancer received preoperative IMRT (47." | 2.77 | Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. ( Arbea, L; Aristu, J; Cambeiro, M; Chopitea, A; Díaz-González, JA; García-Foncillas, J; Gaztañaga, M; Hernández, JL; Martínez-Monge, R; Moreno, M; Nuñez, J; Ramos, LI; Rodríguez, J; Sola, JJ; Subtil, JC, 2012) |
| "Patients with T3/T4 or node positive rectal cancer were treated with capecitabine 1,000 mg/m(2) twice daily (BID) days 1-14, and irinotecan 200 mg/m(2) on day 1 every 21 days for 2 cycles, followed by capecitabine 825 mg/m(2) BID days 1-5 per week with concurrent radiotherapy 50." | 2.77 | Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. ( Bufill, J; Burns, M; Cardenes, H; Chiorean, EG; Clark, R; Coleman, N; Curie, C; Hinkle, DT; LeBlanc, J; Loehrer, PJ; Robb, B; Sanghani, S; Schiel, MA; Tong, Y; Yu, M, 2012) |
| "Gemcitabine was administered intravenously at 1,000 mg/m(2)/week (days 1, 8 and 15) and oral capecitabine from day 1 to day 21 at 1,660 mg/m(2)/day." | 2.77 | Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study. ( Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H, 2012) |
| "To evaluate the efficacy and safety of weekly paclitaxel combined with S-1 or fluorouracil in the first line treatment of advanced gastric carcinoma." | 2.77 | [A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012) |
| " Most frequent drug-related adverse events were hand-foot skin reaction (HFSR, 89%), diarrhea (71%), and fatigue (69%)." | 2.76 | Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. ( Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N, 2011) |
| "Grade 3-4 toxicity during neoadjuvant treatment was diarrhea (38." | 2.76 | Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). ( Aprile, G; Aschele, C; Bardelli, A; Bochicchio, A; Di Fabio, F; Garufi, C; Giaquinta, S; Gion, M; Latiano, T; Maiello, E; Martoni, A; Pini, S; Pinto, C; Rosati, G; Torri, V, 2011) |
| "To observe and compare the response rate and toxicity of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer." | 2.76 | [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. ( Chen, DY; Qi, Q; Zhao, WY, 2011) |
| "Results of this small pilot study in rectal cancer patients receiving preoperative radiochemotherapy, showed that ingestion of larger quantities of glutamine given more often as previously reported did not diminish the incidence and severity of diarrhoea and did not affect inflammatory and metabolic activity compared to the placebo treatment with maltodextrin." | 2.76 | Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. ( Anderluh, F; Kompan, L; Mlakar Mastnak, D; Možina, B; Oblak, I; Rotovnik Kozjek, N; Soeters, P; Velenik, V; Zadnik, V, 2011) |
| "Celecoxib dosage was fixed." | 2.75 | A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. ( Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I, 2010) |
| "Preoperative treatment of rectal cancer with combined chemotherapy and radiation therapy has become a widely accepted strategy." | 2.75 | A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer. ( Chang, M; George, TJ; Grobmyer, S; Hochwald, S; King, J; Larson, B; Marsh, Rde W; Mendenhall, WM; Siddiqui, T; Zlotecki, RA, 2010) |
| " Main adverse events grades 2/3/4 were (n): leukocytopenia 3/2/2, anemia 13/4/0, thrombocytopenia 3/1/0, nausea/vomiting 2/1/0, diarrhea 5/1/0, hand-foot-skin reaction 7/0/0." | 2.75 | Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma. ( Ernst, T; Hochhaus, A; Hofheinz, RD; Hofmann, WK; Kripp, M; Kruth, J; Lukan, N; Merx, K; Nissen, J, 2010) |
| "5, or 50 mg) was administered orally once daily on three dosing schedules: 4 weeks on treatment, 2 weeks off treatment (Schedule 4/2); 2 weeks on treatment, 1 week off treatment (Schedule 2/1); and continuous daily dosing (CDD schedule)." | 2.75 | A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. ( Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF, 2010) |
| "To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer." | 2.74 | Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. ( Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C, 2009) |
| " Follow-up for potential delayed adverse effects and efficacy is ongoing." | 2.74 | Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. ( Allegra, CJ; Atkins, JN; Azar, CA; Chu, L; Colangelo, LH; Fehrenbacher, L; Goldberg, RM; Lopa, SH; O'Connell, MJ; O'Reilly, S; Petrelli, NJ; Seay, TE; Sharif, S; Wolmark, N; Yothers, G, 2009) |
| " This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients." | 2.74 | [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. ( Dong, NN; Liu, ZF; Wang, MY; Zhang, Q, 2009) |
| " Patients exhibited high compliance in dosing administration." | 2.74 | Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy. ( Akhmadullina, LI; Barker, NP; Davidenko, IS; Firsov, I; Gertner, JM; Gotovkin, EA; Kopp, MV; Kulikov, EP; Moiseyenko, VM; Peterson, DE; Rakovskaya, GN; Rodionova, I; Sherman, NZ; Shinkarev, SA; Tuleneva, T; Woon, CW; Yarosh, A, 2009) |
| "Our results show that the regimen of gemcitabine combined with capecitabine is effective and well tolerated in patients with unresectable relapsed or metastatic carcinoma of the biliary tract." | 2.73 | [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma]. ( Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY, 2008) |
| "Capecitabine was administered at a dose of 1,250 mg/m(2) bid for 14 consecutive days in 3-week cycles, with dose modifications if necessary." | 2.73 | Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. ( Altorjai, G; Bartsch, R; Gnant, M; Mader, RM; Pluschnig, U; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC, 2007) |
| "A total of 60 patients with rectal cancer (T3-T4 or N+, M1 allowed) entered the trial at five investigator sites; the data from 58 patients were assessable." | 2.73 | Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. ( Arnold, D; Dellas, K; Hermann, RM; Hinke, A; Hipp, M; Hohenberger, W; Iesalnieks, I; Liersch, T; Lordick, F; Rödel, C; Sauer, R, 2008) |
| "Patients diagnosed with colorectal cancer (n=150) were randomly allocated to receive monthly 5-FU and leucovorin bolus injections (the Mayo regimen) or a bimonthly 5-FU bolus plus continuous infusion (the simplified de Gramont regimen) for 24 weeks as postoperative adjuvant therapy." | 2.73 | Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. ( Elomaa, I; Joensuu, H; Korpela, R; Kouri, M; Ollus, A; Osterlund, P; Ruotsalainen, T; Saxelin, M; Valta, P, 2007) |
| " In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
| "Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor." | 2.73 | Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. ( Antimi, M; Antonuzzo, L; Arcangeli, A; Banducci, S; Bellini, V; Biagioni, F; Bianchini, D; Bilancia, D; Bisagni, G; Biscottini, B; Boni, C; Bracci, R; Bravi, S; Bruno, L; Cabassi, A; Camera, S; Camisa, R; Canaletti, R; Carboni, M; Carlini, P; Carroccio, R; Cascinu, S; Catalano, G; Catalano, V; Cavalli, C; Cesari, M; Cognetti, F; Contu, A; Corgna, E; Cortesi, E; Croce, E; Dalla Mola, A; De Filippis, S; De Stefanis, M; Di Costanzo, F; Dinota, A; Enzo, MR; Farris, A; Figoli, F; Floriani, I; Foa, P; Fornarini, G; Francavilla, F; Frignano, M; Gasperoni, S; Gilli, G; Giunta, A; Grigniani, F; Ionta, MT; Italia, M; Labianca, R; Lastraioli, E; Leoni, M; Lungarotti, F; Luppi, G; Manzione, L; Masoni, L; Massidda, B; Mela, M; Messerini, L; Monzio Compagnoni, B; Muscogiuri, A; Natalini, G; Nelli, F; Nicolosi, A; Oldani, S; Olgiati, A; Olivetti, A; Orselli, G; Pandolfi, U; Papiani, G; Pazzola, A; Piga, A; Pisani Leretti, A; Porrozzi, S; Recchia, F; Romiti, A; Rondini, E; Rossetti, R; Rovei, R; Saggese, M; Sarobba, MG; Scipioni, L; Strafiuso, G; Tomao, S; Tonato, M; Torri, V; Trignano, M; Zironi, S, 2008) |
| "Patients with colorectal cancer (CRC) and liver metastases have a poor prognosis, but can benefit from perioperative chemotherapy and disease resection." | 2.73 | Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. ( Gruenberger, B; Gruenberger, T; Herbst, F; Scheithauer, W; Schueller, J; Tamandl, D; Zielinski, C, 2008) |
| "Capecitabine was administered concurrently with RT in escalating doses, twice daily with a 12-h interval, for two cycles of 14 days separated by a 7-day rest." | 2.72 | A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer. ( Jin, J; Li, N; Li, T; Li, YX; Liu, XF; Liu, YP; Song, YW; Wang, WH; Yu, ZH, 2006) |
| " The most frequent common adverse events were nausea, Grades 1 - 2 in 13 patients (81." | 2.72 | Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. ( Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Wedding, U, 2006) |
| " CPT-11 (50 mg/m(2) weekly) and 5-FU (225 mg/m(2)/day continuous infusion, 5 days/week) were concurrently administered with radiation therapy (RT) (45 Gy, 1." | 2.72 | A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. ( Aranda, E; Cervantes, A; Dotor, E; Gallén, M; García, JL; Navarro, M; Rivera, F; Sánchez-Rovira, P; Vega-Villegas, ME, 2006) |
| "169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B)." | 2.72 | Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. ( Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N, 2006) |
| " A phase I, open-label dose-escalating study was performed to determine the maximum tolerated dose (MTD) of BBR 3464 administered in combination with protracted venous infusional (PVI) 5-fluorouracil (5-FU) for up to six courses in patients with locally advanced and/or metastatic cancer." | 2.71 | A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. ( Bisset, D; Boyle, D; Camboni, G; Cassidy, J; Edwards, C; Gourley, C; Jodrell, D; Samuel, L; Young, A, 2004) |
| "Preoperative chemoradiotherapy in rectal cancer using chronomodulated 5-FU and LV is feasible." | 2.71 | Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer. ( Berry, S; Bjarnason, GA; Davey, P; de Marsh, RW; Mendenhall, W; Parulekar, W; Rout, WR; Wong, R; Zlotecki, R, 2004) |
| "Grade 2/3 neutropenia was observed in 4 (3%) treatment cycles." | 2.71 | Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. ( Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N, 2004) |
| "Capecitabine (Xeloda) is a novel, oral, selectively tumor-activated fluoropyrimidine with proven activity in the treatment of advanced colorectal cancer." | 2.71 | A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. ( Cho, JY; Choi, SH; Chung, HC; Han, JY; Hong, YS; Kang, JH; Lee, KS; Lee, SI; Noh, SH; Park, JN; Song, SY, 2004) |
| "Patients with previously untreated esophageal cancer were eligible if they had performance status 0-1, were 75 years or younger and had adequate organ function." | 2.71 | Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer. ( Fujitani, K; Hirao, M; Tsujinaka, T, 2004) |
| "Advanced pancreatic cancer has limited treatment options." | 2.71 | Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer. ( Baranda, J; Garcia, AA; Leichman, CG; Leichman, L; Lenz, HJ; Pandit, L, 2003) |
| "Capecitabine was administered in twice daily divided doses, and CI-994 was given as a single daily dose." | 2.71 | A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. ( Janisch, L; Kimmel, KA; Kindler, HL; Macek, TA; Olson, SC; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ, 2004) |
| "Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever." | 2.71 | A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005) |
| "Four of 22 patients with colorectal cancer had partial responses, two of which had prior bolus CPT-11/5-FU." | 2.71 | A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors. ( Fioravanti, S; Grem, JL; Guo, X; Harold, N; Hopkins, JL; Leguizamo, JP; Leonard, GD; Lin, P; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Saif, MW; Schuler, B; Szabo, E; Wright, MA, 2005) |
| "5-Fluorouracil (5FU) is an antimetabolite that interferes with DNA synthesis." | 2.70 | Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies. ( Devereux, L; Goldberg, J; Grana, G; Hageboutros, A; Khatri, J; Rodman, WD; Sbar, EI; Tritschler, L, 2002) |
| "Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)." | 2.70 | Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. ( Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002) |
| "Nine patients with colorectal cancer and one with gastric cancer had partial or minor responses." | 2.70 | A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin. ( Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Kaufmann, SH; Miller, LL; Pitot, HC; Rubin, J; Sloan, JA, 2002) |
| " We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma." | 2.70 | Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002) |
| "Capecitabine is a novel fluoropyrimidine carbamate, orally administered and selectively activated to fluorouracil by a sequential triple-enzyme pathway in liver and tumor cells." | 2.70 | Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. ( Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC, 2002) |
| " Pharmacokinetic parameters of capecitabine and its metabolites (5'-deoxy-5-fluorouridine, 5-fluorouracil and alpha-fluoro-beta-alanine) were similar to those reported by other authors." | 2.70 | Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics. ( Budd, GT; Bukowski, R; Chang, DZ; Ganapathi, R; Olencki, T; Osterwalder, B; Peereboom, D, 2001) |
| ", Carlsbad, CA) when administered in combination with 5-fluorouracil (5-FU) and leucovorin (LV)." | 2.70 | Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. ( Dorr, FA; Geary, RS; Holmlund, JT; Kindler, HL; Kunkel, K; Mani, S; Ratain, MJ; Rudin, CM, 2002) |
| "Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay." | 2.69 | Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998) |
| "Thirty-six advanced or metastatic gastric cancer and chemotherapy-naïve patients with measurable or evaluable diseases were scheduled to receive intravenous etoposide 100 mg/m2/day on days 2-4, LV 300 mg/m2/day intravenously and 5-FU 500 mg/m2/day intravenously on days 1-5, every 4 weeks." | 2.69 | Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer. ( Chen, PM; Chiou, TJ; Fan, FS; Hsieh, RK; Liu, JH; Tung, SL; Wang, WS; Yen, CC, 1998) |
| " The recommended 5-FU dosage for phase II evaluations is 1,250 mg/m(2)/wk for 3 weeks every 4 weeks with the intensified PN401 dose schedule (schedule 2)." | 2.69 | Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. ( Campbell, E; Davidson, K; Diab, SG; Drengler, RL; Eckhardt, SG; Garner, AM; Hammond, LA; Hidalgo, M; Louie, A; O'Neil, JD; Rodriguez, G; Rowinsky, EK; Villalona-Calero, MA; von Borstel, R; Von Hoff, DD; Weiss, G, 2000) |
| " infusion of 5FU in patients with advanced solid tumors to determine the maximum tolerated dose, the recommended dose for Phase II studies, and the safety and pharmacokinetic profiles of this combination." | 2.69 | A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors. ( Bartholomeus, S; Bleiberg, H; Brassinne, C; Cazenave, I; de Valeriola, D; Hennebert, P; Kerger, J; Kusenda, Z; Lefresne-Soulas, F; Piccart, M; Selleslags, J; Van Den Neste, E; Wythouck, H, 2000) |
| "To determine the dose-limiting toxicity of CPT-11 in combination with oxaliplatin, and the maximal tolerated dose (MTD) and the recommended dose (RD) of CPT-11 using an every two weeks schedule." | 2.69 | Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients. ( Cvitkovic, E; Di Palma, M; Goldwasser, F; Gross-Goupil, M; Marceau-Suissa, J; Misset, JL; Tigaud, JM; Wasserman, E; Yovine, A, 2000) |
| " l-LV was administered intravenously by a 2-hour infusion at a dosage of 250 mg/m2 and 5-FU at a dosage of 600 mg/m2, intravenously via bolus one hour after administration of l-LV had been started." | 2.68 | [A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Hirabayashi, N; Kurihara, M; Nakano, S; Ohno, T; Ohta, J; Ohtani, T; Taguchi, T; Takeda, S; Yonemura, Y, 1995) |
| " Dosing decisions in older patients are difficult and must integrate assessments of organ function, comorbidities, overall physical status, and goals of treatment, in an effort to ensure the best possible outcome for these patients." | 2.68 | Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. ( Arcangeli, G; Douglass, HO; Driscoll, DL; Meropol, NJ; Petrelli, NJ; Stein, BN, 1995) |
| "Diarrhea was dose-limiting; 6/13 patients had grade II or worse diarrhea at 2,600 mg/m2." | 2.68 | Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer. ( Brennan, J; Hageboutros, A; Hudes, GR; LaCreta, FP; McAleer, C; Newman, EM; O'Dwyer, PJ; Ozols, RF; Rogatko, A, 1995) |
| "Stomatitis was seen more in arm B and C than in arm A." | 2.68 | [A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group]. ( Akazawa, S; Konishi, T; Kumai, K; Kurihara, M; Ogawa, M; Ogawa, N; Ota, K; Sasaki, T; Taguchi, T; Tominaga, T, 1995) |
| "To determine the most effective dose of leucovorin (folinic acid [FA]) within a weekly bolus fluorouracil (FU) schedule, we conducted a randomized multicenter trial to compare therapeutic effects and toxicity of high-dose FA versus low-dose FA combined with FU at equal doses in both treatment groups." | 2.68 | Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1. ( Bernhard, G; Bernhard, H; Heike, M; Jäger, E; Klein, O; Knuth, A; Lautz, D; Meyer zum Büschenfelde, KH; Michaelis, J, 1996) |
| "Diarrhea was less frequent (p = 0." | 2.68 | A phase II study of oral fluorouracil for gastrointestinal cancer. ( Cartei, F; Cartei, G; Giraldi, T; Imperato, A; Interlandi, G; Meneghini, G; Tabaro, G; Vigevani, E, 1996) |
| " On day 1 of treatment, CPT-11 alone was given by 90-minute infusion, and pharmacokinetic sampling was performed over 24 hours." | 2.68 | Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. ( Berkery, R; Dietz, A; Eng, M; Kanowitz, J; Kelsen, DP; Kemeny, NE; Locker, P; Saltz, LB; Schaaf, L; Spriggs, D; Staton, BA; Steger, C, 1996) |
| "Levamisole was administered orally (days 1-3 and 15-17) at doses from 30 to 470 mg/m2 per day." | 2.68 | A phase I study of 5-fluorouracil, leucovorin and levamisole. ( Alberti, D; Arzoomanian, R; Carbone, P; Cleary, JF; Feierabend, C; Storer, B; Wilding, G; Witt, P, 1997) |
| "Grade 4 leukopenia was observed in 1 case and grade 3 to 4 thrombocytopenia was observed in two cases, respectively." | 2.68 | The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD). ( Antón-Torres, A; Aranda, E; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fernández-Martos, C; Massutí, T, 1996) |
| "Therapy for metastatic breast cancer has not improved significantly in recent years." | 2.68 | Metastatic breast cancer: treatment with fluorouracil-based combinations. ( Klaassen, U; Seeber, S, 1997) |
| " Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day." | 2.68 | Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. ( Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996) |
| "Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival." | 2.67 | Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: a phase II study. ( Ackland, SP; Bonaventura, A; Cooper, SG; Denham, JW; Hamilton, CS; Joseph, DJ; Stewart, JF, 1993) |
| " The pharmacokinetic interaction between alpha-IF and LV may play a role in the activity of this regimen." | 2.67 | Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin. ( Buter, J; de Vries, EG; Mulder, NH; Roenhorst, HW; Sinnige, HA; Sleijfer, DT; Uges, DR; Verschueren, RC; Willemse, PH, 1993) |
| "Among patients with primary head and neck cancer, the stage of the disease influenced the response rate." | 2.65 | Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer. ( Archibald, SD; Browman, GP; Hryniuk, WM; Kiehl, K; Levine, MN; Russell, R; Young, JE, 1983) |
| "Thirty patients with recurrent squamous cell carcinoma of the head and neck were treated with methotrexate (250 mg/m2) followed 1 hour later by 5-FU (600 mg/m2)." | 2.65 | Use of methotrexate and 5-FU for recurrent head and neck cancer. ( Jacobs, C, 1982) |
| "To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings." | 2.53 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016) |
| "Chemotherapy-induced diarrhea (CID) is a common and often severe side effect experienced by colorectal cancer (CRC) patients during their treatment." | 2.50 | Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation. ( Doherty, GA; Lee, CS; Ryan, EJ, 2014) |
| "Capecitabine has become a standard treatment option for metastatic breast cancer, as a single agent or in combination." | 2.50 | Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature. ( Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M, 2014) |
| "Treatment with capecitabine is characterized by an increased risk of severe diarrhoea, mainly in patients affected by CRC and treated with polichemotherapy." | 2.50 | Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. ( de Braud, F; Di Bartolomeo, M; Iacovelli, R; Maggi, C; Palazzo, A; Pietrantonio, F; Ricchini, F, 2014) |
| "Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration." | 2.46 | Update on capecitabine alone and in combination regimens in colorectal cancer patients. ( Azzariti, A; Cinieri, S; Colucci, G; De Vita, F; Lorusso, V; Maiello, E; Millaku, A; Numico, G; Petriella, D; Pisconti, S; Russo, A; Santini, D; Silvestris, N; Tommasi, S, 2010) |
| "Combinations for metastatic breast cancer that appear in recently approved labeling include ixabepilone with capecitabine, and the targeted biological agent lapatinib in combination with capecitabine." | 2.45 | Current combination chemotherapy regimens for metastatic breast cancer. ( Schwartz, J, 2009) |
| "Lapatinib is a dual tyrosine kinase inhibitor selective for inhibition of epidermal growth factor receptor (EGFR1/ErbB1) and HER2/ErbB2." | 2.45 | [Lapatinib treatment-option in trastuzumab-resistant breast cancer]. ( Pikó, B, 2009) |
| " Many drugs have been used for the treatment of this disease, but there is little information about how predictive factors can be used to aid treatment response and anticipate toxic effects related to anticancer treatment in colorectal cancer." | 2.44 | Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. ( Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B, 2008) |
| "Colorectal cancer is one of the most common cancers affecting men and women in the United States." | 2.43 | Advanced colorectal cancer: current treatment and nursing management with economic considerations. ( Fung, A; Viale, PH; Zitella, L, 2005) |
| "Adjuvant therapy for colorectal cancer has been one of the most important contributions of medical oncology to the health of the population, saving more lives annually than more effective therapy for less common cancers, such as Hodgkin's disease." | 2.42 | Adjuvant therapy for rectal cancer in the elderly. ( Cohen, SM; Neugut, AI, 2004) |
| " Hand-foot syndrome (HFS) is the only clinical adverse event occurring more often during capecitabine treatment." | 2.42 | Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). ( Grothey, A; Marsé, H; Valverde, S; Van Cutsem, E, 2004) |
| "Capecitabine has a favourable safety profile, the most frequent adverse events being hand-foot syndrome, stomatitis and diarrhoea." | 2.42 | Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours. ( Holland, M; Reichardt, P; Sternberg, CN, 2004) |
| "Capecitabine (Xeloda) is an oral prodrug that is enzymatically converted to fluorouracil (5-FU) within cancer cells." | 2.41 | Current status of capecitabine in the treatment of colorectal cancer. ( Rothenberg, ML, 2002) |
| " The panel agreed that further data from a National Cancer Institute (NCI)-sponsored intergroup trial is required to determine the optimal dosage of octreotide and its cost in the treatment of cancer." | 2.40 | Recommended guidelines for the treatment of chemotherapy-induced diarrhea. ( Benson, AB; Catalano, R; Engelking, C; Field, M; Kornblau, SM; Mitchell, E; Rubin, J; Trotta, P; Vokes, E; Wadler, S, 1998) |
| "Irinotecan (CPT11) is a synthetic camptothecin-derived DNA topoisomerase I inhibitor." | 2.40 | [Irinotecan: various administration schedules, study of drug combinations, phase I experience]. ( Armand, JP; Boige, V; Raymond, E, 1998) |
| "Oral and intestinal mucositis are debilitating inflammatory diseases observed in cancer patients undergoing chemo-radiotherapy." | 1.91 | Characterization of a novel dual murine model of chemotherapy-induced oral and intestinal mucositis. ( Celentano, A; Cirillo, N; Low, JT; McCullough, MJ; Mohammed, AI; O' Reilly, LA; Paolini, R, 2023) |
| "Mucositis was induced through a single injection with 2 mg/kg idarubicin (with saline as control), followed by daily treatments of anakinra (100 mg/kg/day), dexamethasone (10 mg/kg/day) or both for 3 days." | 1.91 | Anakinra and dexamethasone treatment of idarubicin-induced mucositis and diarrhoea in rats. ( Dahlgren, D; Heindryckx, F; Kullenberg, F; Lennernäs, H; Peters, K; Sjöblom, M, 2023) |
| " This study aimed to determine genetic and non-genetic predictors of adverse effects." | 1.91 | Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy. ( Ball, IA; Bowen, JM; Coller, JK; Gibson, RJ; Karapetis, CS; Keefe, DM; Korver, SK; Logan, RM; Mead, KR; Richards, AM; Secombe, KR; Tuke, J; Wain, TJ, 2023) |
| "This study aimed to analyze the effect of Bletilla striata polysaccharide(BSP) on endogenous metabolites in serum of tumor-bearing mice treated with 5-fluorouracil(5-FU) by untargeted metabolomics techniques and explore the mechanism of BSP in alleviating the toxic and side effects induced by 5-FU." | 1.91 | [Bletilla striata polysaccharide improves toxic and side effects induced by 5-FU: an untargeted metabolomics study]. ( Cui, YR; He, TH; Liu, P; Wang, WL; Xie, XX; Yu, J; Zhang, JT, 2023) |
| "Capecitabine is a widely-used antineoplastic drug, a prodrug to 5-fluorouracil which commonly induces gastrointestinal toxicity." | 1.72 | Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile. ( Chen, J; Liu, J; Shao, T; Shou, L; Shu, Q; Zhang, Y, 2022) |
| "Intestinal mucositis is a common side effect of chemotherapy and radiotherapy." | 1.62 | TBHQ attenuates ferroptosis against 5-fluorouracil-induced intestinal epithelial cell injury and intestinal mucositis via activation of Nrf2. ( Deng, S; Li, J; Li, L; Wu, D; Xu, Y, 2021) |
| " Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation." | 1.62 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ( Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021) |
| "5-Fluorouracil (5-FU) is a chemotherapy agent that is widely used in clinical oncologic practice." | 1.62 | Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice. ( Chang, CW; Chen, YJ; Hsieh, CH; Liu, CY; Liu, JH; Tsai, TH, 2021) |
| " Demographics, clinical and dosing characteristics, and treatment outcomes were collected." | 1.56 | Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. ( Ahn, D; Barzi, A; Bekaii-Saab, T; Corvino, FA; Mamlouk, K; Miksad, R; Pulgar, S; Surinach, A; Torres, AZ; Valderrama, A; Wang, S, 2020) |
| "Mucositis was induced by intraperitoneal injection of 5-FU (400 mg/kg)." | 1.51 | Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis. ( Choi, HS; Chun, HJ; Jeen, YT; Keum, B; Kim, CD; Kim, ES; Kim, SH; Lee, HS; Lee, JM; Seo, YS; Um, SH; Yoo, IK, 2019) |
| "Studies of patients treated with bevacizumab and other vascular epithelial growth factor (VEGF) inhibitors have reported that hypertension adverse events (AEs) are associated with improved overall survival (OS) or progression-free survival (PFS)." | 1.51 | Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab. ( Hopkins, AM; Karapetis, CS; Lim, HH; Rowland, A; Sorich, MJ; Yuen, HY, 2019) |
| "Altogether, 11 components were identified or tentatively characterized in dosed plasma." | 1.51 | The protective effects of Aquilariae Lignum Resinatum extract on 5-Fuorouracil-induced intestinal mucositis in mice. ( Gao, J; Gao, W; Jin, Z; Man, S; Zhang, J; Zheng, H, 2019) |
| "Severe treatment-related diarrhea may result in chemotherapy discontinuation." | 1.51 | Fluoropyrimidine-induced intestinal mucosal injury is associated with the severity of chemotherapy-related diarrhea. ( Goto, M; Harada, S; Higuchi, K; Hirata, Y; Kakimoto, K; Kii, T; Kojima, Y; Ota, K; Ozaki, H; Sugawara, N; Takeuchi, T; Terazawa, T; Yamaguchi, T, 2019) |
| "Irinotecan (CPT-11) is a drug used against a wide variety of tumors, which can cause severe toxicity, possibly leading to the delay or suspension of the cycle, with the consequent impact on the prognosis of survival." | 1.51 | Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters. ( Aldaz, A; Insausti, A; Oyaga-Iriarte, E; Sayar, O, 2019) |
| " Patient acute gastrointestinal toxicity was recorded using Common Terminology Criteria of Adverse Events (CTCAE) diarrhoea grading." | 1.48 | Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes. ( Amor, H; Blakey, D; Chao, M; Guerrieri, M; Guiney, M; Ho, H; Macleod, C; Melven, L; Ng, M; Skelton, J; Subramanian, B, 2018) |
| " Although some progress has been made in understanding the intestinal toxicity of 5-FU, confusion remains about animal models of 5-FU-induced intestinal injury, especially the dosage of 5-FU." | 1.48 | Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury. ( Liu, D; Liu, Y; Ren, X; Xiang, D; Yang, J; Zhang, C; Zhang, S, 2018) |
| "Grade 3-4 neutropenia was seen in 10/23 patients (43%)." | 1.46 | PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer. ( Beer, J; Bodis, S; Oehler, C; Vlachopoulou, V; von Moos, R; Zimmermann, M; Zwahlen, DR, 2017) |
| "To investigate the association between polymorphisms of DNA repair genes and xenobiotic with acute adverse effects in locally advanced rectal cancer patients treated with neoadjuvant radiochemotherapy." | 1.46 | Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. ( Agolli, L; Borro, M; Bracci, S; De Sanctis, V; Di Nardo, F; Enrici, RM; Falco, T; Gentile, G; Maglio, M; Minniti, G; Nicosia, L; Osti, MF; Simmaco, M; Valeriani, M, 2017) |
| "Twenty esophageal cancer patients receiving chemotherapy with 5-fluorouracil plus cisplatin were assigned randomly to one of the following two groups: (1) receiving elemental diet with Elental (one pack per day) for 14 days and (2) not receiving Elental during chemotherapy." | 1.46 | A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy. ( Hoshino, A; Kawada, K; Kawano, T; Miyawaki, Y; Nagai, K; Nakajima, Y; Nishikage, T; Okada, T; Ryotokuji, T; Tokairin, Y, 2017) |
| " On the 7th day, the mice were euthanized, and intestinal samples were collected for histopathology and morphometric analysis, as well as for the determination of myeloperoxidase activity and cytokine dosage (TNF-α and IL-6)." | 1.43 | A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice. ( Almeida, PR; Assis-Júnior, EM; Brito, GA; Lima-Júnior, RC; Melo, AT; Pereira, VB; Ribeiro, RA; Wong, DV, 2016) |
| "Curcumin has anti-inflammatory, antitumour and antioxidant properties." | 1.43 | Curcumin Inhibits 5-Fluorouracil-induced Up-regulation of CXCL1 and CXCL2 of the Colon Associated with Attenuation of Diarrhoea Development. ( Kai, Y; Kimura, M; Narita, M; Oguchi, A; Saito, T; Sakai, H; Sato, F; Sato, K; Tabata, S; Yaegashi, M; Yumoto, T, 2016) |
| "Gastrointestinal toxicity is the most common adverse effect of chemotherapy." | 1.43 | Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats. ( Forsgård, RA; Frias, R; Holma, R; Korpela, R; Lindén, J; Österlund, P; Spillmann, T, 2016) |
| "Febrile neutropenia was not reported." | 1.43 | Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. ( Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C, 2016) |
| "Intestinal mucositis is a frequently encountered side effect in oncology patients undergoing chemotherapy." | 1.42 | Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model. ( Chan, WT; Chang, SW; Cheng, ML; Chiang Chiau, JS; Jiang, CB; Lee, HC; Liu, CY; Yeung, CY, 2015) |
| " Severe toxic reactions to 5-FU have been associated with decreased levels of dihydropyrimidine dehydrogenase (DPD) enzyme activity." | 1.40 | A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. ( Diasio, RB; Lee, AM; McConnell, K; Offer, SM; Relias, V; Saif, MW, 2014) |
| "Diarrhea is a common toxicity of chemotherapy, but the practice of reporting only severe grades (≥ 3) in clinical trials results in misleading conclusions of significance." | 1.40 | Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy. ( Aprile, G; Barsevick, A; Bonaventura, A; Elting, LS; Grunberg, SM; Keefe, DM; Koczwara, B; Nguyen, HT; Selva-Nayagam, S; Sonis, ST, 2014) |
| "Irinotecan is a water-soluble camptothecin derivative with clinical activity against colorectal and small cell lung cancers and is currently a standard of care therapeutic in the treatment of colorectal cancer in combination with 5-fluorouracil." | 1.40 | Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities. ( Anantha, M; Bally, MB; Harasym, N; Manisali, I; Masin, D; Osooly, M; Ostlund, C; Santos, ND; Strutt, D; Sutherland, BW; Waterhouse, DN; Webb, MS; Wehbe, M, 2014) |
| " Simultaneous heterozygous UGT1A1 28 and UGT1A1 6 polymorphisms may produce higher exposure to SN-38 and a higher risk of adverse effects related to irinotecan." | 1.39 | Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. ( Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM, 2013) |
| " Grade 3/4 adverse events were: neutropenia (54." | 1.39 | Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer. ( Maruyama, S; Takii, Y, 2013) |
| "Patients with cancer often receive chemotherapeutic agents concurrently with other medications to treat comorbidity." | 1.39 | Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer. ( Fujita, K; Ishida, H; Kato, Y; Miwa, K; Saji, S; Sasaki, T; Sasaki, Y; Sunakawa, Y; Yamashita, K, 2013) |
| "In spite of advances in rectal cancer surgery and the use of preoperative 5-fluorouracil-(5-FU) based chemoradiotherapy (CRT) in stage II and III disease distant metastases still occur in about 35-40% of the patients." | 1.38 | Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life. ( Brade, J; Gencer, D; Hofheinz, RD; Hofmann, WK; Horisberger, K; Kienle, P; Kripp, M; Post, S; Welzel, G; Wenz, F; Wieneke, J, 2012) |
| " Gastro-intestinal adverse events graded according to the WHO criteria were recorded after the first cycle." | 1.38 | Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. ( Bocci, G; Ciccolini, J; Danesi, R; Di Paolo, A; Iliadis, A; Lacarelle, B; Marouani, H; Woloch, C, 2012) |
| "Three patients (20%) had grade 3-4 dysphagia in weeks 3-4 and were continued on intravenous fluids and pain medications." | 1.37 | Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. ( Ad, VB; Bar-Ad, V; Both, S; Hwang, WT; Metz, J; O'Dwyer, P; Plastaras, J; Thukral, A, 2011) |
| "5-fluorouracil (5-FU) is a common cytotoxic agent used to treat solid tumors." | 1.37 | CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis. ( Cheng, Z; Di, J; Du, Y; Han, X; Jin, Z; Pan, Y; Wang, Y; Wang, Z; Wu, Z; Zhang, H; Zhang, P; Zheng, Q, 2011) |
| "The growing number of patients with head and neck cancer is a reason to search for new effective treatment strategies." | 1.36 | [Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results]. ( Chilimoniuk, M; Maksimowicz, T; Olszewska, E, 2010) |
| "The number of elderly patients with colorectal cancer is increasing in Japan." | 1.34 | [Chemotherapy for elderly patients with colorectal cancer]. ( Kuboki, Y; Mizunuma, N, 2007) |
| " In May 2002, we devised a new regimen by intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells, and thirteen patients with advanced colorectal cancer (Stage IV) were treated with this regimen." | 1.34 | [The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007) |
| " The adverse effect included grade 3 or grade 4 leukopenia in 12." | 1.34 | [Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers]. ( Bai, P; Li, XG; Ma, SK; Wu, LY; Zhang, R; Zhang, WH, 2007) |
| " This study was to explore relationship of DPD to serum concentration of 5-FU in colorectal cancer patients treated with FOLFOX6 regimen, and their correlation to treatment response and adverse events." | 1.33 | [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients]. ( Dong, QM; He, YJ; Li, S; Li, YY; Xia, ZJ; Zhang, L; Zhou, ZM; Zhou, ZW, 2005) |
| " These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval." | 1.33 | [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer]. ( Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Ohori, H; Otsuka, K; Sakayori, M; Shibata, H; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T, 2005) |
| "The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5-FU, were reviewed, and the outcome of the groups was compared." | 1.33 | Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. ( Brenner, B; Dreznik, Z; Dror, Y; Fenig, E; Figer, A; Idelevich, E; Loven, D; Nudelman, I; Shani, A; Stemmer, SM; Sulkes, A; Yerushalmi, R, 2006) |
| " This study was to explore the relationship between activity of DPD and concentration of 5-FU, and their correlation to adverse events among advanced gastric cancer patients treated with the same regimen containing 5-FU continuous infusion." | 1.33 | [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients]. ( Cao, Y; Dong, QM; Jiang, WQ; Li, H; Li, S; Peng, RJ; Shi, YX; Yuan, ZY; Zhou, ZM, 2006) |
| "In patients with liver metastases from colorectal cancer, survival can be increased by hepatic resection." | 1.32 | Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy. ( Carlo, WF; Fong, Y; Gonen, M; Hummer, AJ; Jarnagin, W; Kemeny, N; Schwartz, L; Sullivan, D, 2004) |
| "Diarrhea was the major adverse effect of UFT/LV that made patients reduce dosage." | 1.31 | Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer. ( Chen, JS; Hsu, KC; Tang, R; Wang, JY; Yang, TS, 2002) |
| "Diarrhea was the most frequent acute toxicity." | 1.31 | Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. ( Hagihara, PF; John, WJ; Kenady, DE; Marks, G; McGrath, PC; Mohiuddin, M; Regine, WF, 2000) |
| "Deficiency of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in 5-fluorouracil (5-FU) catabolism, has been linked to toxic side effects of 5-FU." | 1.31 | Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. ( Behnke, D; Häusler, P; Höffken, K; Raida, M; Schwabe, W; Van Gennip, AH; Van Kuilenburg, AB, 2001) |
| "Mitomycin C suppository was significantly less toxic compared with intravenous delivery, and higher rectal tissue concentrations were observed from 10 to 30 minutes (P < 0." | 1.30 | Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. ( Ackerman, D; Galandiuk, S; Hofmeister, A; LaRocca, R; Lewis, RK; Myers, SR; Paris, KJ; Pokorny, RM; Wrightson, WR, 1997) |
| "To determine the maximum-tolerated dose (MTD) and recommended dose of irinotecan (CPT-11) in combination with fluorouracil (5-FU) and leucovorin (LV), using a biweekly LV5FU2 regimen and increasing doses of CPT-11, and to assess the efficacy of this combination in pretreated patients with colorectal cancer (CRC)." | 1.30 | Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ( Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M, 1999) |
| "5-Fluorouracil was given every 3 weeks by 5-day continuous chronomodulated venous infusion (CMVI) with peak 5-FU delivery at 4 a." | 1.29 | Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Itzhaki, M; Lévi, F; Misset, JL; Soussan, S, 1993) |
| "Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated." | 1.28 | [Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer]. ( Akebi, N; Josen, T; Kobashi, K; Matsumura, Y; Nanba, K; Nasu, Y; Ochi, J; Ohmori, H; Saika, T; Tanahashi, T, 1991) |
| "Large dosage of 5-fluorouracil given by slow intravenous infusion has proved to be very effective in the treatment of gestational trophoblastic neoplasms." | 1.27 | Reevaluation of 5-fluorouracil as a single therapeutic agent for gestational trophoblastic neoplasms. ( Sung, HC; Wu, PC; Yang, HY, 1984) |
| "Tegafur was administered orally in two or three divided doses." | 1.27 | Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983) |
| "5-Fluorouracil (5-FU) was administered as a continuous ambulatory venous infusion to 25 patients in a Phase I trial." | 1.27 | Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics. ( Ardalan, B; Daniels, JR; Johnson, K; Silberman, H; Spicer, DV, 1988) |
| "We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days." | 1.27 | High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. ( Astone, A; Barone, C; Cassano, A; Cavallaro, A; Garufi, C; Grieco, A; Netri, G; Noviello, MR; Ricevuto, E; Rossi, S, 1987) |
| "Twenty-one patients were treated with sequential doses of MTX and 5-FU so as to be classified by MTX dosage into an intermediate MTX-dose group and a high MTX-dose group." | 1.27 | [Therapeutic effect of sequential doses of methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced gastric cancer: comparison of intermediate-dose MTX with high-dose MTX]. ( Akazawa, S; Futatsuki, K; Honda, T; Kanda, Y; Kitagawa, H; Nakagawa, T; Nakajima, T; Suda, Y; Yoshida, S, 1985) |
| "Thirty patients with symptoms of the carcinoid syndrome and other symptoms not controlled by pharmacological agents were analysed with respect to the value of various treatment measures used." | 1.26 | Use of arterial devascularization and cytotoxic drugs in 30 patients with the carcinoid syndrome. ( Johnson, PJ; Melia, WM; Nunnerley, HB; Williams, R, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 58 (11.20) | 18.7374 |
| 1990's | 76 (14.67) | 18.2507 |
| 2000's | 175 (33.78) | 29.6817 |
| 2010's | 170 (32.82) | 24.3611 |
| 2020's | 39 (7.53) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, G | 1 |
| Williams, J | 1 |
| Washington, MK | 1 |
| Yang, Y | 1 |
| Long, J | 1 |
| Townsend, SD | 1 |
| Yan, F | 1 |
| Deng, S | 1 |
| Wu, D | 1 |
| Li, L | 1 |
| Li, J | 6 |
| Xu, Y | 1 |
| Yoneda, J | 1 |
| Nishikawa, S | 1 |
| Kurihara, S | 1 |
| Glewis, S | 1 |
| Alexander, M | 1 |
| Khabib, MNH | 1 |
| Brennan, A | 1 |
| Lazarakis, S | 1 |
| Martin, J | 1 |
| Tie, J | 1 |
| Lingaratnam, S | 1 |
| Michael, M | 1 |
| Sabry, NM | 1 |
| Naguib, TM | 1 |
| Kabel, AM | 1 |
| Khafagy, ES | 1 |
| Arab, HH | 1 |
| Almorsy, WA | 1 |
| Kim, G | 1 |
| Cockrum, P | 1 |
| Surinach, A | 2 |
| Wang, S | 2 |
| Wainberg, Z | 1 |
| Ji, Y | 1 |
| Zhou, W | 1 |
| Tan, W | 2 |
| Chen, Z | 2 |
| Lu, H | 3 |
| You, Y | 1 |
| Tian, C | 1 |
| Zhou, X | 1 |
| Zhou, L | 1 |
| Luo, R | 1 |
| Zhao, X | 1 |
| Dahlgren, D | 2 |
| Rosenqvist, E | 1 |
| Hellström, PM | 1 |
| Nygren, P | 1 |
| Kullenberg, F | 2 |
| Peters, K | 2 |
| Sjöblom, M | 2 |
| Lennernäs, H | 2 |
| Lu, DX | 1 |
| Liu, F | 1 |
| Wu, H | 1 |
| Liu, HX | 1 |
| Chen, BY | 1 |
| Yan, J | 3 |
| Lu, Y | 1 |
| Sun, ZG | 1 |
| Jardi, F | 2 |
| Kelly, C | 2 |
| Teague, C | 1 |
| Fowler-Williams, H | 1 |
| Sevin, DC | 1 |
| Rodrigues, D | 2 |
| Jo, H | 2 |
| Ferreira, S | 2 |
| Herpers, B | 1 |
| Van Heerden, M | 1 |
| de Kok, T | 1 |
| Pin, C | 2 |
| Lynch, A | 1 |
| Duckworth, CA | 2 |
| De Jonghe, S | 1 |
| Lammens, L | 2 |
| Pritchard, DM | 2 |
| Shao, T | 3 |
| Zhang, Y | 6 |
| Liu, J | 3 |
| Chen, J | 7 |
| Shu, Q | 3 |
| Shou, L | 3 |
| Furuse, J | 3 |
| Ueno, M | 3 |
| Ikeda, M | 3 |
| Okusaka, T | 3 |
| Teng, Z | 3 |
| Furuya, M | 3 |
| Ioka, T | 3 |
| Lukovic, J | 3 |
| Hosni, A | 3 |
| Liu, A | 3 |
| Tadic, T | 3 |
| Patel, T | 3 |
| Li, K | 3 |
| Han, K | 3 |
| Lindsay, P | 3 |
| Craig, T | 3 |
| Brierley, J | 3 |
| Barry, A | 3 |
| Wong, R | 5 |
| Ringash, J | 3 |
| Dawson, LA | 3 |
| Kim, JJ | 3 |
| Mohammed, AI | 1 |
| Celentano, A | 1 |
| Paolini, R | 1 |
| Low, JT | 1 |
| McCullough, MJ | 1 |
| O' Reilly, LA | 1 |
| Cirillo, N | 1 |
| Heindryckx, F | 1 |
| Jakubauskas, M | 1 |
| Jakubauskiene, L | 1 |
| Leber, B | 1 |
| Horvath, A | 1 |
| Strupas, K | 1 |
| Stiegler, P | 1 |
| Schemmer, P | 1 |
| Korver, SK | 1 |
| Bowen, JM | 1 |
| Gibson, RJ | 1 |
| Ball, IA | 1 |
| Secombe, KR | 1 |
| Wain, TJ | 1 |
| Logan, RM | 1 |
| Tuke, J | 1 |
| Mead, KR | 1 |
| Richards, AM | 1 |
| Karapetis, CS | 2 |
| Keefe, DM | 2 |
| Coller, JK | 1 |
| Zhang, JT | 1 |
| Liu, P | 1 |
| Wang, WL | 1 |
| Xie, XX | 1 |
| He, TH | 1 |
| Cui, YR | 1 |
| Yu, J | 1 |
| Gall, L | 1 |
| Piñero, J | 1 |
| Souza, TM | 1 |
| Jennen, DGJ | 1 |
| de Kok, TM | 1 |
| Coyle, L | 1 |
| Chung, SW | 1 |
| Beattie, KA | 1 |
| Liu, D | 3 |
| Tang, F | 3 |
| Zhang, L | 5 |
| Zhang, JN | 1 |
| Zhao, XL | 1 |
| Xu, LY | 1 |
| Peng, C | 3 |
| Ao, H | 3 |
| Vera, G | 2 |
| López-Gómez, L | 1 |
| Girón, R | 2 |
| Martín-Fontelles, MI | 2 |
| Nurgali, K | 1 |
| Abalo, R | 2 |
| Uranga, JA | 2 |
| Yamazaki, K | 3 |
| Ariyoshi, N | 1 |
| Miyauchi, H | 1 |
| Ohira, G | 1 |
| Kaneya, N | 1 |
| Yamamoto, K | 1 |
| Arai, K | 1 |
| Yamazaki, S | 1 |
| Matsubara, H | 1 |
| Suzuki, T | 1 |
| Ishii, I | 1 |
| Ali, J | 1 |
| Khan, AU | 1 |
| Shah, FA | 1 |
| Ali, H | 1 |
| Islam, SU | 1 |
| Kim, YS | 1 |
| Khan, S | 1 |
| Deng, R | 1 |
| Shi, L | 1 |
| Zhu, W | 1 |
| Wang, M | 1 |
| Guan, X | 1 |
| Yang, D | 1 |
| Shen, B | 1 |
| Lee, JM | 2 |
| Yoo, IK | 1 |
| Kim, SH | 2 |
| Choi, HS | 1 |
| Kim, ES | 1 |
| Keum, B | 1 |
| Seo, YS | 1 |
| Jeen, YT | 1 |
| Chun, HJ | 1 |
| Lee, HS | 1 |
| Um, SH | 1 |
| Kim, CD | 1 |
| Lim, HH | 1 |
| Hopkins, AM | 1 |
| Rowland, A | 1 |
| Yuen, HY | 1 |
| Sorich, MJ | 1 |
| Lindner, AU | 1 |
| Resler, AJ | 1 |
| Carberry, S | 1 |
| Oficjalska, K | 1 |
| Bacon, O | 1 |
| Lee, CS | 2 |
| Choudhry, A | 1 |
| Burke, JP | 1 |
| Sheahan, K | 1 |
| Cremona, M | 1 |
| Hennessy, BT | 1 |
| McNamara, D | 1 |
| Doherty, G | 1 |
| Ryan, EJ | 2 |
| Prehn, JHM | 1 |
| Gan, Y | 1 |
| Ai, G | 1 |
| Wu, J | 1 |
| Luo, H | 2 |
| Chen, L | 3 |
| Huang, Q | 1 |
| Wu, X | 3 |
| Xu, N | 5 |
| Li, M | 3 |
| Su, Z | 1 |
| Liu, Y | 2 |
| Huang, X | 1 |
| Barzi, A | 1 |
| Miksad, R | 1 |
| Corvino, FA | 1 |
| Torres, AZ | 1 |
| Mamlouk, K | 1 |
| Pulgar, S | 1 |
| Valderrama, A | 1 |
| Bekaii-Saab, T | 1 |
| Ahn, D | 1 |
| Holma, R | 3 |
| Laatikainen, R | 1 |
| Orell, H | 1 |
| Joensuu, H | 2 |
| Peuhkuri, K | 1 |
| Poussa, T | 3 |
| Korpela, R | 4 |
| Österlund, P | 5 |
| Loi, M | 1 |
| Magallon-Baro, A | 1 |
| Suker, M | 1 |
| Van Eijck, C | 1 |
| Hoogeman, M | 1 |
| Nuyttens, JJ | 1 |
| Xiang, DC | 1 |
| Yang, JY | 1 |
| Xu, YJ | 1 |
| Zhang, S | 4 |
| Zhu, C | 1 |
| Zhang, CL | 1 |
| Park, H | 1 |
| Jin, RU | 1 |
| Wang-Gillam, A | 2 |
| Suresh, R | 1 |
| Rigden, C | 1 |
| Amin, M | 1 |
| Tan, BR | 1 |
| Pedersen, KS | 1 |
| Lim, KH | 1 |
| Trikalinos, NA | 1 |
| Acharya, A | 1 |
| Copsey, ML | 1 |
| Navo, KA | 1 |
| Morton, AE | 1 |
| Gao, F | 2 |
| Lockhart, AC | 1 |
| Wagner, AD | 1 |
| Grothey, A | 3 |
| Andre, T | 2 |
| Dixon, JG | 1 |
| Wolmark, N | 3 |
| Haller, DG | 3 |
| Allegra, CJ | 3 |
| de Gramont, A | 4 |
| VanCutsem, E | 1 |
| Alberts, SR | 3 |
| George, TJ | 2 |
| O'Connell, MJ | 6 |
| Twelves, C | 2 |
| Taieb, J | 3 |
| Saltz, LB | 7 |
| Blanke, CD | 4 |
| Francini, E | 1 |
| Kerr, R | 2 |
| Yothers, G | 3 |
| Seitz, JF | 3 |
| Marsoni, S | 2 |
| Goldberg, RM | 7 |
| Shi, Q | 2 |
| Cheng, H | 1 |
| Zhao, L | 2 |
| Ju, Z | 1 |
| Wang, F | 3 |
| Qin, M | 1 |
| Mao, H | 1 |
| Shen, X | 1 |
| Gui, MX | 1 |
| Huang, B | 1 |
| Peng, J | 2 |
| Chen, X | 3 |
| Muthu, R | 1 |
| Gao, Y | 2 |
| Wang, RG | 1 |
| Lin, JM | 1 |
| Ghidini, M | 1 |
| Nicoletti, M | 1 |
| Ratti, M | 1 |
| Tomasello, G | 1 |
| Lonati, V | 1 |
| Ghilardi, M | 1 |
| Parati, MC | 1 |
| Borgonovo, K | 1 |
| Cabiddu, M | 1 |
| Petrelli, F | 1 |
| Liu, JH | 2 |
| Hsieh, CH | 1 |
| Liu, CY | 2 |
| Chang, CW | 1 |
| Chen, YJ | 1 |
| Tsai, TH | 1 |
| Chang, TK | 1 |
| Yin, TC | 1 |
| Su, WC | 1 |
| Tsai, HL | 1 |
| Huang, CW | 1 |
| Chen, YC | 1 |
| Li, CC | 1 |
| Chen, PJ | 1 |
| Ma, CJ | 1 |
| Chuang, KH | 1 |
| Cheng, TL | 1 |
| Wang, JY | 3 |
| Watts, K | 1 |
| Wills, C | 1 |
| Madi, A | 1 |
| Palles, C | 1 |
| Maughan, TS | 1 |
| Kaplan, R | 1 |
| Al-Tassan, NA | 1 |
| Kerr, D | 1 |
| Gray, V | 1 |
| West, H | 1 |
| Houlston, RS | 1 |
| Escott-Price, V | 1 |
| Cheadle, JP | 1 |
| Arima, S | 1 |
| Kawahira, M | 1 |
| Shimokawa, M | 1 |
| Ido, A | 1 |
| Koga, F | 1 |
| Ueda, Y | 1 |
| Nakazawa, J | 1 |
| Komori, A | 1 |
| Otsu, S | 1 |
| Fukahori, M | 1 |
| Makiyama, A | 1 |
| Taguchi, H | 1 |
| Honda, T | 2 |
| Shibuki, T | 1 |
| Mitsugi, K | 1 |
| Nio, K | 1 |
| Ide, Y | 1 |
| Ureshino, N | 1 |
| Mizuta, T | 1 |
| Shirakawa, T | 1 |
| Otsuka, T | 1 |
| van Rees, JM | 1 |
| Hartman, W | 1 |
| Nuyttens, JJME | 1 |
| Oomen-de Hoop, E | 1 |
| van Vugt, JLA | 1 |
| Rothbarth, J | 1 |
| Verhoef, C | 1 |
| van Meerten, E | 1 |
| Hamouda, N | 2 |
| Sano, T | 2 |
| Oikawa, Y | 2 |
| Ozaki, T | 1 |
| Shimakawa, M | 2 |
| Matsumoto, K | 6 |
| Amagase, K | 4 |
| Higuchi, K | 3 |
| Kato, S | 6 |
| Utsumi, D | 2 |
| Tominaga, M | 1 |
| Takeuchi, T | 2 |
| Zimmermann, M | 1 |
| Beer, J | 1 |
| Bodis, S | 1 |
| von Moos, R | 2 |
| Vlachopoulou, V | 1 |
| Zwahlen, DR | 1 |
| Oehler, C | 1 |
| Kano, Y | 1 |
| Tanaka, Y | 1 |
| Park, JJ | 1 |
| Hajj, C | 1 |
| Reyngold, M | 1 |
| Shi, W | 1 |
| Zhang, Z | 3 |
| Cuaron, JJ | 1 |
| Crane, CH | 2 |
| O'Reilly, EM | 2 |
| Lowery, MA | 1 |
| Yu, KH | 1 |
| Goodman, KA | 3 |
| Wu, AJ | 2 |
| Liu, Z | 1 |
| Xie, W | 1 |
| Teng, N | 1 |
| Liang, X | 1 |
| Yang, Z | 1 |
| Wang, X | 3 |
| Lévi, F | 2 |
| Karaboué, A | 1 |
| Saffroy, R | 1 |
| Desterke, C | 1 |
| Boige, V | 2 |
| Smith, D | 1 |
| Hebbar, M | 1 |
| Innominato, P | 1 |
| Carvalho, C | 1 |
| Guimbaud, R | 1 |
| Focan, C | 1 |
| Bouchahda, M | 1 |
| Adam, R | 2 |
| Ducreux, M | 3 |
| Milano, G | 3 |
| Lemoine, A | 1 |
| Mi, H | 1 |
| Dong, Y | 1 |
| Zhang, B | 1 |
| Wang, H | 2 |
| Peter, CCK | 1 |
| Gao, P | 1 |
| Fu, H | 1 |
| Chao, YL | 1 |
| Anders, CK | 1 |
| Sakai, H | 4 |
| Tabata, S | 2 |
| Kimura, M | 2 |
| Yabe, S | 1 |
| Isa, Y | 1 |
| Kai, Y | 2 |
| Sato, F | 2 |
| Yumoto, T | 2 |
| Miyano, K | 1 |
| Narita, M | 4 |
| Uezono, Y | 1 |
| Pastorino, A | 1 |
| Di Bartolomeo, M | 5 |
| Maiello, E | 4 |
| Iaffaioli, V | 1 |
| Ciuffreda, L | 1 |
| Fasola, G | 1 |
| Di Costanzo, F | 3 |
| Frassineti, GL | 2 |
| Marchetti, P | 1 |
| Antoniotti, C | 1 |
| Leone, F | 1 |
| Zaniboni, A | 2 |
| Aprile, G | 3 |
| Zilocchi, C | 1 |
| Sobrero, A | 4 |
| Bordonaro, R | 3 |
| Kanbayashi, Y | 1 |
| Ishikawa, T | 2 |
| Kanazawa, M | 1 |
| Nakajima, Y | 2 |
| Tabuchi, Y | 1 |
| Kawano, R | 1 |
| Yoshioka, T | 3 |
| Yoshida, N | 1 |
| Hosokawa, T | 1 |
| Takayama, K | 1 |
| Taguchi, T | 6 |
| Tejpar, S | 1 |
| Yan, P | 2 |
| Piessevaux, H | 1 |
| Dietrich, D | 2 |
| Brauchli, P | 2 |
| Klingbiel, D | 1 |
| Fiocca, R | 1 |
| Delorenzi, M | 1 |
| Bosman, F | 2 |
| Roth, AD | 2 |
| Deng, B | 1 |
| Jia, L | 1 |
| Tan, H | 1 |
| Lou, Y | 1 |
| Li, X | 1 |
| Li, Y | 2 |
| Yu, L | 1 |
| Levit, R | 1 |
| Savoy de Giori, G | 1 |
| de Moreno de LeBlanc, A | 1 |
| LeBlanc, JG | 1 |
| Ng, M | 1 |
| Ho, H | 1 |
| Skelton, J | 1 |
| Guerrieri, M | 1 |
| Guiney, M | 1 |
| Chao, M | 1 |
| Blakey, D | 1 |
| Macleod, C | 1 |
| Amor, H | 1 |
| Subramanian, B | 1 |
| Melven, L | 1 |
| Xiang, D | 3 |
| Yang, J | 1 |
| Ren, X | 1 |
| Zhang, C | 1 |
| Zheng, H | 2 |
| Gao, J | 5 |
| Man, S | 1 |
| Zhang, J | 4 |
| Jin, Z | 3 |
| Gao, W | 2 |
| Iwazu, Y | 1 |
| Kotani, K | 1 |
| Yamada, T | 1 |
| Ota, K | 3 |
| Kojima, Y | 1 |
| Harada, S | 1 |
| Ozaki, H | 1 |
| Sugawara, N | 1 |
| Hirata, Y | 2 |
| Yamaguchi, T | 3 |
| Terazawa, T | 1 |
| Kakimoto, K | 1 |
| Kii, T | 1 |
| Goto, M | 1 |
| Wang, J | 2 |
| Feng, W | 2 |
| Sheng, Y | 2 |
| He, J | 2 |
| Xu, X | 1 |
| Paula, DP | 1 |
| do Brasil Costa, VI | 1 |
| Jorge, RV | 1 |
| Nobre, FF | 1 |
| Ng, SY | 1 |
| Colborn, KL | 1 |
| Cambridge, L | 1 |
| Cercek, A | 1 |
| Reidy-Lagunes, DL | 1 |
| Segal, N | 1 |
| Stadler, Z | 1 |
| Paty, PB | 1 |
| Guillem, J | 1 |
| Weiser, MR | 1 |
| Nash, G | 1 |
| Garcia-Aguilar, J | 1 |
| Oyaga-Iriarte, E | 1 |
| Insausti, A | 1 |
| Sayar, O | 1 |
| Aldaz, A | 1 |
| Riechelmann, RP | 1 |
| Srimuninnimit, V | 1 |
| Kavan, P | 1 |
| Cicin, I | 1 |
| García-Alfonso, P | 3 |
| Chau, I | 4 |
| Fedyanin, MY | 1 |
| Martos, CF | 1 |
| Ter-Ovanesov, M | 1 |
| Peeters, M | 2 |
| Ko, YJ | 1 |
| Yalcin, S | 1 |
| Karthaus, M | 1 |
| Aparicio, J | 2 |
| Heinemann, V | 1 |
| Picard, P | 1 |
| Bury, D | 1 |
| Drea, E | 1 |
| Jin, Y | 1 |
| Chen, W | 1 |
| Lisha, L | 1 |
| Lin, J | 1 |
| Bajetta, E | 2 |
| Pietrantonio, F | 2 |
| Buzzoni, R | 2 |
| Ferrario, E | 2 |
| Valvo, F | 1 |
| Mariani, L | 2 |
| Dotti, KF | 1 |
| Biondani, P | 1 |
| Formisano, B | 1 |
| Gevorgyan, A | 2 |
| Grassi, P | 1 |
| Hubner, RA | 2 |
| Worsnop, F | 1 |
| Cunningham, D | 8 |
| Schmiegel, W | 1 |
| Reinacher-Schick, A | 1 |
| Arnold, D | 3 |
| Kubicka, S | 1 |
| Freier, W | 1 |
| Dietrich, G | 1 |
| Geißler, M | 1 |
| Hegewisch-Becker, S | 1 |
| Tannapfel, A | 1 |
| Pohl, M | 1 |
| Hinke, A | 2 |
| Schmoll, HJ | 3 |
| Graeven, U | 1 |
| Deenen, MJ | 1 |
| Dewit, L | 1 |
| Boot, H | 1 |
| Beijnen, JH | 1 |
| Schellens, JH | 1 |
| Cats, A | 1 |
| Köhne, CH | 4 |
| Bedenne, L | 2 |
| Carrato, A | 6 |
| Bouché, O | 1 |
| Popov, I | 1 |
| Gaspà, L | 1 |
| Valladares, M | 2 |
| Rougier, P | 7 |
| Gog, C | 1 |
| Reichardt, P | 2 |
| Wils, J | 1 |
| Pignatti, F | 1 |
| Biertz, F | 1 |
| Lück, HJ | 1 |
| Du Bois, A | 1 |
| Loibl, S | 1 |
| Schrader, I | 1 |
| Huober, J | 1 |
| Heilmann, V | 1 |
| Beckmann, M | 1 |
| Stähler, A | 1 |
| Jackisch, C | 1 |
| Hubalek, M | 1 |
| Richter, B | 1 |
| Stickeler, E | 1 |
| Eidtmann, H | 1 |
| Thomssen, C | 1 |
| Untch, M | 1 |
| Wollschläger, K | 1 |
| Schuster, T | 2 |
| von Minckwitz, G | 1 |
| Xu, JM | 4 |
| Wang, Y | 7 |
| Ge, FJ | 2 |
| Lin, L | 2 |
| Liu, ZY | 1 |
| Sharma, MR | 1 |
| Takii, Y | 1 |
| Maruyama, S | 2 |
| Martin, M | 2 |
| Bonneterre, J | 2 |
| Geyer, CE | 2 |
| Ito, Y | 2 |
| Ro, J | 1 |
| Lang, I | 2 |
| Kim, SB | 2 |
| Germa, C | 2 |
| Vermette, J | 1 |
| Wang, K | 4 |
| Awada, A | 2 |
| Qiao, Y | 1 |
| Ren, H | 1 |
| Huang, Y | 1 |
| DU, ZL | 1 |
| Yu, DK | 1 |
| Jin, J | 2 |
| Li, YX | 2 |
| Lin, DX | 1 |
| Shi, SB | 1 |
| Ma, TH | 1 |
| Tang, XY | 1 |
| Li, CH | 1 |
| Fukudome, I | 1 |
| Kobayashi, M | 3 |
| Dabanaka, K | 1 |
| Maeda, H | 2 |
| Okamoto, K | 1 |
| Okabayashi, T | 1 |
| Baba, R | 1 |
| Kumagai, N | 1 |
| Oba, K | 2 |
| Fujita, M | 1 |
| Hanazaki, K | 2 |
| Oh, MJ | 1 |
| Lee, HJ | 1 |
| Lee, SH | 2 |
| Tabernero, J | 2 |
| Van Cutsem, E | 5 |
| Lakomý, R | 1 |
| Prausová, J | 1 |
| Ruff, P | 2 |
| van Hazel, GA | 3 |
| Moiseyenko, VM | 2 |
| Ferry, DR | 1 |
| McKendrick, JJ | 1 |
| Soussan-Lazard, K | 1 |
| Chevalier, S | 1 |
| Mahaseth, H | 1 |
| Brutcher, E | 1 |
| Kauh, J | 1 |
| Hawk, N | 1 |
| Kim, S | 1 |
| Kooby, DA | 1 |
| Maithel, SK | 1 |
| Landry, J | 1 |
| El-Rayes, BF | 1 |
| Welslau, M | 1 |
| Diéras, V | 1 |
| Sohn, JH | 2 |
| Hurvitz, SA | 1 |
| Lalla, D | 1 |
| Fang, L | 1 |
| Althaus, B | 1 |
| Guardino, E | 1 |
| Miles, D | 2 |
| Likhacheva, A | 1 |
| Jhingran, A | 1 |
| Bodurka, DC | 1 |
| Sun, C | 1 |
| Sam, M | 1 |
| Eifel, PJ | 1 |
| Gao, YH | 1 |
| An, X | 1 |
| Sun, WJ | 1 |
| Cai, J | 1 |
| Cai, MY | 1 |
| Kong, LH | 1 |
| Lin, JZ | 1 |
| Liu, GC | 1 |
| Tang, JH | 1 |
| Wu, XJ | 1 |
| Chen, G | 2 |
| Pan, ZZ | 1 |
| Ding, PR | 1 |
| Suenaga, M | 2 |
| Fuse, N | 1 |
| Yamanaka, Y | 1 |
| Motomura, S | 1 |
| Matsumoto, H | 1 |
| Hamamoto, Y | 2 |
| Mizunuma, N | 3 |
| Doi, T | 1 |
| Hatake, K | 2 |
| Iwasaki, J | 1 |
| Ohtsu, A | 1 |
| Saif, MW | 2 |
| Lee, AM | 2 |
| Offer, SM | 1 |
| McConnell, K | 1 |
| Relias, V | 1 |
| Diasio, RB | 5 |
| Meyer, T | 1 |
| Qian, W | 1 |
| Caplin, ME | 1 |
| Armstrong, G | 1 |
| Lao-Sirieix, SH | 1 |
| Hardy, R | 1 |
| Valle, JW | 2 |
| Talbot, DC | 1 |
| Reed, N | 1 |
| Shaw, A | 1 |
| Navalkissoor, S | 1 |
| Luong, TV | 1 |
| Corrie, PG | 1 |
| Hoff, PM | 2 |
| Saragiotto, DF | 1 |
| Barrios, CH | 1 |
| del Giglio, A | 1 |
| Coutinho, AK | 1 |
| Andrade, AC | 1 |
| Dutra, C | 1 |
| Forones, NM | 1 |
| Correa, M | 1 |
| Portella, Mdo S | 1 |
| Passos, VQ | 1 |
| Chinen, RN | 1 |
| van Eyll, B | 1 |
| Soldini, D | 1 |
| Gaspert, A | 1 |
| Montani, M | 1 |
| Reineke, T | 1 |
| Rogler, G | 1 |
| Odze, R | 1 |
| Weber, A | 1 |
| Doherty, GA | 1 |
| Mokrim, M | 1 |
| Aftimos, PG | 1 |
| Errihani, H | 1 |
| Piccart-Gebhart, M | 1 |
| Qian, L | 2 |
| Wu, M | 4 |
| Ye, H | 2 |
| Zhu, S | 4 |
| Yu, Y | 4 |
| Han, W | 4 |
| Roxburgh, P | 1 |
| Lumsden, GR | 1 |
| Paul, J | 1 |
| Harden, S | 1 |
| Sweeting, L | 1 |
| James, A | 1 |
| Crellin, A | 1 |
| Morrison, R | 1 |
| Evans, TR | 1 |
| McDonald, AC | 3 |
| Karaca, H | 1 |
| Bozkurt, O | 1 |
| Ozaslan, E | 1 |
| Baldane, S | 1 |
| Berk, V | 1 |
| Inanc, M | 1 |
| Duran, AO | 1 |
| Dikilitas, M | 1 |
| Er, O | 1 |
| Ozkan, M | 1 |
| Mini, E | 2 |
| Subtil, F | 1 |
| Folprecht, G | 1 |
| Van Laethem, JL | 2 |
| Thaler, J | 2 |
| Bridgewater, J | 2 |
| Petersen, LN | 1 |
| Blons, H | 1 |
| Collette, L | 1 |
| Salazar, R | 1 |
| Emile, JF | 1 |
| Laurent-Puig, P | 1 |
| Lepage, C | 1 |
| Nakamura, T | 2 |
| Yamashita, K | 3 |
| Sato, T | 1 |
| Ema, A | 1 |
| Naito, M | 1 |
| Watanabe, M | 1 |
| Kang, YK | 3 |
| Rha, SY | 1 |
| Tassone, P | 1 |
| Barriuso, J | 1 |
| Yu, R | 1 |
| Szado, T | 1 |
| Garg, A | 1 |
| Bang, YJ | 1 |
| Iacovelli, R | 1 |
| Palazzo, A | 1 |
| Maggi, C | 1 |
| Ricchini, F | 1 |
| de Braud, F | 3 |
| Sagara, A | 2 |
| Jo, A | 1 |
| Hirosaki, A | 1 |
| Takase, K | 1 |
| Sugiyama, R | 1 |
| Sato, K | 3 |
| Ikegami, D | 1 |
| Horie, S | 3 |
| Matoba, M | 1 |
| Guan, W | 1 |
| Elting, LS | 1 |
| Nguyen, HT | 1 |
| Grunberg, SM | 1 |
| Bonaventura, A | 2 |
| Selva-Nayagam, S | 1 |
| Barsevick, A | 1 |
| Koczwara, B | 1 |
| Sonis, ST | 1 |
| Waterhouse, DN | 1 |
| Sutherland, BW | 1 |
| Santos, ND | 1 |
| Masin, D | 1 |
| Osooly, M | 1 |
| Strutt, D | 1 |
| Ostlund, C | 1 |
| Anantha, M | 1 |
| Harasym, N | 1 |
| Manisali, I | 1 |
| Wehbe, M | 1 |
| Bally, MB | 1 |
| Webb, MS | 1 |
| Dranitsaris, G | 2 |
| Lacouture, ME | 1 |
| Li, C | 1 |
| Gu, Y | 1 |
| Zhao, M | 1 |
| Yuan, Y | 1 |
| Wang, Z | 4 |
| Li, W | 1 |
| Chen, C | 1 |
| Ding, P | 1 |
| Lu, Z | 1 |
| Pan, Z | 1 |
| Xu, R | 1 |
| He, Y | 1 |
| Wan, D | 1 |
| Soveri, LM | 1 |
| Hermunen, K | 1 |
| Quinaux, E | 1 |
| Bono, P | 1 |
| Araki, K | 1 |
| Fukada, I | 1 |
| Horii, R | 1 |
| Takahashi, S | 2 |
| Akiyama, F | 1 |
| Iwase, T | 1 |
| Nishina, T | 1 |
| Ura, T | 2 |
| Nakajima, T | 2 |
| Goto, A | 1 |
| Shimada, K | 1 |
| Nakayama, N | 1 |
| Sakamoto, J | 1 |
| Morita, S | 1 |
| Yamada, Y | 2 |
| Saura, C | 1 |
| Garcia-Saenz, JA | 1 |
| Xu, B | 1 |
| Harb, W | 1 |
| Moroose, R | 1 |
| Pluard, T | 1 |
| Cortés, J | 2 |
| Kiger, C | 1 |
| Baselga, J | 1 |
| Chen, HM | 1 |
| Lin, JK | 1 |
| Chen, WS | 1 |
| Jiang, JK | 1 |
| Yang, SH | 1 |
| Lan, YT | 1 |
| Lin, CC | 1 |
| Teng, HW | 1 |
| Pavey, E | 1 |
| Sargent, DJ | 4 |
| Sinicrope, FA | 1 |
| Berenberg, JL | 1 |
| Namikawa, T | 1 |
| Munekage, E | 1 |
| Kitagawa, H | 2 |
| Osti, MF | 1 |
| Nicosia, L | 1 |
| Agolli, L | 1 |
| Gentile, G | 1 |
| Falco, T | 1 |
| Bracci, S | 1 |
| Di Nardo, F | 1 |
| Minniti, G | 1 |
| De Sanctis, V | 1 |
| Valeriani, M | 1 |
| Maglio, M | 1 |
| Borro, M | 1 |
| Simmaco, M | 1 |
| Enrici, RM | 1 |
| Julie, DA | 1 |
| Oh, JH | 1 |
| Apte, AP | 1 |
| Deasy, JO | 1 |
| Tom, A | 1 |
| Hong, TS | 3 |
| Moughan, J | 1 |
| Garofalo, MC | 1 |
| Bendell, J | 1 |
| Berger, AC | 1 |
| Oldenburg, NB | 2 |
| Anne, PR | 1 |
| Perera, F | 1 |
| Lee, RJ | 1 |
| Jabbour, SK | 1 |
| Nowlan, A | 1 |
| DeNittis, A | 1 |
| Crane, C | 1 |
| Balboa-Beltrán, E | 1 |
| Duran, G | 1 |
| Lamas, MJ | 1 |
| Carracedo, A | 1 |
| Barros, F | 1 |
| Voong, KR | 1 |
| Rashid, A | 1 |
| Minsky, BD | 1 |
| Krishnan, S | 1 |
| Yao, JC | 1 |
| Wolff, RA | 1 |
| Skibber, JM | 1 |
| Feig, BW | 1 |
| Chang, GJ | 1 |
| Das, P | 1 |
| Ko, AH | 1 |
| LoConte, N | 1 |
| Tempero, MA | 1 |
| Walker, EJ | 1 |
| Kate Kelley, R | 1 |
| Lewis, S | 1 |
| Chang, WC | 2 |
| Kantoff, E | 1 |
| Vannier, MW | 1 |
| Catenacci, DV | 1 |
| Venook, AP | 1 |
| Kindler, HL | 3 |
| Kawashima, R | 1 |
| Fujimaki, M | 1 |
| Ikenoue, Y | 1 |
| Danjo, K | 1 |
| Koizumi, W | 1 |
| Ichikawa, T | 1 |
| Yeung, CY | 1 |
| Chan, WT | 1 |
| Jiang, CB | 1 |
| Cheng, ML | 1 |
| Chang, SW | 1 |
| Chiang Chiau, JS | 1 |
| Lee, HC | 1 |
| Matsuda, C | 1 |
| Honda, M | 1 |
| Tanaka, C | 1 |
| Fukunaga, M | 1 |
| Ishibashi, K | 1 |
| Munemoto, Y | 1 |
| Hata, T | 1 |
| Bando, H | 1 |
| Oshiro, M | 1 |
| Tokunaga, Y | 1 |
| Fujii, A | 1 |
| Nagata, N | 1 |
| Mishima, H | 1 |
| Abdel-Rahman, O | 1 |
| ElHalawani, H | 1 |
| Essam-Eldin, S | 1 |
| Li, CP | 1 |
| Bodoky, G | 2 |
| Dean, A | 1 |
| Shan, YS | 1 |
| Jameson, G | 1 |
| Macarulla, T | 1 |
| Lee, KH | 3 |
| Blanc, JF | 1 |
| Chiu, CF | 1 |
| Schwartsmann, G | 1 |
| Siveke, JT | 1 |
| Braiteh, F | 1 |
| Moyo, V | 1 |
| Belanger, B | 1 |
| Dhindsa, N | 1 |
| Bayever, E | 1 |
| Von Hoff, DD | 4 |
| Chen, LT | 1 |
| Singh, S | 1 |
| Kotla, NG | 1 |
| Tomar, S | 1 |
| Maddiboyina, B | 1 |
| Webster, TJ | 1 |
| Sharma, D | 1 |
| Sunnapu, O | 1 |
| Pereira, VB | 1 |
| Melo, AT | 1 |
| Assis-Júnior, EM | 1 |
| Wong, DV | 1 |
| Brito, GA | 1 |
| Almeida, PR | 1 |
| Ribeiro, RA | 1 |
| Lima-Júnior, RC | 1 |
| Tebbutt, NC | 4 |
| Price, TJ | 2 |
| Ferraro, DA | 1 |
| Wong, N | 1 |
| Veillard, AS | 1 |
| Hall, M | 1 |
| Sjoquist, KM | 1 |
| Pavlakis, N | 1 |
| Strickland, A | 1 |
| Varma, SC | 1 |
| Cooray, P | 1 |
| Young, R | 1 |
| Underhill, C | 1 |
| Shannon, JA | 1 |
| Ganju, V | 2 |
| Gebski, V | 2 |
| Wulaningsih, W | 1 |
| Wardhana, A | 1 |
| Watkins, J | 1 |
| Yoshuantari, N | 1 |
| Repana, D | 1 |
| Van Hemelrijck, M | 1 |
| Liu, R | 1 |
| Li, T | 2 |
| Li, F | 2 |
| Liu, H | 1 |
| Li, G | 1 |
| Oguchi, A | 1 |
| Yaegashi, M | 1 |
| Saito, T | 1 |
| Chen, Y | 1 |
| Wang, L | 2 |
| van Ramshorst, MS | 1 |
| van Werkhoven, E | 1 |
| Honkoop, AH | 1 |
| Dezentjé, VO | 1 |
| Oving, IM | 1 |
| Mandjes, IA | 1 |
| Kemper, I | 1 |
| Smorenburg, CH | 1 |
| Stouthard, JM | 1 |
| Linn, SC | 1 |
| Sonke, GS | 1 |
| Forsgård, RA | 1 |
| Lindén, J | 1 |
| Frias, R | 1 |
| Spillmann, T | 1 |
| Choi, Y | 1 |
| Kim, JH | 3 |
| Kim, JW | 2 |
| Lee, KW | 1 |
| Oh, HK | 1 |
| Kim, DW | 1 |
| Kang, SB | 1 |
| Song, C | 1 |
| Kim, JS | 3 |
| Pérez-García, I | 1 |
| de Andrés, R | 1 |
| López-Pérez, AE | 1 |
| Pasquini, G | 1 |
| Vasile, E | 1 |
| Caparello, C | 1 |
| Vivaldi, C | 1 |
| Musettini, G | 1 |
| Lencioni, M | 1 |
| Petrini, I | 1 |
| Fornaro, L | 1 |
| Falcone, A | 4 |
| Okada, T | 1 |
| Nishikage, T | 1 |
| Ryotokuji, T | 1 |
| Miyawaki, Y | 1 |
| Hoshino, A | 1 |
| Tokairin, Y | 1 |
| Kawada, K | 1 |
| Nagai, K | 1 |
| Kawano, T | 1 |
| Azria, D | 1 |
| Ballonoff, A | 1 |
| Kavanagh, B | 1 |
| McCarter, M | 1 |
| Kane, M | 1 |
| Pearlman, N | 1 |
| Nash, R | 1 |
| Shah, RJ | 1 |
| Raben, D | 1 |
| Schefter, TE | 1 |
| Vincenzi, B | 1 |
| Schiavon, G | 1 |
| Pantano, F | 1 |
| Santini, D | 2 |
| Tonini, G | 1 |
| Yu, ZY | 1 |
| Ouyang, XN | 1 |
| Chen, ZS | 1 |
| Xie, FW | 1 |
| Grouls, V | 1 |
| Kamisugi, K | 1 |
| Matsusaka, S | 1 |
| Imada, H | 1 |
| Shoji, D | 1 |
| Nakamoto, E | 1 |
| Yokokawa, T | 1 |
| Kawakami, K | 1 |
| Nawano, K | 1 |
| Ogawa, M | 3 |
| Shinozaki, E | 1 |
| Hama, T | 1 |
| Aranda, E | 5 |
| Martinez-Villacampa, M | 1 |
| Benavides, M | 2 |
| Gomez, A | 2 |
| Massutti, B | 2 |
| Marcuello, E | 3 |
| Constenla, M | 1 |
| Cámara, JC | 1 |
| Dueñas, R | 2 |
| Reboredo, M | 1 |
| Navarro, M | 2 |
| Díaz-Rubio, E | 4 |
| Sirohi, B | 1 |
| Pluzanska, A | 2 |
| Utracka-Hutka, B | 1 |
| Zaluski, J | 2 |
| Glynne-Jones, R | 2 |
| Koralewski, P | 2 |
| Mainwaring, P | 1 |
| Wasan, H | 1 |
| Szczylik, C | 1 |
| Clingan, P | 1 |
| Chan, RT | 1 |
| Tabah-Fisch, I | 1 |
| Cassidy, J | 4 |
| Horisberger, K | 2 |
| Treschl, A | 1 |
| Mai, S | 1 |
| Barreto-Miranda, M | 1 |
| Kienle, P | 2 |
| Ströbel, P | 1 |
| Erben, P | 1 |
| Woernle, C | 1 |
| Dinter, D | 1 |
| Kähler, G | 1 |
| Hochhaus, A | 3 |
| Post, S | 2 |
| Willeke, F | 1 |
| Wenz, F | 2 |
| Hofheinz, RD | 4 |
| Ku, GY | 1 |
| Schrag, D | 1 |
| Maki, RG | 1 |
| Kelsen, DP | 3 |
| Ilson, DH | 1 |
| Xue, H | 1 |
| Le Roy, S | 1 |
| Sawyer, MB | 1 |
| Field, CJ | 1 |
| Dieleman, LA | 1 |
| Baracos, VE | 1 |
| Moore, S | 1 |
| Raoul, JL | 1 |
| Brezault, C | 1 |
| Husseini, F | 1 |
| Cals, L | 2 |
| Nippgen, J | 1 |
| Loos, AH | 1 |
| Skof, E | 1 |
| Rebersek, M | 1 |
| Hlebanja, Z | 1 |
| Ocvirk, J | 1 |
| Sharif, S | 1 |
| Colangelo, LH | 1 |
| Lopa, SH | 1 |
| Petrelli, NJ | 7 |
| Atkins, JN | 1 |
| Seay, TE | 3 |
| Fehrenbacher, L | 2 |
| O'Reilly, S | 2 |
| Chu, L | 1 |
| Azar, CA | 1 |
| Lorenzen, S | 1 |
| Porschen, R | 1 |
| Al-Batran, SE | 1 |
| Hofheinz, R | 1 |
| Thuss-Patience, P | 1 |
| Moehler, M | 2 |
| Grabowski, P | 1 |
| Greten, T | 1 |
| Müller, L | 2 |
| Röthling, N | 1 |
| Peschel, C | 1 |
| Langer, R | 1 |
| Lordick, F | 2 |
| Dong, NN | 1 |
| Wang, MY | 1 |
| Zhang, Q | 1 |
| Liu, ZF | 1 |
| Peterson, DE | 1 |
| Barker, NP | 1 |
| Akhmadullina, LI | 1 |
| Rodionova, I | 1 |
| Sherman, NZ | 1 |
| Davidenko, IS | 1 |
| Rakovskaya, GN | 1 |
| Gotovkin, EA | 1 |
| Shinkarev, SA | 1 |
| Kopp, MV | 1 |
| Kulikov, EP | 1 |
| Gertner, JM | 1 |
| Firsov, I | 1 |
| Tuleneva, T | 1 |
| Yarosh, A | 1 |
| Woon, CW | 1 |
| Robertson, JM | 3 |
| Söhn, M | 1 |
| Yan, D | 3 |
| Jones, A | 1 |
| O'Brien, M | 1 |
| Sommer, H | 1 |
| Nowara, E | 1 |
| Welt, A | 1 |
| Pienkowski, T | 1 |
| Rolski, J | 1 |
| Pham, ML | 1 |
| Perraud, K | 1 |
| Trillet-Lenoir, V | 2 |
| Yim, KL | 1 |
| Malik, I | 2 |
| Hussein, F | 1 |
| Bush, D | 1 |
| Alqaisi, M | 1 |
| Bernal, P | 2 |
| Byrd, J | 2 |
| Garberoglio, C | 1 |
| Marsh, Rde W | 1 |
| Siddiqui, T | 1 |
| Mendenhall, WM | 1 |
| Zlotecki, RA | 1 |
| Grobmyer, S | 1 |
| Hochwald, S | 1 |
| Chang, M | 1 |
| Larson, B | 1 |
| King, J | 1 |
| Schwartz, J | 1 |
| Letari, O | 1 |
| Booth, C | 1 |
| Bonazzi, A | 1 |
| Garofalo, P | 1 |
| Makovec, F | 1 |
| Rovati, LC | 1 |
| Caselli, G | 1 |
| Bin, Q | 1 |
| Liao, C | 1 |
| Cao, Y | 3 |
| Pikó, B | 1 |
| Chen, RC | 2 |
| Mamon, HJ | 2 |
| Chen, YH | 1 |
| Gelman, RS | 1 |
| Suh, WW | 1 |
| Talcott, JA | 1 |
| Clark, JW | 1 |
| Seront, E | 1 |
| Marot, L | 1 |
| Coche, E | 1 |
| Gala, JL | 1 |
| Sempoux, C | 1 |
| Humblet, Y | 1 |
| Bao, HY | 2 |
| Fang, WJ | 1 |
| Zhang, XC | 1 |
| Shi, GM | 1 |
| Huang, S | 1 |
| Yu, LF | 1 |
| Mou, HB | 1 |
| Deng, J | 1 |
| Shen, P | 1 |
| Kruth, J | 1 |
| Nissen, J | 1 |
| Ernst, T | 2 |
| Kripp, M | 3 |
| Lukan, N | 2 |
| Merx, K | 2 |
| Hofmann, WK | 2 |
| Avallone, A | 1 |
| Delrio, P | 1 |
| Pecori, B | 1 |
| Tatangelo, F | 1 |
| Petrillo, A | 1 |
| Scott, N | 1 |
| Marone, P | 1 |
| Aloi, L | 1 |
| Sandomenico, C | 1 |
| Lastoria, S | 1 |
| Iaffaioli, VR | 1 |
| Scala, D | 1 |
| Iodice, G | 1 |
| Budillon, A | 1 |
| Comella, P | 1 |
| Wilson, K | 1 |
| Gebski, VJ | 1 |
| Cummins, MM | 1 |
| Zannino, D | 1 |
| Robinson, B | 2 |
| Broad, A | 1 |
| Ackland, SP | 3 |
| Forgeson, G | 1 |
| Saunders, MP | 1 |
| Stockler, MR | 1 |
| Chua, Y | 1 |
| Zalcberg, JR | 1 |
| Simes, RJ | 2 |
| Shabaruddin, FH | 1 |
| Elliott, RA | 1 |
| Newman, WG | 1 |
| Payne, K | 1 |
| Sweeney, CJ | 1 |
| Chiorean, EG | 2 |
| Verschraegen, CF | 1 |
| Lee, FC | 1 |
| Jones, S | 2 |
| Royce, M | 1 |
| Tye, L | 1 |
| Liau, KF | 1 |
| Bello, A | 1 |
| Chao, R | 1 |
| Burris, HA | 4 |
| Schønnemann, KR | 1 |
| Yilmaz, M | 1 |
| Andersen, M | 1 |
| Pfeiffer, P | 2 |
| Wu, ZQ | 1 |
| Han, XD | 1 |
| Yuan, KL | 1 |
| Jin, ZM | 1 |
| Di, JZ | 1 |
| Pan, Y | 2 |
| Zhang, P | 2 |
| Huang, XY | 1 |
| Wang, ZG | 1 |
| Zheng, Q | 4 |
| Wu, Z | 3 |
| Han, X | 3 |
| Qin, S | 2 |
| Dipetrillo, T | 1 |
| Pricolo, V | 1 |
| Lagares-Garcia, J | 1 |
| Vrees, M | 1 |
| Klipfel, A | 1 |
| Cataldo, T | 1 |
| Sikov, W | 1 |
| McNulty, B | 1 |
| Shipley, J | 1 |
| Anderson, E | 1 |
| Khurshid, H | 1 |
| Oconnor, B | 1 |
| Radie-Keane, K | 1 |
| Husain, S | 1 |
| Safran, H | 1 |
| Garufi, C | 3 |
| Torsello, A | 1 |
| Tumolo, S | 1 |
| Ettorre, GM | 1 |
| Zeuli, M | 2 |
| Campanella, C | 1 |
| Vennarecci, G | 1 |
| Mottolese, M | 1 |
| Sperduti, I | 1 |
| Cognetti, F | 3 |
| Silvestris, N | 1 |
| De Vita, F | 1 |
| Cinieri, S | 1 |
| Russo, A | 1 |
| Tommasi, S | 1 |
| Azzariti, A | 1 |
| Numico, G | 1 |
| Pisconti, S | 1 |
| Petriella, D | 1 |
| Lorusso, V | 1 |
| Millaku, A | 1 |
| Colucci, G | 1 |
| Thukral, A | 1 |
| Metz, J | 1 |
| Hwang, WT | 1 |
| O'Dwyer, P | 1 |
| Plastaras, J | 1 |
| Both, S | 1 |
| Bar-Ad, V | 1 |
| Ad, VB | 1 |
| Liu, LJ | 1 |
| Zhao, CH | 1 |
| Li, SS | 1 |
| Liu, JZ | 1 |
| Li, ZQ | 1 |
| Gallerani, E | 1 |
| Bauer, J | 1 |
| Hess, D | 1 |
| Boehm, S | 1 |
| Droege, C | 1 |
| Jeckelmann, S | 1 |
| Miani, M | 1 |
| Herrmann, R | 2 |
| Sperka, S | 1 |
| Sessa, C | 1 |
| Gil, T | 1 |
| Whenham, N | 1 |
| Van Hamme, J | 1 |
| Besse-Hammer, T | 1 |
| Brendel, E | 1 |
| Delesen, H | 1 |
| Joosten, MC | 1 |
| Lathia, CD | 1 |
| Loembé, BA | 1 |
| Piccart-Ghebart, M | 1 |
| Hendlisz, A | 1 |
| Chilimoniuk, M | 1 |
| Olszewska, E | 1 |
| Maksimowicz, T | 1 |
| Ishida, H | 2 |
| Fujita, K | 2 |
| Akiyama, Y | 1 |
| Sunakawa, Y | 2 |
| Mizuno, K | 1 |
| Miwa, K | 2 |
| Kawara, K | 1 |
| Ichikawa, W | 1 |
| Ando, Y | 1 |
| Saji, S | 2 |
| Sasaki, Y | 2 |
| Pinto, C | 1 |
| Di Fabio, F | 1 |
| Pini, S | 1 |
| Latiano, T | 1 |
| Aschele, C | 2 |
| Bochicchio, A | 1 |
| Rosati, G | 3 |
| Giaquinta, S | 1 |
| Torri, V | 2 |
| Bardelli, A | 1 |
| Gion, M | 1 |
| Martoni, A | 1 |
| Cabebe, EC | 1 |
| Fisher, GA | 1 |
| Sikic, BI | 1 |
| Xu, BH | 1 |
| Jiang, ZF | 2 |
| Chua, D | 1 |
| Shao, ZM | 1 |
| Luo, RC | 2 |
| Wang, XJ | 1 |
| Liu, DG | 1 |
| Yeo, W | 1 |
| Yu, SY | 2 |
| Newstat, B | 1 |
| Preston, A | 2 |
| Martin, AM | 1 |
| Chi, HD | 1 |
| Goto, T | 1 |
| Matsubara, T | 1 |
| Yoshizawa, Y | 1 |
| Sasaya, S | 1 |
| Nemoto, H | 1 |
| Sanada, Y | 1 |
| Moriyama, K | 1 |
| Kouchi, Y | 1 |
| Zhao, WY | 1 |
| Chen, DY | 1 |
| Qi, Q | 1 |
| Saridaki, Z | 1 |
| Malamos, N | 1 |
| Kourakos, P | 1 |
| Polyzos, A | 1 |
| Ardavanis, A | 1 |
| Androulakis, N | 3 |
| Kalbakis, K | 2 |
| Vamvakas, L | 1 |
| Georgoulias, V | 3 |
| Mavroudis, D | 3 |
| Winterhalder, R | 2 |
| Hoesli, P | 1 |
| Delmore, G | 1 |
| Pederiva, S | 1 |
| Bressoud, A | 1 |
| Hermann, F | 1 |
| Shin, SJ | 2 |
| Kim, SY | 1 |
| Park, YS | 2 |
| Park, SH | 1 |
| Kim, TW | 3 |
| Hong, YS | 3 |
| Ahn, JB | 3 |
| Bot, BM | 1 |
| Thomas, DM | 1 |
| Bleyer, A | 1 |
| Seymour, MT | 2 |
| Clarke, SJ | 2 |
| Yip, S | 1 |
| Brown, C | 1 |
| Ransom, DT | 1 |
| Goldstein, D | 2 |
| Jeffrey, GM | 1 |
| Buck, M | 1 |
| Lowenthal, RM | 1 |
| Boland, A | 1 |
| Zalcberg, J | 2 |
| Rotovnik Kozjek, N | 1 |
| Kompan, L | 1 |
| Soeters, P | 1 |
| Oblak, I | 1 |
| Mlakar Mastnak, D | 1 |
| Možina, B | 1 |
| Zadnik, V | 1 |
| Anderluh, F | 1 |
| Velenik, V | 1 |
| Di, J | 1 |
| Zhang, H | 1 |
| Du, Y | 1 |
| Cheng, Z | 1 |
| Kambe, M | 1 |
| Kikuchi, H | 1 |
| Gamo, M | 1 |
| Ohashi, Y | 1 |
| Kanamaru, R | 1 |
| Guan, ZZ | 2 |
| Feng, FY | 1 |
| Wang, LW | 2 |
| Shen, L | 2 |
| Ba, Y | 2 |
| Liang, J | 1 |
| Wang, D | 1 |
| Qin, SK | 2 |
| Wang, JJ | 1 |
| Qi, C | 1 |
| Xu, RH | 2 |
| Membrive Conejo, I | 1 |
| Reig Castillejo, A | 1 |
| Rodríguez de Dios, N | 1 |
| Foro Arnalot, P | 1 |
| Sanz Latiesas, J | 1 |
| Lozano Galán, J | 1 |
| Lacruz Bassols, M | 1 |
| Quera Jordana, J | 1 |
| Fernández-Velilla Cepria, E | 1 |
| Algara López, M | 1 |
| Wettergren, Y | 1 |
| Carlsson, G | 1 |
| Odin, E | 1 |
| Gustavsson, B | 1 |
| Arbea, L | 1 |
| Martínez-Monge, R | 2 |
| Díaz-González, JA | 1 |
| Moreno, M | 1 |
| Rodríguez, J | 2 |
| Hernández, JL | 1 |
| Sola, JJ | 1 |
| Ramos, LI | 1 |
| Subtil, JC | 1 |
| Nuñez, J | 1 |
| Chopitea, A | 1 |
| Cambeiro, M | 1 |
| Gaztañaga, M | 1 |
| García-Foncillas, J | 1 |
| Aristu, J | 1 |
| Kadoyama, K | 1 |
| Miki, I | 1 |
| Tamura, T | 1 |
| Brown, JB | 1 |
| Sakaeda, T | 1 |
| Okuno, Y | 1 |
| Xiang, XJ | 1 |
| Qiu, F | 1 |
| Yu, F | 1 |
| Zhan, ZY | 1 |
| Feng, M | 1 |
| Zhao, JG | 1 |
| Xiong, JP | 2 |
| Huang, HY | 1 |
| Wang, T | 1 |
| Zhang, SH | 1 |
| Bian, L | 1 |
| Wu, SK | 1 |
| Song, ST | 2 |
| Wieneke, J | 1 |
| Welzel, G | 1 |
| Brade, J | 1 |
| Gencer, D | 1 |
| Pericay, C | 1 |
| Valladares-Ayerbes, M | 1 |
| Gil-Calle, S | 1 |
| Massutí, B | 1 |
| González-Flores, E | 1 |
| Cabrera, E | 1 |
| Queralt, B | 1 |
| Gómez, MJ | 1 |
| Guasch, I | 1 |
| Etxeberría, A | 1 |
| Alfaro, J | 1 |
| Campos, JM | 1 |
| Reina, JJ | 1 |
| Ancukiewicz, M | 1 |
| Killoran, JH | 1 |
| Crowley, EM | 1 |
| Blaszkowsky, LS | 1 |
| Wo, JY | 1 |
| Ryan, DP | 2 |
| Tarver, K | 1 |
| Conibear, J | 1 |
| Raouf, S | 1 |
| Cai, X | 1 |
| Xue, P | 1 |
| Song, WF | 1 |
| Hu, J | 1 |
| Gu, HL | 1 |
| Yang, HY | 2 |
| Sanghani, S | 1 |
| Schiel, MA | 1 |
| Yu, M | 1 |
| Burns, M | 1 |
| Tong, Y | 1 |
| Hinkle, DT | 1 |
| Coleman, N | 1 |
| Robb, B | 1 |
| LeBlanc, J | 1 |
| Clark, R | 1 |
| Bufill, J | 1 |
| Curie, C | 1 |
| Loehrer, PJ | 1 |
| Cardenes, H | 1 |
| Sasaki, T | 3 |
| Kato, Y | 1 |
| Farid, M | 1 |
| Chowbay, B | 1 |
| Tan, SH | 1 |
| Ramasamy, S | 1 |
| Koo, WH | 3 |
| Toh, HC | 1 |
| Choo, SP | 1 |
| Ong, SY | 1 |
| Sargen, M | 1 |
| Wanat, KA | 1 |
| Jambusaria, A | 1 |
| Rosenbach, M | 1 |
| Sobanko, J | 1 |
| Miller, CJ | 1 |
| Qi, WX | 1 |
| Tang, LN | 1 |
| He, AN | 1 |
| Shen, Z | 1 |
| Yao, Y | 2 |
| Woloch, C | 1 |
| Di Paolo, A | 3 |
| Marouani, H | 1 |
| Bocci, G | 2 |
| Ciccolini, J | 1 |
| Lacarelle, B | 1 |
| Danesi, R | 3 |
| Iliadis, A | 1 |
| Vassiliou, V | 1 |
| Kountourakis, P | 1 |
| Yasuda, M | 1 |
| Yamanaka, N | 1 |
| Iimori, M | 1 |
| Kitahara, Y | 1 |
| Takeuchi, K | 1 |
| Sairanen, U | 1 |
| Blom, M | 1 |
| Rautio, M | 1 |
| Saxelin, M | 2 |
| Lee, SS | 1 |
| Kim, KP | 1 |
| Lee, JL | 1 |
| Jung, KH | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Helbling, D | 1 |
| Gautschi, O | 1 |
| Sun, H | 1 |
| Gloor, B | 1 |
| Burkhard, R | 1 |
| Madlung, A | 1 |
| Rauch, D | 1 |
| Saletti, P | 2 |
| Widmer, L | 1 |
| Borner, M | 2 |
| Baertschi, D | 1 |
| Benhattar, J | 1 |
| Leibundgut, EO | 1 |
| Bougel, S | 1 |
| Koeberle, D | 1 |
| Andoh, A | 1 |
| Shioya, M | 1 |
| Francois, E | 5 |
| Bennouna, J | 2 |
| Chamorey, E | 2 |
| Etienne-Grimaldi, MC | 2 |
| Renée, N | 2 |
| Senellart, H | 1 |
| Michel, C | 1 |
| Follana, P | 1 |
| Mari, V | 2 |
| Douillard, JY | 4 |
| Huang, DZ | 1 |
| Yan, Z | 1 |
| Zhuang, ZX | 1 |
| Yu, Z | 1 |
| Wan, HP | 1 |
| Deng, T | 1 |
| Zheng, RS | 1 |
| Guo, ZQ | 1 |
| Hu, CH | 1 |
| Wang, ML | 1 |
| Yu, ZH | 2 |
| Meng, JC | 1 |
| Adenis, A | 3 |
| Pignon, JP | 1 |
| Chauffert, B | 1 |
| Ichanté, JL | 1 |
| Boucher, E | 1 |
| Ychou, M | 4 |
| Pierga, JY | 1 |
| Montoto-Grillot, C | 1 |
| Conroy, T | 2 |
| Swieboda-Sadlej, A | 1 |
| Staszewska-Skurczynska, M | 1 |
| Lim, R | 1 |
| Roman, L | 1 |
| Shparyk, Y | 1 |
| Bondarenko, I | 1 |
| Jonker, DJ | 1 |
| Sun, Y | 1 |
| De la Cruz, JA | 1 |
| Williams, JA | 1 |
| Korytowsky, B | 1 |
| Christensen, JG | 1 |
| Lin, X | 1 |
| Tursi, JM | 1 |
| Lechuga, MJ | 1 |
| Russo, F | 1 |
| Linsalata, M | 1 |
| Clemente, C | 1 |
| D'Attoma, B | 1 |
| Orlando, A | 1 |
| Campanella, G | 1 |
| Giotta, F | 1 |
| Riezzo, G | 1 |
| Hasegawa, S | 2 |
| Nishizaki, M | 1 |
| Shoji, T | 1 |
| Nakagawa, T | 2 |
| Tokuyama, S | 1 |
| Sbar, EI | 1 |
| Khatri, J | 1 |
| Rodman, WD | 1 |
| Tritschler, L | 1 |
| Goldberg, J | 1 |
| Grana, G | 1 |
| Devereux, L | 1 |
| Hageboutros, A | 3 |
| Mohiuddin, M | 2 |
| Marks, G | 2 |
| Marks, J | 1 |
| Miller, RC | 2 |
| Martenson, JA | 3 |
| Macdonald, JS | 5 |
| Haller, D | 1 |
| Mayer, RJ | 4 |
| Gunderson, LL | 2 |
| Rich, TA | 1 |
| Cha, SS | 1 |
| Rothenberg, ML | 3 |
| Benedetti, JK | 1 |
| Neubauer, MA | 1 |
| George, CS | 1 |
| Tanaka, MS | 1 |
| Giguere, JK | 1 |
| Pruitt, BT | 1 |
| Abbruzzese, JL | 1 |
| Scheithauer, W | 5 |
| Kornek, GV | 1 |
| Raderer, M | 1 |
| Schüll, B | 1 |
| Schmid, K | 1 |
| Längle, F | 1 |
| Huber, H | 1 |
| Kaufmann, SH | 1 |
| Atherton, P | 1 |
| Sloan, JA | 1 |
| Adjei, AA | 1 |
| Pitot, HC | 1 |
| Rubin, J | 3 |
| Miller, LL | 3 |
| Erlichman, C | 4 |
| Carlomagno, C | 1 |
| Lauria, R | 1 |
| De Laurentiis, M | 1 |
| Arpino, G | 1 |
| Massarelli, E | 1 |
| Ferrara, C | 1 |
| Milano, A | 1 |
| Vernaglia Lombardi, A | 1 |
| Costanzo, R | 1 |
| Catalano, G | 8 |
| Bianco, AR | 1 |
| De Placido, S | 1 |
| Calvo, E | 1 |
| González-Cao, M | 1 |
| Aramendía, JM | 1 |
| Fernández-Hidalgo, O | 1 |
| Martín-Algarra, S | 1 |
| Salgado, JE | 1 |
| de Irala, J | 1 |
| Brugarolas, A | 1 |
| Yang, TS | 1 |
| Tang, R | 1 |
| Hsu, KC | 1 |
| Chen, JS | 2 |
| Leonard, P | 1 |
| James, R | 1 |
| Hochhauser, D | 1 |
| Ledermann, JA | 1 |
| Emens, LA | 1 |
| Kennedy, MJ | 1 |
| Fetting, JH | 1 |
| Davidson, NE | 1 |
| Garrett, E | 1 |
| Armstrong, DK | 1 |
| Allegrini, G | 2 |
| Innocenti, F | 2 |
| Conte, PF | 1 |
| Del Tacca, M | 2 |
| Farrell, MP | 1 |
| Kummar, S | 1 |
| Okabe, S | 1 |
| Tanami, H | 1 |
| Kuwabara, H | 1 |
| Fukahara, T | 1 |
| Udagawa, M | 1 |
| Ootsukasa, S | 1 |
| Arai, T | 1 |
| Murase, N | 1 |
| Yamashita, H | 1 |
| Iwai, T | 1 |
| Alimonti, A | 1 |
| Satta, F | 1 |
| Pavese, I | 1 |
| Burattini, E | 1 |
| Zoffoli, V | 1 |
| Vecchione, A | 1 |
| Videtic, GM | 1 |
| Campbell, C | 1 |
| Vincent, MD | 1 |
| Norman, AR | 1 |
| Allen, M | 1 |
| Oates, J | 1 |
| Hill, M | 2 |
| Schneider, HB | 1 |
| Becker, H | 1 |
| Von Bültzingslöwen, I | 1 |
| Adlerberth, I | 1 |
| Wold, AE | 1 |
| Dahlén, G | 1 |
| Jontell, M | 1 |
| Cassinello, J | 1 |
| Escudero, P | 1 |
| Salud, A | 1 |
| Marcos, F | 1 |
| Pujol, E | 1 |
| Pérez-Carrión, R | 1 |
| Colmenarejo, A | 1 |
| González del Val, R | 1 |
| Valero, J | 1 |
| Oruezábal, MJ | 1 |
| Guillem, V | 1 |
| García, I | 1 |
| Arcediano, A | 1 |
| Marfà, X | 1 |
| Tsavaris, N | 1 |
| Kosmas, C | 1 |
| Vadiaka, M | 1 |
| Zonios, D | 1 |
| Papalambros, E | 1 |
| Papantoniou, N | 1 |
| Margaris, H | 1 |
| Zografos, G | 1 |
| Rokana, S | 1 |
| Retalis, G | 1 |
| Koufos, C | 1 |
| ANSFIELD, FJ | 4 |
| CURRERI, AR | 1 |
| CUDMORE, JT | 1 |
| GROESBECK, HP | 1 |
| SCHELL, HW | 1 |
| HURLEY, JD | 1 |
| MCCAFFERY, JF | 1 |
| Stickel, F | 1 |
| Jüngert, B | 1 |
| Brueckl, V | 1 |
| Schirner, I | 1 |
| Brueckl, WM | 1 |
| Männlein, G | 1 |
| Hegewald, J | 1 |
| Mühldorfer, S | 1 |
| Bittorf, B | 1 |
| Hohenberger, W | 2 |
| Hahn, EG | 1 |
| Wein, A | 1 |
| Shirao, K | 1 |
| Gourley, C | 1 |
| Edwards, C | 1 |
| Samuel, L | 2 |
| Bisset, D | 1 |
| Camboni, G | 1 |
| Young, A | 1 |
| Boyle, D | 1 |
| Jodrell, D | 2 |
| McKendrick, J | 1 |
| Begbie, S | 1 |
| Burns, WI | 1 |
| Levine, EL | 1 |
| Marschner, N | 1 |
| Maroun, J | 2 |
| Tujakowski, J | 1 |
| Van Hazel, G | 1 |
| Wong, A | 2 |
| Antón, A | 1 |
| Cervantes, A | 4 |
| Abad, A | 1 |
| Sastre, J | 1 |
| Fenández-Martos, C | 1 |
| Gallén, M | 2 |
| Huarte, L | 1 |
| Balcells, M | 1 |
| Viele, CS | 1 |
| Kalofonos, HP | 1 |
| Skarlos, D | 1 |
| Bafaloukos, D | 1 |
| Papakostas, P | 1 |
| Bamias, A | 1 |
| Janinis, J | 1 |
| Timotheadou, E | 1 |
| Kouvatseas, G | 1 |
| Stavropoulos, M | 1 |
| Economopulos, T | 1 |
| Fountzilas, G | 1 |
| Masi, G | 1 |
| Barbara, C | 1 |
| Cupini, S | 1 |
| Parulekar, W | 1 |
| de Marsh, RW | 1 |
| Mendenhall, W | 1 |
| Davey, P | 1 |
| Zlotecki, R | 1 |
| Berry, S | 1 |
| Rout, WR | 1 |
| Bjarnason, GA | 1 |
| Cohen, SM | 1 |
| Neugut, AI | 1 |
| Akaike, M | 1 |
| Yamamoto, Y | 1 |
| Shiraishi, R | 1 |
| Ozawa, Y | 1 |
| Suzuki, H | 1 |
| Miyazaki, T | 1 |
| Kasahara, A | 1 |
| Makino, T | 1 |
| Tamura, I | 1 |
| Tanabe, H | 1 |
| Rino, Y | 1 |
| Schultz, M | 1 |
| Schölmerich, J | 1 |
| Kullmann, F | 1 |
| Rixe, O | 1 |
| Favre, R | 1 |
| Merad, L | 1 |
| Deplanque, G | 1 |
| Laadem, A | 1 |
| Juin, P | 1 |
| Bereder, JM | 1 |
| Bernardini, D | 1 |
| Herait, P | 3 |
| Jordan, K | 1 |
| Kellner, O | 1 |
| Kegel, T | 1 |
| Kakolyris, S | 2 |
| Souglakos, J | 2 |
| Kouroussis, C | 1 |
| Samonis, G | 2 |
| Vardakis, N | 2 |
| Amarantidis, K | 1 |
| Agelaki, S | 2 |
| Xenidis, N | 1 |
| Kuehr, T | 1 |
| Rapoport, BL | 1 |
| Falk, S | 1 |
| Daniel, F | 1 |
| Jacobs, C | 2 |
| Davidson, N | 1 |
| Boussard, B | 1 |
| Carmichael, J | 1 |
| Teufel, A | 1 |
| Steinmann, S | 1 |
| Siebler, J | 1 |
| Zanke, C | 1 |
| Hohl, H | 1 |
| Adami, B | 1 |
| Schroeder, M | 1 |
| Klein, O | 2 |
| Höhler, T | 1 |
| Galle, PR | 1 |
| Heike, M | 2 |
| Schmittel, A | 1 |
| Jahnke, K | 1 |
| Thiel, E | 2 |
| Keilholz, U | 1 |
| Carlo, WF | 1 |
| Hummer, AJ | 1 |
| Schwartz, L | 1 |
| Sullivan, D | 1 |
| Gonen, M | 1 |
| Jarnagin, W | 1 |
| Fong, Y | 1 |
| Kemeny, N | 3 |
| Song, SY | 1 |
| Lee, SI | 1 |
| Chung, HC | 1 |
| Choi, SH | 1 |
| Noh, SH | 1 |
| Park, JN | 1 |
| Han, JY | 1 |
| Kang, JH | 1 |
| Lee, KS | 2 |
| Cho, JY | 1 |
| Tucci, A | 2 |
| Rinaldi, A | 1 |
| Colarusso, D | 1 |
| Pizza, C | 2 |
| Reggiardo, G | 1 |
| Manzione, L | 3 |
| Marsé, H | 1 |
| Valverde, S | 1 |
| Sternberg, CN | 1 |
| Holland, M | 1 |
| Hirao, M | 1 |
| Fujitani, K | 1 |
| Tsujinaka, T | 1 |
| Garcia, AA | 1 |
| Leichman, L | 2 |
| Baranda, J | 1 |
| Pandit, L | 1 |
| Lenz, HJ | 1 |
| Leichman, CG | 3 |
| Lebowitz, PF | 1 |
| Eng-Wong, J | 1 |
| Swain, SM | 1 |
| Berman, A | 1 |
| Merino, MJ | 1 |
| Chow, CK | 1 |
| Venzon, D | 1 |
| Zia, F | 1 |
| Danforth, D | 1 |
| Liu, E | 1 |
| Zujewski, J | 1 |
| Mackey, JR | 1 |
| Tonkin, KS | 1 |
| Koski, SL | 1 |
| Scarfe, AG | 1 |
| Smylie, MG | 1 |
| Joy, AA | 1 |
| Au, HJ | 1 |
| Bodnar, DM | 1 |
| Soulieres, D | 1 |
| Smith, SW | 1 |
| Undevia, SD | 1 |
| Janisch, L | 1 |
| Olson, SC | 1 |
| Schilsky, RL | 1 |
| Vogelzang, NJ | 1 |
| Kimmel, KA | 1 |
| Macek, TA | 1 |
| Ratain, MJ | 3 |
| Lokich, J | 3 |
| Carlini, LE | 1 |
| Meropol, NJ | 5 |
| Bever, J | 1 |
| Andria, ML | 1 |
| Hill, T | 1 |
| Gold, P | 1 |
| Rogatko, A | 2 |
| Blanchard, RL | 1 |
| Mattek, NC | 1 |
| Deloughery, TG | 1 |
| Koop, DR | 1 |
| Dong, QM | 2 |
| He, YJ | 2 |
| Li, S | 2 |
| Zhou, ZM | 2 |
| Zhou, ZW | 1 |
| Xia, ZJ | 1 |
| Li, YY | 1 |
| Veronese, ML | 1 |
| Sun, W | 1 |
| Giantonio, B | 1 |
| Berlin, J | 1 |
| Shults, J | 1 |
| Davis, L | 1 |
| O'Dwyer, PJ | 2 |
| Wright, MA | 1 |
| Morrison, G | 1 |
| Lin, P | 1 |
| Leonard, GD | 1 |
| Nguyen, D | 1 |
| Guo, X | 1 |
| Szabo, E | 1 |
| Hopkins, JL | 1 |
| Leguizamo, JP | 1 |
| Harold, N | 1 |
| Fioravanti, S | 1 |
| Schuler, B | 1 |
| Monahan, BP | 1 |
| Quinn, MG | 1 |
| Pang, J | 1 |
| Grem, JL | 3 |
| Chiba, N | 1 |
| Shibata, H | 1 |
| Sakayori, M | 1 |
| Otsuka, K | 1 |
| Kakudo, Y | 1 |
| Ohori, H | 1 |
| Yamaura, G | 1 |
| Takahashi, M | 1 |
| Yasuda, K | 1 |
| Ishioka, C | 1 |
| Kang, WK | 1 |
| Chang, HM | 1 |
| Park, JO | 1 |
| Ryoo, BY | 1 |
| Ahn, JS | 1 |
| Zang, DY | 1 |
| Kim, SR | 1 |
| Kim, HK | 1 |
| Prévost, A | 1 |
| Mérol, JC | 1 |
| Aimé, P | 1 |
| Moutel, K | 1 |
| Roger-Liautaud, F | 1 |
| Nasca, S | 1 |
| Legros, M | 1 |
| Coninx, P | 1 |
| Pan, CX | 1 |
| Loehrer, P | 1 |
| Seitz, D | 1 |
| Helft, P | 1 |
| Juliar, B | 1 |
| Ansari, R | 2 |
| Pletcher, W | 1 |
| Vinson, J | 1 |
| Cheng, L | 1 |
| Sweeney, C | 1 |
| Lee, A | 1 |
| Ezzeldin, H | 1 |
| Fourie, J | 1 |
| Diasio, R | 1 |
| Viale, PH | 1 |
| Fung, A | 1 |
| Zitella, L | 1 |
| Liu, YP | 1 |
| Wang, WH | 1 |
| Song, YW | 1 |
| Li, N | 1 |
| Liu, XF | 1 |
| Ferrari, V | 1 |
| Valcamonico, F | 1 |
| Amoroso, V | 1 |
| Simoncini, E | 1 |
| Vassalli, L | 1 |
| Marpicati, P | 1 |
| Rangoni, G | 1 |
| Grisanti, S | 1 |
| Pasinetti, N | 1 |
| Marini, G | 2 |
| Kim, SJ | 1 |
| Miyoshi, Y | 1 |
| Tanji, Y | 1 |
| Tamaki, Y | 1 |
| Noguchi, S | 1 |
| Catalano, PJ | 1 |
| O'Rourke, MA | 1 |
| Frontiera, MS | 1 |
| Jackson, DV | 1 |
| Stathopoulos, GP | 1 |
| Rigatos, SK | 1 |
| Stathopoulos, JG | 1 |
| Xynotroulas, JP | 1 |
| Dimou, E | 1 |
| Levy, C | 1 |
| Fumoleau, P | 1 |
| Farker, K | 1 |
| Merkel, U | 1 |
| Wedding, U | 1 |
| Hippius, M | 1 |
| Höffken, K | 2 |
| Hoffmann, A | 1 |
| Martinez, J | 1 |
| Martin, C | 1 |
| Chacon, M | 1 |
| Korbenfeld, E | 1 |
| Bella, S | 1 |
| Senna, S | 1 |
| Richardet, E | 1 |
| Coppola, F | 1 |
| Bas, C | 1 |
| Hidalgo, J | 1 |
| Escobar, E | 1 |
| Reale, M | 1 |
| Smilovich, AM | 1 |
| Wasserman, E | 2 |
| Cho, BC | 1 |
| Kim, CB | 1 |
| Choi, HJ | 1 |
| Lee, YC | 1 |
| Cho, MJ | 1 |
| Yoon, WH | 1 |
| Song, KS | 1 |
| Shimomatsuya, T | 1 |
| Kobuchi, T | 1 |
| Kitamura, N | 1 |
| Hata, K | 1 |
| Shiraishi, S | 1 |
| Fujino, H | 1 |
| Maruhashi, K | 1 |
| Sharma, R | 1 |
| Rivory, L | 1 |
| Beale, P | 1 |
| Ong, S | 1 |
| Horvath, L | 1 |
| Niedzwiecki, D | 1 |
| Hollis, D | 2 |
| Mediema, BE | 1 |
| Wadler, S | 3 |
| Tepper, JE | 2 |
| Yerushalmi, R | 1 |
| Idelevich, E | 1 |
| Dror, Y | 1 |
| Stemmer, SM | 1 |
| Figer, A | 2 |
| Sulkes, A | 1 |
| Brenner, B | 1 |
| Loven, D | 1 |
| Dreznik, Z | 1 |
| Nudelman, I | 1 |
| Shani, A | 1 |
| Fenig, E | 1 |
| Dotor, E | 1 |
| Rivera, F | 1 |
| Sánchez-Rovira, P | 1 |
| Vega-Villegas, ME | 1 |
| García, JL | 1 |
| Tho, LM | 1 |
| Glegg, M | 1 |
| Paterson, J | 1 |
| Yap, C | 1 |
| MacLeod, A | 1 |
| McCabe, M | 1 |
| Berg, DT | 1 |
| Peng, RJ | 1 |
| Shi, YX | 2 |
| Yuan, ZY | 1 |
| Li, H | 1 |
| Jiang, WQ | 2 |
| Rosen, LS | 3 |
| Abdi, E | 1 |
| Davis, ID | 1 |
| Gutheil, J | 1 |
| Schnell, FM | 1 |
| Cesano, A | 1 |
| Gayko, U | 1 |
| Chen, MG | 1 |
| Clarke, S | 1 |
| Shah, A | 1 |
| Spirovski, B | 1 |
| Vincent, M | 1 |
| Kuboki, Y | 1 |
| Zhang, W | 1 |
| Zhao, ZY | 1 |
| Wu, Q | 1 |
| Cheng, J | 1 |
| Wu, CP | 1 |
| Xu, LG | 1 |
| Czito, BG | 1 |
| Bendell, JC | 1 |
| Willett, CG | 1 |
| Morse, MA | 1 |
| Blobe, GC | 1 |
| Tyler, DS | 1 |
| Thomas, J | 1 |
| Ludwig, KA | 1 |
| Mantyh, CR | 1 |
| Ashton, J | 1 |
| Yu, D | 1 |
| Hurwitz, HI | 1 |
| Zampino, MG | 1 |
| Magni, E | 1 |
| Massacesi, C | 1 |
| Martignetti, A | 1 |
| Zorzino, L | 1 |
| Lorizzo, K | 1 |
| Santoro, L | 1 |
| Boselli, S | 1 |
| Wisinski, K | 1 |
| Benson, A | 1 |
| Zhang, HG | 1 |
| Zhang, YJ | 1 |
| Song, SP | 1 |
| Chu, DT | 1 |
| Vénat-Bouvet, L | 1 |
| Saint-Marcoux, F | 1 |
| Lagarde, C | 1 |
| Peyronnet, P | 1 |
| Lebrun-Ly, V | 1 |
| Tubiana-Mathieu, N | 1 |
| Bartsch, R | 1 |
| Wenzel, C | 2 |
| Altorjai, G | 1 |
| Pluschnig, U | 1 |
| Rudas, M | 1 |
| Mader, RM | 1 |
| Gnant, M | 1 |
| Zielinski, CC | 2 |
| Steger, GG | 2 |
| Yamamitsu, S | 1 |
| Kimura, H | 1 |
| Inui, N | 1 |
| Hiyama, S | 1 |
| Hirata, K | 1 |
| Kimura, Y | 1 |
| Shirasaka, T | 2 |
| Luo, HY | 1 |
| Li, YH | 1 |
| Yoshino, T | 1 |
| Boku, N | 1 |
| Onozawa, Y | 1 |
| Hironaka, S | 1 |
| Fukutomi, A | 1 |
| Yamaguchi, Y | 1 |
| Hasuike, N | 1 |
| Machida, N | 1 |
| Ono, H | 1 |
| Kuebler, JP | 1 |
| Colangelo, L | 1 |
| Smith, RE | 1 |
| Begovic, M | 1 |
| Katia, D | 1 |
| Zilembo, N | 1 |
| Bochicchio, AM | 1 |
| Massidda, B | 2 |
| Ardizzoia, A | 2 |
| Ardizzoni, A | 1 |
| Aitini, E | 1 |
| Schieppati, G | 1 |
| Comella, G | 1 |
| Pinotti, G | 1 |
| Palazzo, S | 1 |
| Cicero, G | 1 |
| Villa, E | 1 |
| Fagnani, D | 1 |
| Reguzzoni, G | 1 |
| Agostana, B | 1 |
| Oliani, C | 1 |
| Kildani, B | 1 |
| Duro, M | 1 |
| Botta, M | 1 |
| Mozzana, R | 1 |
| Mantovani, G | 1 |
| Topkan, E | 1 |
| Karaoglu, A | 1 |
| Rödel, C | 1 |
| Hipp, M | 1 |
| Liersch, T | 1 |
| Dellas, K | 1 |
| Iesalnieks, I | 1 |
| Hermann, RM | 1 |
| Sauer, R | 1 |
| Ruotsalainen, T | 1 |
| Ollus, A | 1 |
| Valta, P | 1 |
| Kouri, M | 1 |
| Elomaa, I | 1 |
| Lockman, D | 1 |
| Wallace, M | 1 |
| Cardot, JM | 1 |
| Gamelin, E | 2 |
| Château, Y | 1 |
| Bai, P | 1 |
| Zhang, R | 1 |
| Li, XG | 1 |
| Ma, SK | 1 |
| Wu, LY | 1 |
| Zhang, WH | 1 |
| Gnad-Vogt, U | 1 |
| Schultheis, B | 1 |
| De Greve, J | 1 |
| Hartmann, JT | 1 |
| Vergauwe, P | 1 |
| Becker, K | 1 |
| Braumann, D | 2 |
| Joosens, E | 1 |
| Janssens, J | 1 |
| Bokemeyer, C | 3 |
| Reimer, P | 1 |
| Link, H | 1 |
| Späth-Schwalbe, E | 1 |
| Wilke, HJ | 2 |
| Bleiberg, H | 3 |
| Van Den Brande, J | 1 |
| Debois, M | 1 |
| Bethe, U | 1 |
| Crown, JP | 1 |
| Boyle, F | 1 |
| Koehler, M | 1 |
| Newstat, BO | 1 |
| Parikh, R | 1 |
| Oliva, C | 1 |
| Byrne, J | 1 |
| Chan, S | 1 |
| Berdah, JF | 1 |
| Lesbats, G | 1 |
| Teissier, E | 1 |
| Codoul, JF | 1 |
| Badetti, JL | 1 |
| Hébert, C | 1 |
| Ezzeldin, HH | 1 |
| Schwab, M | 1 |
| Zanger, UM | 1 |
| Marx, C | 1 |
| Schaeffeler, E | 1 |
| Klein, K | 1 |
| Dippon, J | 1 |
| Kerb, R | 1 |
| Blievernicht, J | 1 |
| Fischer, J | 1 |
| Hofmann, U | 1 |
| Eichelbaum, M | 1 |
| Gasperoni, S | 2 |
| Bisagni, G | 1 |
| Labianca, R | 4 |
| Bravi, S | 1 |
| Cortesi, E | 2 |
| Carlini, P | 1 |
| Bracci, R | 1 |
| Tomao, S | 1 |
| Messerini, L | 1 |
| Arcangeli, A | 1 |
| Bilancia, D | 1 |
| Floriani, I | 1 |
| Tonato, M | 1 |
| Dinota, A | 1 |
| Strafiuso, G | 1 |
| Corgna, E | 1 |
| Porrozzi, S | 1 |
| Boni, C | 2 |
| Rondini, E | 1 |
| Giunta, A | 1 |
| Monzio Compagnoni, B | 1 |
| Biagioni, F | 1 |
| Cesari, M | 1 |
| Fornarini, G | 1 |
| Nelli, F | 1 |
| Carboni, M | 1 |
| Enzo, MR | 1 |
| Piga, A | 1 |
| Romiti, A | 1 |
| Olivetti, A | 1 |
| Masoni, L | 1 |
| De Stefanis, M | 1 |
| Dalla Mola, A | 1 |
| Camera, S | 1 |
| Recchia, F | 1 |
| De Filippis, S | 1 |
| Scipioni, L | 1 |
| Zironi, S | 1 |
| Luppi, G | 2 |
| Italia, M | 1 |
| Banducci, S | 1 |
| Pisani Leretti, A | 1 |
| Ionta, MT | 1 |
| Nicolosi, A | 1 |
| Canaletti, R | 1 |
| Biscottini, B | 1 |
| Grigniani, F | 1 |
| Rovei, R | 1 |
| Croce, E | 1 |
| Carroccio, R | 1 |
| Gilli, G | 1 |
| Cavalli, C | 1 |
| Olgiati, A | 1 |
| Pandolfi, U | 1 |
| Rossetti, R | 1 |
| Natalini, G | 1 |
| Foa, P | 1 |
| Oldani, S | 1 |
| Bruno, L | 1 |
| Cascinu, S | 7 |
| Catalano, V | 2 |
| Lungarotti, F | 1 |
| Farris, A | 1 |
| Sarobba, MG | 1 |
| Trignano, M | 1 |
| Muscogiuri, A | 1 |
| Francavilla, F | 1 |
| Figoli, F | 1 |
| Leoni, M | 1 |
| Papiani, G | 1 |
| Orselli, G | 1 |
| Antimi, M | 1 |
| Bellini, V | 1 |
| Cabassi, A | 1 |
| Contu, A | 1 |
| Pazzola, A | 1 |
| Frignano, M | 1 |
| Lastraioli, E | 1 |
| Saggese, M | 1 |
| Bianchini, D | 1 |
| Antonuzzo, L | 1 |
| Mela, M | 1 |
| Camisa, R | 1 |
| Valentini, V | 2 |
| De Paoli, A | 1 |
| Gambacorta, MA | 1 |
| Mantini, G | 2 |
| Ratto, C | 1 |
| Vecchio, FM | 1 |
| Barbaro, B | 2 |
| Innocente, R | 1 |
| Rossi, C | 1 |
| Boz, G | 1 |
| Barba, MC | 1 |
| Frattegiani, A | 1 |
| Lupattelli, M | 1 |
| Doglietto, GB | 1 |
| Gruenberger, B | 1 |
| Tamandl, D | 1 |
| Schueller, J | 1 |
| Zielinski, C | 1 |
| Herbst, F | 1 |
| Gruenberger, T | 1 |
| Punt, CJ | 1 |
| Koopman, M | 1 |
| Meadows, H | 1 |
| Wan, S | 1 |
| Gollins, S | 1 |
| Leslie, M | 1 |
| Levine, E | 1 |
| Myint, S | 1 |
| Sebag-Montefiore, D | 1 |
| Wang, JW | 1 |
| Jiao, SC | 1 |
| Zhang, JS | 1 |
| Yang, L | 1 |
| Sung, HC | 1 |
| Wu, PC | 1 |
| Habeshaw, T | 1 |
| Adam, JS | 1 |
| Kirk, J | 1 |
| Melia, WM | 1 |
| Nunnerley, HB | 1 |
| Johnson, PJ | 1 |
| Williams, R | 1 |
| Kemeny, NE | 3 |
| Ahmed, T | 1 |
| Michaelson, RA | 1 |
| Harper, HD | 1 |
| Yip, LC | 1 |
| Ardalan, B | 3 |
| Jamin, D | 1 |
| Jayaram, HN | 1 |
| Presant, CA | 2 |
| Singer, Z | 1 |
| Kozaczka, A | 1 |
| Wilk, J | 1 |
| Janas, J | 1 |
| Becker, HD | 1 |
| Browman, GP | 1 |
| Archibald, SD | 1 |
| Young, JE | 1 |
| Hryniuk, WM | 1 |
| Russell, R | 1 |
| Kiehl, K | 1 |
| Levine, MN | 1 |
| Denes, AE | 1 |
| Liu, C | 1 |
| Bartolucci, AA | 1 |
| Bedikian, AY | 1 |
| Bodey, GP | 1 |
| Valdivieso, M | 1 |
| Burgess, MA | 1 |
| Windschitl, H | 1 |
| Scott, M | 1 |
| Schutt, A | 1 |
| McCormack, G | 1 |
| Everson, L | 1 |
| Cullinan, S | 1 |
| Gerstner, J | 1 |
| Krook, J | 1 |
| Laurie, J | 1 |
| Shreck, R | 1 |
| Chlebowski, RT | 1 |
| Silverberg, I | 1 |
| Pajak, T | 1 |
| Weiner, J | 1 |
| Kardinal, C | 1 |
| Bateman, JR | 1 |
| Vogl, SE | 1 |
| Lanham, R | 1 |
| Kaplan, BH | 1 |
| Gasser, RW | 1 |
| Schmalzl, F | 1 |
| Gardner, ML | 1 |
| Plumb, JA | 1 |
| Creaven, PJ | 3 |
| Francini, G | 1 |
| Petrioli, R | 1 |
| Aquino, A | 1 |
| Gonnelli, S | 1 |
| Sugano, K | 1 |
| Ogawa, N | 2 |
| Kurihara, M | 3 |
| Akazawa, S | 3 |
| Tominaga, T | 2 |
| Konishi, T | 2 |
| Dorval, ED | 1 |
| Regimbeau, C | 1 |
| Picon, L | 1 |
| Bérard, H | 1 |
| Fleming, TR | 1 |
| Muggia, FM | 2 |
| Tangen, CM | 1 |
| Doroshow, JH | 1 |
| Meyers, FJ | 1 |
| Holcombe, RF | 1 |
| Weiss, GR | 2 |
| Mangalik, A | 1 |
| Takeda, S | 1 |
| Ohta, J | 1 |
| Abe, T | 2 |
| Ohtani, T | 1 |
| Yonemura, Y | 1 |
| Ohno, T | 1 |
| Hirabayashi, N | 1 |
| Nakano, S | 1 |
| Konishi, K | 1 |
| Yabushita, K | 1 |
| Ota, J | 1 |
| Takashima, S | 1 |
| Kikkawa, N | 1 |
| Yasutomi, M | 1 |
| Sowa, M | 1 |
| Maehara, Y | 1 |
| Haynes, H | 1 |
| Wiernik, PH | 1 |
| Stein, BN | 1 |
| Douglass, HO | 4 |
| Driscoll, DL | 1 |
| Arcangeli, G | 1 |
| Newman, EM | 1 |
| McAleer, C | 1 |
| Brennan, J | 1 |
| LaCreta, FP | 1 |
| Hudes, GR | 1 |
| Ozols, RF | 1 |
| Conti, JA | 1 |
| André, AM | 1 |
| Grossano, DD | 1 |
| Bertino, JR | 1 |
| Kumai, K | 1 |
| Fine, S | 2 |
| Kaizer, L | 1 |
| Warr, D | 1 |
| Gadalla, T | 2 |
| Stöger, H | 1 |
| Bauernhofer, T | 1 |
| Schmid, M | 1 |
| Ploner, F | 1 |
| Moser, R | 1 |
| Derstvenscheg, E | 1 |
| Steindorfer, P | 1 |
| Wilders-Truschnig, M | 1 |
| Kuss, I | 1 |
| Samonigg, H | 1 |
| Huan, SD | 1 |
| Aitken, SE | 2 |
| Stewart, DJ | 2 |
| Depisch, D | 1 |
| Kornek, G | 1 |
| Pidlich, J | 1 |
| Rosen, H | 1 |
| Karall, M | 1 |
| Prochaska, M | 1 |
| Ernst, A | 1 |
| Sebesta, C | 1 |
| Eckhardt, S | 1 |
| Rosso, R | 4 |
| Mazzei, T | 1 |
| Cartei, G | 2 |
| Conte, P | 1 |
| Cartei, F | 2 |
| Pancera, G | 1 |
| Bertheault-Cvitkovic, F | 1 |
| Soussan, S | 1 |
| Brienza, S | 1 |
| Itzhaki, M | 1 |
| Misset, JL | 2 |
| Bismuth, H | 1 |
| Balaban, EP | 1 |
| Graham, M | 1 |
| Perkins, S | 1 |
| Sheehan, RG | 1 |
| Frenkel, EP | 1 |
| Ross, M | 1 |
| Bull, J | 1 |
| Pruitt, B | 1 |
| Periman, P | 1 |
| Ruud, C | 1 |
| Cooper, SG | 1 |
| Joseph, DJ | 1 |
| Stewart, JF | 1 |
| Hamilton, CS | 1 |
| Denham, JW | 1 |
| Rodriguez-Bigas, M | 1 |
| Rustum, Y | 1 |
| Herrera, L | 1 |
| Creaven, P | 1 |
| Sinnige, HA | 1 |
| Buter, J | 1 |
| de Vries, EG | 1 |
| Uges, DR | 1 |
| Roenhorst, HW | 1 |
| Verschueren, RC | 1 |
| Sleijfer, DT | 1 |
| Willemse, PH | 1 |
| Mulder, NH | 1 |
| Fedeli, A | 2 |
| Fedeli, SL | 2 |
| Seiter, K | 1 |
| Martin, D | 1 |
| Schneider, A | 1 |
| Williams, L | 1 |
| Colofiore, J | 1 |
| Sawyer, R | 1 |
| Zalupski, MM | 1 |
| Baker, LH | 1 |
| Feliu, J | 2 |
| González Barón, M | 2 |
| García-Girón, C | 1 |
| Espinosa, E | 2 |
| Belón, J | 1 |
| Blanco, E | 1 |
| Garrido, P | 1 |
| Ordónez, A | 2 |
| Gómez-Navarro, J | 1 |
| Zamora, P | 1 |
| Tiersten, A | 1 |
| Ginopoulos, P | 1 |
| Papagiannis, T | 1 |
| Safridi, C | 1 |
| Karvelas, F | 1 |
| Spyropoulos, K | 1 |
| Papadas, T | 1 |
| Gogos, C | 1 |
| Jäger, E | 1 |
| Bernhard, H | 1 |
| Bernhard, G | 1 |
| Lautz, D | 1 |
| Michaelis, J | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Knuth, A | 1 |
| Galandiuk, S | 2 |
| Wrightson, W | 1 |
| Marr, L | 1 |
| Myers, S | 1 |
| LaRocca, RV | 1 |
| Giraldi, T | 1 |
| Interlandi, G | 1 |
| Meneghini, G | 1 |
| Imperato, A | 1 |
| Vigevani, E | 1 |
| Tabaro, G | 1 |
| Del Ferro, E | 2 |
| Ligi, M | 2 |
| Kanowitz, J | 1 |
| Schaaf, L | 1 |
| Spriggs, D | 1 |
| Staton, BA | 1 |
| Berkery, R | 1 |
| Steger, C | 1 |
| Eng, M | 1 |
| Dietz, A | 1 |
| Locker, P | 1 |
| García Girón, C | 1 |
| Vicent, JM | 1 |
| Gómez Navarro, J | 1 |
| Berrocal, A | 1 |
| Vilches, Y | 1 |
| de Castro, J | 1 |
| Díaz, J | 1 |
| Bugat, R | 2 |
| Culine, S | 2 |
| Suc, E | 1 |
| Brunet, P | 1 |
| Becouarn, Y | 2 |
| Marty, M | 3 |
| Extra, JM | 1 |
| Ganem, G | 1 |
| Namer, M | 1 |
| Negrier, S | 1 |
| Merrouche, Y | 1 |
| Burki, F | 2 |
| Mousseau, M | 2 |
| Mahjoubi, M | 2 |
| Cleary, JF | 1 |
| Arzoomanian, R | 1 |
| Alberti, D | 1 |
| Feierabend, C | 1 |
| Storer, B | 1 |
| Witt, P | 1 |
| Carbone, P | 1 |
| Wilding, G | 1 |
| Petroni, GR | 1 |
| Cooke, E | 1 |
| Benson, AB | 3 |
| Cummings, B | 1 |
| Antón-Torres, A | 1 |
| Massutí, T | 1 |
| Fernández-Martos, C | 1 |
| Barni, S | 1 |
| Rocchi, MB | 1 |
| Pessi, MA | 2 |
| Cazzaniga, M | 1 |
| Zamparelli, G | 1 |
| Ugolini, G | 1 |
| Ghiandoni, G | 1 |
| Luporini, G | 1 |
| Klaassen, U | 1 |
| Seeber, S | 2 |
| González-Larriba, JL | 1 |
| Garcia Carbonero, I | 1 |
| Sastre Valera, J | 1 |
| Perez Segura, P | 1 |
| Pokorny, RM | 1 |
| Wrightson, WR | 1 |
| Lewis, RK | 1 |
| Paris, KJ | 1 |
| Hofmeister, A | 1 |
| LaRocca, R | 1 |
| Myers, SR | 1 |
| Ackerman, D | 1 |
| Shimamoto, Y | 1 |
| Kato, T | 1 |
| Fukushima, M | 1 |
| Blumenson, LE | 2 |
| Cao, S | 1 |
| Troutt, AB | 1 |
| Rustum, YM | 5 |
| Kahn, MJ | 1 |
| Krook, JE | 1 |
| Siu, LL | 1 |
| Rowinsky, EK | 4 |
| Jan, YY | 1 |
| Lin, YC | 1 |
| Wang, HM | 1 |
| Liau, CT | 1 |
| Yamashita, F | 1 |
| Tanaka, M | 1 |
| Fukumori, K | 1 |
| Ando, E | 1 |
| Yano, Y | 1 |
| Kato, O | 1 |
| Yamamoto, H | 1 |
| Fukuda, H | 1 |
| Kusaba, T | 1 |
| Tanikawa, K | 1 |
| Sata, M | 1 |
| Chiou, TJ | 1 |
| Tung, SL | 1 |
| Hsieh, RK | 1 |
| Wang, WS | 1 |
| Yen, CC | 1 |
| Fan, FS | 1 |
| Chen, PM | 1 |
| Engelking, C | 1 |
| Catalano, R | 1 |
| Field, M | 1 |
| Kornblau, SM | 1 |
| Mitchell, E | 2 |
| Trotta, P | 1 |
| Vokes, E | 1 |
| Chiara, S | 1 |
| Nobile, MT | 2 |
| Vincenti, M | 1 |
| Lionetto, R | 1 |
| Gozza, A | 1 |
| Barzacchi, MC | 1 |
| Sanguineti, O | 1 |
| Repetto, L | 1 |
| Spicer, D | 1 |
| Groshen, S | 1 |
| Jeffers, S | 1 |
| Chan, KK | 1 |
| Dikken, C | 1 |
| Sitzia, J | 1 |
| Raymond, E | 1 |
| Armand, JP | 2 |
| Vanhoefer, U | 1 |
| Harstrick, A | 1 |
| Achterrath, W | 1 |
| Wilke, H | 1 |
| Cox, JV | 2 |
| DeVore, RF | 1 |
| Hainsworth, JD | 1 |
| Pazdur, R | 1 |
| Rivkin, SE | 1 |
| Sandbach, J | 1 |
| Wolf, DL | 1 |
| Mohrland, JS | 1 |
| Elfring, GL | 2 |
| Johnson, MR | 1 |
| High, L | 1 |
| Smith, JB | 1 |
| Lim, WT | 1 |
| Au, E | 2 |
| Khoo, KS | 1 |
| Fata, F | 1 |
| Ron, IG | 1 |
| O'Reilly, E | 1 |
| Klimstra, D | 1 |
| Villalona-Calero, MA | 2 |
| Kraynak, M | 1 |
| Rodrigues, G | 1 |
| Drengler, RL | 2 |
| Eckhardt, SG | 2 |
| Reigner, B | 1 |
| Moczygemba, J | 1 |
| Burger, HU | 3 |
| Griffin, T | 1 |
| Bonnay, M | 1 |
| Bexon, A | 1 |
| Méry-Mignard, D | 1 |
| Lenfers, BH | 1 |
| Loeffler, TM | 1 |
| Droege, CM | 1 |
| Hausamen, TU | 1 |
| Hidalgo, M | 1 |
| Rodriguez, G | 1 |
| Hammond, LA | 1 |
| Diab, SG | 1 |
| Weiss, G | 1 |
| Garner, AM | 1 |
| Campbell, E | 1 |
| Davidson, K | 1 |
| Louie, A | 1 |
| O'Neil, JD | 1 |
| von Borstel, R | 1 |
| Bichisao, E | 1 |
| Amadori, D | 1 |
| Silingardi, V | 1 |
| Giordani, P | 1 |
| Sansoni, E | 1 |
| Agostinelli, R | 1 |
| Van Den Neste, E | 1 |
| de Valeriola, D | 1 |
| Kerger, J | 1 |
| Kusenda, Z | 1 |
| Brassinne, C | 1 |
| Bartholomeus, S | 1 |
| Selleslags, J | 1 |
| Hennebert, P | 1 |
| Wythouck, H | 1 |
| Cazenave, I | 1 |
| Lefresne-Soulas, F | 1 |
| Piccart, M | 1 |
| Baker, SD | 1 |
| Lucas, VS | 1 |
| Khor, SP | 1 |
| Sartorius, SE | 1 |
| Donehower, RC | 1 |
| Grochow, LB | 1 |
| Spector, T | 1 |
| Hohneker, JA | 1 |
| Regine, WF | 1 |
| John, WJ | 1 |
| Hagihara, PF | 1 |
| McGrath, PC | 1 |
| Kenady, DE | 1 |
| Dufour, P | 1 |
| Wendling, JL | 1 |
| Mignard, D | 2 |
| Szelényi, H | 1 |
| Hohenberger, P | 1 |
| Lochs, H | 1 |
| Haboubi, N | 1 |
| Berdel, WE | 1 |
| Kreuser, ED | 1 |
| Yoshisue, K | 1 |
| Hironaga, K | 1 |
| Yamaguchi, S | 1 |
| Yamamoto, A | 1 |
| Nagayama, S | 1 |
| Kawaguchi, Y | 1 |
| Seymour, M | 1 |
| Homerin, M | 1 |
| Hmissi, A | 1 |
| Cortes-Funes, H | 1 |
| Freyer, G | 2 |
| Papamichael, D | 1 |
| Le Bail, N | 1 |
| Louvet, C | 1 |
| Hendler, D | 1 |
| Wilson, C | 1 |
| Morvan, F | 1 |
| Bonetti, A | 1 |
| Droz, JP | 1 |
| Awad, L | 1 |
| Kucuk, O | 1 |
| Shevrin, DH | 1 |
| Pandya, KJ | 1 |
| Bonomi, PD | 1 |
| Frank, C | 1 |
| Blanke, C | 1 |
| Moore, MJ | 1 |
| Maroun, JA | 2 |
| Locker, PK | 1 |
| Pirotta, N | 1 |
| Daniele, B | 1 |
| Perrone, F | 1 |
| Gallo, C | 1 |
| Pignata, S | 1 |
| De Martino, S | 1 |
| De Vivo, R | 1 |
| Barletta, E | 1 |
| Tambaro, R | 1 |
| Abbiati, R | 1 |
| D'Agostino, L | 1 |
| Goldwasser, F | 1 |
| Gross-Goupil, M | 1 |
| Tigaud, JM | 1 |
| Di Palma, M | 1 |
| Marceau-Suissa, J | 1 |
| Yovine, A | 1 |
| Cvitkovic, E | 1 |
| Pestalozzi, BC | 2 |
| Stipanov, M | 1 |
| Morrow, J | 1 |
| Rothenberg, M | 1 |
| Chinery, R | 1 |
| Shyr, Y | 1 |
| Coffey, R | 1 |
| Johnson, DH | 1 |
| Leach, SD | 1 |
| Beauchamp, RD | 1 |
| Batist, G | 1 |
| Cox, J | 1 |
| Kocha, W | 1 |
| Kuperminc, M | 1 |
| Walde, D | 1 |
| Weaver, C | 1 |
| Harrison, E | 1 |
| Osterwalder, B | 3 |
| Wong, AO | 1 |
| Guglielmi, A | 2 |
| Cirillo, M | 1 |
| Recaldin, E | 1 |
| Ravaioli, A | 1 |
| Testore, P | 1 |
| Caroti, C | 1 |
| Gallo, L | 2 |
| Turci, D | 1 |
| Grossi, F | 1 |
| Chua, EJ | 1 |
| Soo, KC | 1 |
| Seow-Choen, F | 1 |
| Low, CH | 1 |
| Ng, BK | 1 |
| Hoe, M | 1 |
| Ngan, SY | 1 |
| Burmeister, BH | 1 |
| Fisher, R | 1 |
| Rischin, D | 1 |
| Schache, DJ | 1 |
| Kneebone, A | 1 |
| MacKay, JR | 1 |
| Joseph, D | 1 |
| Bell, A | 1 |
| Rossi, A | 1 |
| Raida, M | 1 |
| Schwabe, W | 1 |
| Häusler, P | 1 |
| Van Kuilenburg, AB | 1 |
| Van Gennip, AH | 1 |
| Behnke, D | 1 |
| Coco, C | 1 |
| Cellini, N | 1 |
| Picciocchi, A | 1 |
| Fares, MC | 1 |
| Rosetto, ME | 1 |
| Morganti, AG | 1 |
| Cogliandolo, S | 1 |
| Nuzzo, G | 1 |
| Tedesco, M | 1 |
| Ambesi-Impiombato, F | 1 |
| Cosimelli, M | 1 |
| Rotman, M | 1 |
| Oshaughnessy, JA | 1 |
| Blum, J | 1 |
| Moiseyenko, V | 1 |
| Jones, SE | 1 |
| Bell, D | 1 |
| Mauriac, L | 1 |
| Laws, S | 1 |
| Patt, YZ | 1 |
| Hassan, MM | 1 |
| Lozano, RD | 1 |
| Waugh, KA | 1 |
| Hoque, AM | 1 |
| Frome, AI | 1 |
| Lahoti, S | 1 |
| Ellis, L | 1 |
| Vauthey, JN | 1 |
| Curley, SA | 1 |
| Schnirer, II | 1 |
| Raijman, I | 1 |
| Webb, A | 1 |
| Waters, JS | 1 |
| Norman, A | 1 |
| Massey, A | 1 |
| Locker, GJ | 1 |
| Schmidinger, M | 1 |
| Mader, R | 2 |
| Kramer, G | 1 |
| Marberger, M | 1 |
| Rauchenwald, M | 1 |
| Baglan, KL | 1 |
| Frazier, RC | 1 |
| Huang, RR | 1 |
| Martinez, AA | 1 |
| Chang, DZ | 1 |
| Olencki, T | 1 |
| Budd, GT | 1 |
| Peereboom, D | 1 |
| Ganapathi, R | 1 |
| Bukowski, R | 1 |
| Di Costanzo, E | 1 |
| Sdrobolini, A | 1 |
| Paoloni, FP | 1 |
| Carpi, A | 1 |
| Moscetti, L | 1 |
| Cherubini, R | 1 |
| Borner, MM | 1 |
| Stupp, R | 1 |
| Morant, R | 1 |
| Honegger, H | 1 |
| Wernli, M | 1 |
| Hanselmann, S | 1 |
| Müller, S | 1 |
| Castiglione-Gertsch, M | 1 |
| Goldhirsch, A | 1 |
| Mani, S | 1 |
| Rudin, CM | 1 |
| Kunkel, K | 1 |
| Holmlund, JT | 1 |
| Geary, RS | 1 |
| Dorr, FA | 1 |
| Luoma, ML | 1 |
| Hakamies-Blomqvist, L | 1 |
| Sjöström, J | 1 |
| Mouridsen, H | 1 |
| Malmström, P | 1 |
| Bengtsson, NO | 1 |
| Hultborn, R | 1 |
| Ostenstaad, B | 1 |
| Mjaaland, I | 1 |
| Valvere, V | 1 |
| Wist, E | 1 |
| Baldursson, G | 1 |
| Ahigren, J | 1 |
| Blomqvist, C | 1 |
| Kourousis, Ch | 1 |
| Tsetis, D | 1 |
| Athanasiadis, N | 1 |
| Abramson, N | 1 |
| Klencke, B | 1 |
| Ritch, P | 1 |
| Burnhan, JP | 1 |
| McGuirt, C | 1 |
| Bonny, T | 1 |
| Levin, J | 1 |
| Hohneker, J | 1 |
| Amado, RG | 1 |
| Hecht, JR | 1 |
| Lin, LS | 1 |
| Rosen, PJ | 1 |
| Adimi, P | 1 |
| Hansen, F | 1 |
| Kjaer, M | 1 |
| Aabo, K | 1 |
| Keldsen, N | 1 |
| Sandberg, E | 1 |
| Jakobsen, A | 1 |
| Hardy, JD | 1 |
| Doolittle, PD | 1 |
| Stanford, JR | 1 |
| King, D | 1 |
| Carey, L | 1 |
| Anderson, G | 1 |
| Ramirez, G | 1 |
| Biran, S | 1 |
| krasnokuki, D | 1 |
| Brufman, G | 1 |
| Scialla, SJ | 1 |
| Miskoff, RA | 1 |
| Ingis, DA | 1 |
| Farmer, RG | 1 |
| Steinberg, J | 1 |
| Weh, HJ | 1 |
| Platz, D | 1 |
| Buggisch, P | 1 |
| Eckardt, N | 1 |
| Schmiegel, WH | 1 |
| Drescher, S | 1 |
| Kleeberg, UR | 1 |
| Müllerleile, U | 1 |
| Crone-Munzebrock, W | 1 |
| Pyrhönen, SO | 1 |
| Kouri, MO | 1 |
| Sertoli, MR | 1 |
| Rubagotti, A | 1 |
| Vidili, MG | 1 |
| Venturini, M | 1 |
| Canobbio, L | 1 |
| Fassio, T | 1 |
| Schöber, C | 1 |
| Stahl, M | 1 |
| Poliwoda, H | 1 |
| Ohmori, H | 1 |
| Matsumura, Y | 1 |
| Ochi, J | 1 |
| Kobashi, K | 1 |
| Akebi, N | 1 |
| Saika, T | 1 |
| Nanba, K | 1 |
| Tanahashi, T | 1 |
| Josen, T | 1 |
| Nasu, Y | 1 |
| Baur, M | 1 |
| Schlappack, O | 1 |
| Havelec, L | 1 |
| Marosi, C | 1 |
| Dittrich, C | 1 |
| Evans, WK | 1 |
| Wierzbicki, R | 1 |
| Shepherd, FA | 1 |
| Rusthoven, J | 1 |
| Ezzat, A | 1 |
| Torosian, MH | 1 |
| Jalali, S | 1 |
| Nguyen, HQ | 1 |
| Anderson, N | 1 |
| Bern, M | 1 |
| Wallach, S | 1 |
| Moore, C | 1 |
| Williams, D | 1 |
| Sischy, B | 1 |
| Doggett, RL | 1 |
| Krall, JM | 1 |
| Taylor, DG | 1 |
| Sause, WT | 1 |
| Lipsett, JA | 1 |
| Seydel, HG | 1 |
| Watson, KJ | 1 |
| Shulkes, A | 1 |
| Smallwood, RA | 1 |
| Douglas, MC | 1 |
| Hurley, R | 1 |
| Kalnins, R | 1 |
| Moran, L | 1 |
| Moertel, CG | 2 |
| Schutt, AJ | 1 |
| Wieand, HS | 1 |
| Bruckner, H | 1 |
| Stablein, D | 1 |
| Calabet, J | 1 |
| Brunet, R | 1 |
| Shoemaker, DD | 2 |
| Spicer, DV | 1 |
| Daniels, JR | 1 |
| Silberman, H | 1 |
| Johnson, K | 1 |
| Arbuck, SG | 1 |
| Trave, F | 1 |
| Milliron, S | 1 |
| Baroni, M | 1 |
| Nava, H | 1 |
| Emrich, LJ | 1 |
| Barone, C | 1 |
| Astone, A | 1 |
| Grieco, A | 1 |
| Cavallaro, A | 1 |
| Netri, G | 1 |
| Rossi, S | 1 |
| Cassano, A | 1 |
| Ricevuto, E | 1 |
| Noviello, MR | 1 |
| Asbury, RF | 1 |
| Boros, L | 1 |
| Brower, M | 1 |
| Woll, J | 1 |
| Chang, A | 1 |
| Bennett, J | 1 |
| Kanda, Y | 1 |
| Futatsuki, K | 1 |
| Suda, Y | 1 |
| Yoshida, S | 1 |
| Bounous, G | 1 |
| Gentile, JM | 1 |
| Hugon, J | 1 |
| Fennelly, JJ | 1 |
| Fitzgerald, MX | 1 |
| Reitemeier, RJ | 1 |
| Hahn, RG | 1 |
| Zollinger, RM | 1 |
| Tormey, DC | 1 |
| Gailani, S | 2 |
| Leone, L | 2 |
| Holland, JF | 1 |
| Falkson, G | 1 |
| Burningham, R | 1 |
| Larsen, V | 1 |
| Bevan, PG | 1 |
| Riedel, B | 1 |
| Brosig, W | 1 |
| Nagel, R | 1 |
| Pust, R | 1 |
| Karev, N | 1 |
| Blokhina, N | 1 |
| Voznyi, E | 1 |
| Perscin, M | 1 |
| Nadler, SH | 2 |
| Moore, GE | 1 |
| Weiss, AJ | 1 |
| Mastrangelo, MJ | 1 |
| Piro, AJ | 1 |
| Wilson, RE | 1 |
| Hall, TC | 1 |
| Aliapoulios, MA | 1 |
| Nevinny, HB | 1 |
| Moore, FD | 1 |
| Hill, GJ | 1 |
| Grage, TB | 1 |
| Wilson, W | 1 |
| Karev, NI | 1 |
| Blokhina, NG | 1 |
| Vozny, EK | 1 |
| Pershin, MP | 1 |
| White, RS | 1 |
| Fuqua, WB | 1 |
| Barrett, O | 1 |
| Horton, J | 1 |
| Olson, KB | 1 |
| Hosley, HF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy Wit[NCT01183780] | Phase 3 | 1,072 participants (Actual) | Interventional | 2010-12-02 | Completed | ||
| Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors[NCT01928290] | Phase 2 | 67 participants (Actual) | Interventional | 2013-11-08 | Completed | ||
| A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen[NCT01571284] | Phase 3 | 781 participants (Actual) | Interventional | 2012-05-30 | Completed | ||
| A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250] | Phase 2 | 264 participants (Actual) | Interventional | 2019-11-28 | Active, not recruiting | ||
| A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer[NCT00777101] | Phase 2 | 233 participants (Actual) | Interventional | 2009-02-04 | Completed | ||
| An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without Trastuzumab[NCT03094052] | Phase 2 | 11 participants (Actual) | Interventional | 2018-10-09 | Completed | ||
| A Phase II Clinical Trial Study on Apatinib and XELOX Combination Regimen in the First-line Treatment of End-stage Colorectal Cancer Patients[NCT02829385] | Phase 2 | 53 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxalipla[NCT00561470] | Phase 3 | 1,226 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis[NCT02869802] | 190 participants (Anticipated) | Observational | 2016-10-06 | Recruiting | |||
| LARCID: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea[NCT00582426] | Phase 3 | 139 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| The Effectiveness of Topical Oral Vitamin D Gel in Prevention of Radiation-induced Oral Mucositis[NCT04308161] | Phase 2 | 45 participants (Anticipated) | Interventional | 2019-11-02 | Recruiting | ||
| The Effectiveness of Melatonin in Prevention of Radiation-induced Oral Mucositis[NCT03833570] | Phase 2 | 40 participants (Actual) | Interventional | 2018-01-12 | Completed | ||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab[NCT00265811] | Phase 3 | 2,559 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Ancillary Study of miR-31-3p and miR-31-5p Expression Levels in Patients Enrolled in the PETACC-8 Study, and of the Predictive Role of miR-31-3p Expression Level on Clinical Outcomes of Patients Treated With Cetuximab[NCT03362684] | Phase 3 | 1,808 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)[NCT02364024] | 856 participants (Actual) | Observational | 2005-11-30 | Completed | |||
| A Phase 1/2, Open-Label Study Of Neratinib (HKI-272) In Combination With Capecitabine In Subjects With Solid Tumors And ErbB-2 Positive Metastatic Or Locally Advanced Breast Cancer[NCT00741260] | Phase 1/Phase 2 | 105 participants (Actual) | Interventional | 2008-12-09 | Completed | ||
| A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506] | Phase 3 | 417 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766] | Phase 1 | 45 participants (Anticipated) | Interventional | 2022-11-21 | Recruiting | ||
| Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma[NCT04662112] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2021-06-15 | Active, not recruiting | ||
| A Phase Ib/II Study of Ramucirumab (Cyramza®), Nal-IRI (ONIVYDE®) and Trifluridine/Tipiracil (Lonsurf®) in Second Line Metastatic Gastric Cancer (COOL Study).[NCT05927857] | Phase 1/Phase 2 | 45 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers[NCT06135896] | Phase 2 | 98 participants (Anticipated) | Interventional | 2023-12-10 | Not yet recruiting | ||
| Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin[NCT03524508] | Phase 2 | 178 participants (Actual) | Interventional | 2018-09-04 | Completed | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174] | 54,000 participants (Anticipated) | Observational | 2021-08-04 | Recruiting | |||
| Phase I Trial of Irinotecan, Cisplatin, and Fluorouracil in Patients With Advanced Solid Tumor Malignancies[NCT00005791] | Phase 1 | 0 participants | Interventional | 1999-10-31 | Completed | ||
| An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-05-31 | Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.) | ||
| An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women With Advanced or Metastatic Breast Cancer[NCT00508274] | Phase 3 | 52 participants (Actual) | Interventional | 2007-07-18 | Terminated (stopped due to Primary analysis was completed in 2015 and data collection post 1-Jul-2019 was not reportable due to local regulations in China.) | ||
| Frequency and Classification of Radiation-induced Diarrhoea in Patients With Prostate and Rectal Cancer During Curative External Radiotherapy[NCT05684432] | 100 participants (Anticipated) | Observational | 2022-06-01 | Recruiting | |||
| A Phase II Trial of Preoperative Capecitabine Plus Irinotecan Followed by Combined Modality Capecitabine and Radiation for Locally Advanced Rectal Cancer: Hoosier Oncology Group GI03-53[NCT00216086] | Phase 2 | 22 participants (Actual) | Interventional | 2005-05-31 | Terminated (stopped due to Funding withdrawn) | ||
| Neoadjuvant Radiotherapy and Capecitabine With or Without Panitumumab in Patients With Advanced, K-ras Unmutated Rectal Cancer. A Randomized Multicenter Phase II Trial[NCT00814619] | Phase 2 | 68 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Multicenter, Randomised, Double-Blind, Phase 3 Study Of Sunitinib In Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (FOLFIRI) As First Line Treatment[NCT00457691] | Phase 3 | 768 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Evaluation of Dyspeptic Symptoms in Oncological Frail Patients With Extraintestinal Cancer in Chemotherapy. Assessment of Circulating Levels of Glucagon-like Peptide 2 (GLP-2) in Relation to Mucositis[NCT01382667] | 70 participants (Actual) | Observational | 2011-07-31 | Completed | |||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma[NCT04000737] | Phase 2 | 125 participants (Anticipated) | Interventional | 2020-01-10 | Recruiting | ||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| A Pilot Trial of Sequential Primary (Neoadjuvant) Combination Chemotherapy With Docetaxel/Capecitabine (TX) and Doxorubicin/Cyclophosphamide (AC) in Primary Breast Cancer With Evaluation of Chemotherapy Effects on Gene Expression[NCT00005908] | Phase 2 | 30 participants (Actual) | Interventional | 2000-06-30 | Completed | ||
| Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC[NCT01282658] | 200 participants (Anticipated) | Observational | 2010-11-30 | Recruiting | |||
| A Phase II Study of Oral Xeloda (Capecitabine) in Combination With Intravenous Irinotecan for Patients With Locally Advanced and/or Metastatic Colorectal Cancer[NCT00022698] | Phase 2 | 67 participants (Actual) | Interventional | 2001-05-31 | Completed | ||
| A Phase II, Randomized, Open-label, Controlled, Dose-elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal [NCT00040391] | Phase 2 | 0 participants | Interventional | 2002-06-30 | Terminated | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.[NCT03428529] | Phase 2/Phase 3 | 63 participants (Actual) | Interventional | 2011-01-12 | Completed | ||
| Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study[NCT00842686] | Phase 2 | 60 participants (Anticipated) | Interventional | 2009-01-31 | Active, not recruiting | ||
| Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Bre[NCT01367028] | Phase 2 | 100 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon[NCT00004931] | Phase 3 | 2,472 participants (Anticipated) | Interventional | 2000-02-29 | Completed | ||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| The Influence of Probiotics on Vancomycin-Resistant Enterococcus[NCT00591474] | 8 participants (Actual) | Interventional | 2007-12-31 | Terminated (stopped due to Participant lost to followup) | |||
| A Pilot Study Investigating Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma[NCT00901836] | 2 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Study closed due to feasability) | |||
| Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer[NCT00064181] | Phase 3 | 86 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662] | Phase 2 | 4 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to due to poor recrutment) | ||
| Exploration of New Biologic Factors' Predictive Value , Especially Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab[NCT01405430] | 63 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined With Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer[NCT05424692] | 200 participants (Anticipated) | Interventional | 2021-09-01 | Recruiting | |||
| Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer[NCT01856322] | Phase 2 | 3 participants (Actual) | Interventional | 2013-04-30 | Terminated (stopped due to The trial was prematurely closed due to lack of accrual.) | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639] | Phase 2 | 8 participants (Actual) | Interventional | 2012-04-30 | Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.) | ||
| A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094] | Phase 3 | 49 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients- A Prospective, Randomised, Single Blind, Three Arm, Phase Four Prevention Trial[NCT00772824] | Phase 4 | 23 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262] | Phase 3 | 803 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628] | 10 participants (Anticipated) | Interventional | 2012-01-31 | Not yet recruiting | |||
| A Phase I-II Study of Capecitabine and Oxaliplatin in Chemotherapy-Naive and Thymidylate Synthase Inhibitor Pretreated Advanced or Metastatic Colorectal Cancer[NCT00004187] | Phase 1/Phase 2 | 0 participants | Interventional | 1999-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The EORTC QLQ-C30 (v. 3.0) is a self-administered, cancer-specific questionnaire with multidimensional scales assessing 15 domains (5 functional domains, 9 symptoms, and global health status). A linear transformation was applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For the functional domains and global health status scale, higher scores represent a better level of functioning. For symptom scales, higher scores represent a greater degree of symptoms. Maximum improvement is the best post-baseline change. (NCT01183780)
Timeframe: Baseline Up to 171 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ramucirumab + FOLFIRI | 4.0 |
| Placebo + FOLFIRI | 6.6 |
The EQ-5D is a generic, multidimensional, health status instrument. The profile allows participants to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood using a 3-level scale (no problem, some problems, and major problems). These combinations of attributes were converted into a weighted health-state Index Score according to the United Kingdom (UK) population-based algorithm. The possible values for the Index Score ranged from -0.59 (severe problems in all 5 dimensions) to 1.0 (no problem in any dimension). A negative change indicated a worsening of the participant's health status. (NCT01183780)
Timeframe: Baseline and 30-Day Follow-Up (FU) up to 171 Weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ramucirumab + FOLFIRI | -0.097 |
| Placebo + FOLFIRI | -0.103 |
OS was defined as the time in months from the date of randomization to the date of death from any cause. For participants not known to have died as of the cut-off date, OS was censored at the last known date alive. (NCT01183780)
Timeframe: Randomization to Date of Death from Any Cause Up to 39.36 Months
| Intervention | months (Median) |
|---|---|
| Ramucirumab + FOLFIRI | 13.3 |
| Placebo + FOLFIRI | 11.7 |
The objective response rate is equal to the proportion of participants achieving a best overall response of partial response or complete response (PR + CR). Response was defined using RECIST, v. 1.1 criteria. CR was defined as the disappearance of all target and non-target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm and normalization of tumor marker level of non-target lesions; PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions taking as reference the baseline sum diameter. (NCT01183780)
Timeframe: Randomization until Disease Progression Up to 38.01 Months
| Intervention | percentage of participants (Number) |
|---|---|
| Ramucirumab + FOLFIRI | 13.4 |
| Placebo + FOLFIRI | 12.5 |
PFS was defined as the time from the date of randomization until the date of objectively determined progressive disease (PD) [according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v). 1.1] or death due to any cause, whichever was first. PD is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters (mm). Participants who died without a reported prior progression were considered to have progressed on the day of their death. Participants who did not progress or were lost to follow-up were censored at the day of their last radiographic tumor assessment. (NCT01183780)
Timeframe: Randomization to Measured PD or Date of Death from Any Cause Up to 38.01 Months
| Intervention | months (Median) |
|---|---|
| Ramucirumab + FOLFIRI | 5.7 |
| Placebo + FOLFIRI | 4.5 |
(NCT01183780)
Timeframe: Preinfusion and 1 hour postinfusion in Cycles 3, 5, 9, 13, and 17
| Intervention | micrograms/milliliter (ug/mL) (Geometric Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cmin Dose 3 (n=248) | Cmin Dose 5 (n=154) | Cmin Dose 9 (n=27) | Cmin Dose 13 (n=11) | Cmin Dose 17 (n=5) | Cmax Dose 3 (n=88) | Cmax Dose 5 (n=51) | Cmax Dose 9 (n=18) | Cmax Dose 13 (n=12) | Cmax Dose 17 (n=7) | |
| Ramucirumab + FOLFIRI | 46.3 | 65.1 | 77.9 | 75.9 | 72.0 | 221.0 | 243.0 | 262.0 | 307.0 | 253.0 |
Blood samples were tested to determine if a participant reacted to ramucirumab by producing anti-ramucirumab antibodies. Samples were identified as treatment emergent anti-drug antibody (TE ADA) if the post-treatment sample had an increase of at least 4 fold in titer from pre-treatment values. If the pre-treatment value was not detected or was not present, a 1:20 post-treatment titer was required to indicate treatment emergence. The percentage of participants with TE ADA was calculated as: (the number of participants with TE ADA / total number of participants with at least 1 post-treatment immunogenicity sample analyzed)*100. (NCT01183780)
Timeframe: Cycles 1, 3, 5, and 30-Day FU
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Immunogenicity Any Time During Study (n=516, 512) | Immunogenicity Post-Treatment (n=477, 473) | |
| Placebo + FOLFIRI | 5.5 | 3.8 |
| Ramucirumab + FOLFIRI | 5.6 | 3.1 |
"Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 33 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 5.8 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 10.5 |
"Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 25 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Overall survival is defined as the time interval from date of diagnosis to date of death from any cause. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 15.5 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 19.6 |
Duration of time from start of treatment to time of progression or death, whichever occurs first. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.4 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.8 |
Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.9 |
(NCT01928290)
Timeframe: 30 days after completion of treatment (estimated to be 5 months)
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | Febrile neutropenia | Anal Fistula | Diarrhea | Hematemesis | Nausea | Peripheral ischemia | Vomiting | Fatigue | Laparoscopy surgery | Pain | Sepsis | Lung infection | Pneumonia | Hypernatremia | Neutrophil count decreased | Platelet count decreased | Anorexia | Dehydration | Hypokalemia | Back pain | Peripheral sensory neuropathy | Syncope | Dyspnea | Pleural embolism | Skin infection | Thromboembolic event | Abdominal pain | Enterocolitis | Hemorrhoids | G-tube infection | Neutropenic entercolitis | Alkaline phosphatase increased | |
| Arm A: FOLFIRINOX (HER2-negative) | 1 | 2 | 1 | 4 | 1 | 2 | 1 | 3 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 19 | 3 | 3 | 4 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 0 | 0 | 0 | 5 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance was calculated using the Cockroft-Gault or Modification of Diet in Renal Disease (MDRD). (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | mL/min (Mean) |
|---|---|
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 71.4 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | participants (Number) |
|---|---|
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 182 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue - Baseline | Fatigue - Change at Cycle 3 | Fatigue - Change at Cycle 5 | Fatigue - Change at Cycle 7 | Fatigue - Change at Cycle 9 | Fatigue - Change at Cycle 11 | Fatigue - Change at Cycle 13 | Fatigue - Change at Cycle 15 | Fatigue - Change at Cycle 17 | Fatigue - Change at Cycle 19 | Fatigue - Change at Cycle 21 | Fatigue - Change at Cycle 23 | Fatigue - Change at Cycle 25 | Fatigue - Change at Cycle 27 | Fatigue - Change at Cycle 29 | Fatigue - Change at Cycle 31 | Fatigue - Change at Cycle 33 | Fatigue - Change at Cycle 35 | Fatigue - Change at EOT | Nausea and Vomiting - Baseline | Nausea and Vomiting - Change at Cycle 3 | Nausea and Vomiting - Change at Cycle 5 | Nausea and Vomiting - Change at Cycle 7 | Nausea and Vomiting - Change at Cycle 9 | Nausea and Vomiting - Change at Cycle 11 | Nausea and Vomiting - Change at Cycle 13 | Nausea and Vomiting - Change at Cycle 15 | Nausea and Vomiting - Change at Cycle 17 | Nausea and Vomiting - Change at Cycle 19 | Nausea and Vomiting - Change at Cycle 21 | Nausea and Vomiting - Change at Cycle 23 | Nausea and Vomiting - Change at Cycle 25 | Nausea and Vomiting - Change at Cycle 27 | Nausea and Vomiting - Change at Cycle 29 | Nausea and Vomiting - Change at Cycle 31 | Nausea and Vomiting - Change at Cycle 33 | Nausea and Vomiting - Change at Cycle 35 | Nausea and Vomiting - Change at EOT | Pain - Baseline | Pain - Change at Cycle 3 | Pain - Change at Cycle 5 | Pain - Change at Cycle 7 | Pain - Change at Cycle 9 | Pain - Change at Cycle 11 | Pain - Change at Cycle 13 | Pain - Change at Cycle 15 | Pain - Change at Cycle 17 | Pain - Change at Cycle 19 | Pain - Change at Cycle 21 | Pain - Change at Cycle 23 | Pain - Change at Cycle 25 | Pain - Change at Cycle 27 | Pain - Change at Cycle 29 | Pain - Change at Cycle 31 | Pain - Change at Cycle 33 | Pain - Change at Cycle 35 | Pain - Change at EOT | Dyspnoea - Baseline | Dyspnoea - Change at Cycle 3 | Dyspnoea - Change at Cycle 5 | Dyspnoea - Change at Cycle 7 | Dyspnoea - Change at Cycle 9 | Dyspnoea - Change at Cycle 11 | Dyspnoea - Change at Cycle 13 | Dyspnoea - Change at Cycle 15 | Dyspnoea - Change at Cycle 17 | Dyspnoea - Change at Cycle 19 | Dyspnoea - Change at Cycle 21 | Dyspnoea - Change at Cycle 23 | Dyspnoea - Change at Cycle 25 | Dyspnoea - Change at Cycle 27 | Dyspnoea - Change at Cycle 29 | Dyspnoea - Change at Cycle 31 | Dyspnoea - Change at Cycle 33 | Dyspnoea - Change at Cycle 35 | Dyspnoea - Change at EOT | Insomnia - Baseline | Insomnia - Change at Cycle 3 | Insomnia - Change at Cycle 5 | Insomnia - Change at Cycle 7 | Insomnia - Change at Cycle 9 | Insomnia - Change at Cycle 11 | Insomnia - Change at Cycle 13 | Insomnia - Change at Cycle 15 | Insomnia - Change at Cycle 17 | Insomnia - Change at Cycle 19 | Insomnia - Change at Cycle 21 | Insomnia - Change at Cycle 23 | Insomnia - Change at Cycle 25 | Insomnia - Change at Cycle 27 | Insomnia - Change at Cycle 29 | Insomnia - Change at Cycle 31 | Insomnia - Change at Cycle 33 | Insomnia - Change at Cycle 35 | Insomnia - Change at EOT | Appetite loss - Baseline | Appetite loss - Change at Cycle 3 | Appetite loss - Change at Cycle 5 | Appetite loss - Change at Cycle 7 | Appetite loss - Change at Cycle 9 | Appetite loss - Change at Cycle 11 | Appetite loss - Change at Cycle 13 | Appetite loss - Change at Cycle 15 | Appetite loss - Change at Cycle 17 | Appetite loss - Change at Cycle 19 | Appetite loss - Change at Cycle 21 | Appetite loss - Change at Cycle 23 | Appetite loss - Change at Cycle 25 | Appetite loss - Change at Cycle 27 | Appetite loss - Change at Cycle 29 | Appetite loss - Change at Cycle 31 | Appetite loss - Change at Cycle 33 | Appetite loss - Change at Cycle 35 | Appetite loss - Change at EOT | Constipation - Baseline | Constipation - Change at Cycle 3 | Constipation - Change at Cycle 5 | Constipation - Change at Cycle 7 | Constipation - Change at Cycle 9 | Constipation - Change at Cycle 11 | Constipation - Change at Cycle 13 | Constipation - Change at Cycle 15 | Constipation - Change at Cycle 17 | Constipation - Change at Cycle 19 | Constipation - Change at Cycle 21 | Constipation - Change at Cycle 23 | Constipation - Change at Cycle 25 | Constipation - Change at Cycle 27 | Constipation - Change at Cycle 29 | Constipation - Change at Cycle 31 | Constipation - Change at Cycle 33 | Constipation - Change at Cycle 35 | Constipation - Change at EOT | Diarrhoea - Baseline | Diarrhoea - Change at Cycle 3 | Diarrhoea - Change at Cycle 5 | Diarrhoea - Change at Cycle 7 | Diarrhoea - Change at Cycle 9 | Diarrhoea - Change at Cycle 11 | Diarrhoea - Change at Cycle 13 | Diarrhoea - Change at Cycle 15 | Diarrhoea - Change at Cycle 17 | Diarrhoea - Change at Cycle 19 | Diarrhoea - Change at Cycle 21 | Diarrhoea - Change at Cycle 23 | Diarrhoea - Change at Cycle 25 | Diarrhoea - Change at Cycle 27 | Diarrhoea - Change at Cycle 29 | Diarrhoea - Change at Cycle 31 | Diarrhoea - Change at Cycle 33 | Diarrhoea - Change at Cycle 35 | Diarrhoea - Change at EOT | Financial difficulties - Baseline | Financial difficulties - Change at Cycle 3 | Financial difficulties - Change at Cycle 5 | Financial difficulties - Change at Cycle 7 | Financial difficulties - Change at Cycle 9 | Financial difficulties - Change at Cycle 11 | Financial difficulties - Change at Cycle 13 | Financial difficulties - Change at Cycle 15 | Financial difficulties - Change at Cycle 17 | Financial difficulties - Change at Cycle 19 | Financial difficulties - Change at Cycle 21 | Financial difficulties - Change at Cycle 23 | Financial difficulties - Change at Cycle 25 | Financial difficulties - Change at Cycle 27 | Financial difficulties - Change at Cycle 29 | Financial difficulties - Change at Cycle 31 | Financial difficulties - Change at Cycle 33 | Financial difficulties - Change at Cycle 35 | Financial difficulties - Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 29.16 | 7.35 | 8.40 | 9.54 | 7.89 | 11.30 | 8.33 | 7.41 | 6.70 | 8.93 | 10.39 | 10.80 | 7.66 | 9.66 | 11.67 | 14.07 | 15.15 | 14.44 | 12.31 | 5.88 | 6.68 | 6.98 | 6.61 | 6.20 | 8.97 | 6.82 | 6.85 | 3.45 | 6.56 | 3.99 | 7.87 | 4.02 | 7.25 | 1.67 | 13.33 | 3.03 | 3.33 | 6.64 | 20.47 | 2.68 | 2.52 | 3.00 | 2.72 | 6.64 | 5.16 | 7.26 | 9.39 | 8.74 | 7.25 | 8.33 | 5.75 | 5.07 | 4.17 | 10.00 | 7.58 | 6.67 | 10.85 | 13.45 | 3.63 | 5.75 | 6.98 | 6.89 | 8.19 | 6.36 | 3.58 | 5.16 | 6.78 | 3.79 | 4.04 | 1.23 | 3.03 | -1.75 | 16.67 | 16.67 | 16.67 | 6.53 | 24.15 | 0.37 | -0.08 | -2.37 | -0.24 | 2.56 | 0.65 | -2.19 | -1.92 | 1.64 | 0.74 | -0.93 | -0.00 | -1.52 | -3.33 | -4.44 | -6.06 | -3.33 | 5.31 | 17.38 | 9.10 | 9.02 | 9.84 | 9.98 | 14.53 | 10.67 | 10.74 | 8.91 | 9.84 | 13.04 | 12.38 | 11.49 | 15.94 | 15.00 | 15.56 | 15.15 | 16.67 | 12.03 | 12.71 | 2.42 | 3.77 | 2.63 | 5.35 | 4.42 | 4.58 | 4.92 | 5.43 | 8.33 | 6.06 | 9.26 | 5.75 | 1.45 | 6.67 | 22.22 | 12.12 | 10.00 | 3.78 | 10.37 | 11.72 | 10.85 | 14.63 | 11.44 | 15.46 | 11.26 | 11.02 | 10.34 | 15.25 | 14.07 | 18.52 | 10.34 | 13.64 | 16.67 | 20.00 | 18.18 | 30.00 | 7.31 | 20.12 | -1.83 | -1.32 | -0.99 | -0.49 | 3.30 | 1.11 | -0.27 | 0.77 | 1.67 | 4.44 | 2.94 | -4.60 | -2.90 | 0.00 | -2.22 | -3.03 | 0.00 | 2.97 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 0.77 | -0.02 | -0.03 | -0.04 | -0.05 | -0.07 | -0.05 | -0.06 | -0.05 | -0.05 | -0.09 | -0.14 | -0.08 | -0.08 | -0.08 | -0.12 | 0.02 | -0.05 | -0.11 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. The VAS recorded the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. This information can be used as a quantitative measure of health outcome as judged by the individual respondents. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 72.81 | -1.85 | -2.15 | -2.20 | -2.74 | -3.10 | -2.36 | -1.05 | -1.91 | -3.06 | -2.13 | -5.77 | -7.28 | -4.94 | -8.80 | -6.69 | -7.90 | -8.88 | -6.67 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent).EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at the end of treatment (EOT) (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 68.61 | -3.34 | -4.70 | -3.63 | -3.97 | -5.85 | -2.26 | -3.05 | -1.18 | -2.36 | -5.56 | -6.86 | -8.05 | -10.14 | -8.33 | -9.44 | -11.36 | -5.83 | -8.82 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28).Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical - Baseline | Physical - Change at Cycle 3 | Physical - Change at Cycle 5 | Physical - Change at Cycle 7 | Physical - Change at Cycle 9 | Physical - Change at Cycle 11 | Physical - Change at Cycle 13 | Physical - Change at Cycle 15 | Physical - Change at Cycle 17 | Physical - Change at Cycle 19 | Physical - Change at Cycle 21 | Physical - Change at Cycle 23 | Physical - Change at Cycle 25 | Physical - Change at Cycle 27 | Physical - Change at Cycle 29 | Physical - Change at Cycle 31 | Physical - Change at Cycle 33 | Physical - Change at Cycle 35 | Physical - Change at EOT | Role - Baseline | Role - Change at Cycle 3 | Role - Change at Cycle 5 | Role - Change at Cycle 7 | Role - Change at Cycle 9 | Role - Change at Cycle 11 | Role - Change at Cycle 13 | Role - Change at Cycle 15 | Role - Change at Cycle 17 | Role - Change at Cycle 19 | Role - Change at Cycle 21 | Role - Change at Cycle 23 | Role - Change at Cycle 25 | Role - Change at Cycle 27 | Role - Change at Cycle 29 | Role - Change at Cycle 31 | Role - Change at Cycle 33 | Role - Change at Cycle 35 | Role - Change at EOT | Emotional - Baseline | Emotional - Change at Cycle 3 | Emotional - Change at Cycle 5 | Emotional - Change at Cycle 7 | Emotional - Change at Cycle 9 | Emotional - Change at Cycle 11 | Emotional - Change at Cycle 13 | Emotional - Change at Cycle 15 | Emotional - Change at Cycle 17 | Emotional - Change at Cycle 19 | Emotional - Change at Cycle 21 | Emotional - Change at Cycle 23 | Emotional - Change at Cycle 25 | Emotional - Change at Cycle 27 | Emotional - Change at Cycle 29 | Emotional - Change at Cycle 31 | Emotional - Change at Cycle 33 | Emotional - Change at Cycle 35 | Emotional - Change at EOT | Cognitive - Baseline | Cognitive - Change at Cycle 3 | Cognitive - Change at Cycle 5 | Cognitive - Change at Cycle 7 | Cognitive - Change at Cycle 9 | Cognitive - Change at Cycle 11 | Cognitive - Change at Cycle 13 | Cognitive - Change at Cycle 15 | Cognitive - Change at Cycle 17 | Cognitive - Change at Cycle 19 | Cognitive - Change at Cycle 21 | Cognitive - Change at Cycle 23 | Cognitive - Change at Cycle 25 | Cognitive - Change at Cycle 27 | Cognitive - Change at Cycle 29 | Cognitive - Change at Cycle 31 | Cognitive - Change at Cycle 33 | Cognitive - Change at Cycle 35 | Cognitive- Change at EOT | Social - Baseline | Social - Change at Cycle 3 | Social - Change at Cycle 5 | Social - Change at Cycle 7 | Social - Change at Cycle 9 | Social - Change at Cycle 11 | Social - Change at Cycle 13 | Social - Change at Cycle 15 | Social - Change at Cycle 17 | Social - Change at Cycle 19 | Social - Change at Cycle 21 | Social - Change at Cycle 23 | Social - Change at Cycle 25 | Social - Change at Cycle 27 | Social - Change at Cycle 29 | Social - Change at Cycle 31 | Social - Change at Cycle 33 | Social - Change at Cycle 35 | Social - Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 81.79 | -3.73 | -3.95 | -4.62 | -4.36 | -6.99 | -4.99 | -3.54 | -5.10 | -5.68 | -5.70 | -7.87 | -5.75 | -6.59 | -7.67 | -9.33 | -5.45 | -10.00 | -11.16 | 79.91 | -6.26 | -5.66 | -6.68 | -6.55 | -8.76 | -7.36 | -7.18 | -9.58 | -9.84 | -9.78 | -10.65 | -10.92 | -10.14 | -10.83 | -14.44 | -15.15 | -15.00 | -12.11 | 78.96 | 1.14 | 0.74 | 1.58 | 1.69 | 0.08 | 0.93 | 2.51 | 2.91 | 1.39 | 0.06 | 1.75 | 4.98 | 1.57 | 2.64 | 1.30 | 0.25 | -0.00 | -2.87 | 86.90 | -1.77 | -1.87 | -1.99 | -2.18 | -4.27 | -2.83 | -2.28 | -3.45 | -5.00 | -5.56 | -5.71 | -6.90 | -5.80 | -6.67 | -5.56 | -10.61 | -11.67 | -4.98 | 80.57 | -2.05 | -2.86 | -4.78 | -4.56 | -7.09 | -5.56 | -6.18 | -5.56 | -5.28 | -5.56 | -7.62 | -4.60 | -2.17 | -5.00 | -7.78 | -1.52 | -1.67 | -9.01 |
Abnormal electrolytes parameters included: hyponatremia, hypernatremia, hypocalcemia, hypercalcemia, hypokalemia, and hyperkalemia. Number of participants with each of these parameters were analyzed by grades ( All Grades and Grades 3-4 as per NCI CTCAE Version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hyponatremia: All Grades | Hyponatremia: Grades 3-4 | Hypernatremia: All Grades | Hypernatremia: Grades 3-4 | Hypocalcemia: All Grades | Hypocalcemia: Grades 3-4 | Hypercalcemia: All Grades | Hypercalcemia: Grades 3-4 | Hypokalemia: All Grades | Hypokalemia: Grades 3-4 | Hyperkalemia: All Grades | Hyperkalemia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 181 | 32 | 75 | 1 | 213 | 5 | 52 | 2 | 121 | 16 | 166 | 10 |
Abnormal hematological parameters included: anaemia, thrombocytopenia, leukopenia and neutropenia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4 as per NCI CTCAE (Version 4.03), where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Anaemia: All Grades | Anaemia: Grades 3-4 | Thrombocytopenia: All Grades | Thrombocytopenia: Grades 3-4 | Leukopenia: All Grades | Leukopenia: Grades 3-4 | Neutropenia: All Grades | Neutropenia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 535 | 14 | 293 | 13 | 532 | 72 | 450 | 227 |
Non-gradeable biochemistry parameters included; chloride, urea, total protein, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH). Number of participants with
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Chloride| Chloride>ULN | BUN | BUN>ULN | UREA | UREA>ULN | LDH | LDH>ULN | Total proteins | Total proteins>ULN | | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 135 | 217 | 41 | 83 | 60 | 250 | 79 | 423 | 162 | 77 |
Renal and liver function parameters included: creatinine, hyperbilirubinemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Creatinine: All Grades | Creatinine: Grades 3-4 | Hyperbilirubinemia: All Grades | Hyperbilirubinemia: Grades 3-4 | AST: All Grades | AST: Grades 3-4 | ALT: All Grades | ALT: Grades 3-4 | Alkaline phosphatase: All Grades | Alkaline phosphatase: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 161 | 2 | 130 | 9 | 342 | 12 | 270 | 10 | 465 | 23 |
A theoretical cycle is a 2 week period i.e. 14 days. A cycle is delayed if duration of previous cycle is greater than 14+2 days ; dose modification includes dose reduction and dose omission. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No delay and no dose modification | Any delay and/or dose modification | Delay only | Delay and Aflibercept modified | Delay and FOLFIRI modified | Delay and Aflibercept and Folfiri modified | Only Aflibercept modified | Only FOLFIRI modified | Both Aflibercept and FOLFIRI modified | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 119 | 660 | 163 | 39 | 308 | 97 | 5 | 43 | 5 |
The INR is a derived measure of the prothrombin time. The INR is the ratio of a participant's prothrombin time to a normal control sample. Normal range (without anti coagulation therapy): 0.8-1.2; Targeted range (with anti coagulation therapy) 2.0-3.0. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| INR<1.5 | INR>=1.5 to <3 | INR>=3 to <5 | INR>=5 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 106 | 0 | 2 | 2 |
Other abnormal biochemistry parameters included: hypoglycemia, hyperglycemia and hypoalbuminemia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE Version 4.03, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Hypoglycemia: All Grades | Hypoglycemia: Grades 3-4 | Hyperglycemia: All Grades | Hyperglycemia: Grades 3-4 | Hypoalbuminemia: All Grades | Hypoalbuminemia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 90 | 6 | 403 | 30 | 241 | 6 |
Proteinuria is defined as the presence of excess proteins in the urine (assessed either by spot sample, dipstick/ urine protein or 24 hour urine collection). Hematuria is defined as the presence of blood in urine (positive dipstick for RBC or reported AE). Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. Hypertension (high blood pressure) is defined as having a blood pressure reading of more than 140/90 mmHg over a number of weeks. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Proteinuria with hematuria | Proteinuria with hypertension | Proteinuria with hematuria and hypertension | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 72 | 4 | 3 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria were analyzed by grades (Grades 1, 2, 3 ,4) as per NCI CTCAE Version 4.03 where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 286 | 123 | 54 | 5 |
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. A serious AE (SAE): Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version 4.03 was used to assess severity (Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling) of AEs. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Any TEAE (All Grades) | Any TEAEs (Grades 3-4) | Any serious TEAE | Any serious related TEAE | Any TEAE leading to death | Any TEAE (permanent treatment discontinuation) | Any TEAE (premature treatment discontinuation) | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 769 | 609 | 272 | 159 | 47 | 208 | 104 |
Urinary protein creatinine ratio (UPCR) corresponds to the ratio of the urinary protein and urinary creatinine concentration (expressed in mg/dL). This ratio provides an accurate quantification of 24-hours urinary protein excretion. There is a high correlation between morning UPCR and 24-hour proteinuria in participants with normal or reduced renal functions. Normal ratio is < or = 1. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| UPCR<=1 | UPCR>=1 to <=2 | UPCR>=2 to <=3 | UPCR>3 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 265 | 51 | 24 | 27 |
"Clinical benefit rate (CR, PR, or SD = 24 weeks) for women For ErbB2 Positive Advanced Breast Cancer. Clinical benefit rate was the percentage of subjects who achieved overall tumor response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.~Clinical Benefit (CB) = CR + PR + SD >= 24 weeks." (NCT00777101)
Timeframe: From randomization date to progression or last tumor assessment, assessed up to 69 months
| Intervention | percentage of participants (Median) |
|---|---|
| Neratinib | 44.4 |
| Lapatinib+Capecitabine | 63.8 |
Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death. For subjects without death or progression, censorship was at the last valid tumor assessment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00777101)
Timeframe: From start date of response to first PD, assessed up to 69 months after the first subject was randomized.
| Intervention | months (Median) |
|---|---|
| Neratinib | 12.48 |
| Lapatinib+Capecitabine | 7.98 |
The percent of patients with symptomatic or progressive CNS lesions was the proportion of subjects who had PD considering CNS lesions only, according to RECIST criteria. (NCT00777101)
Timeframe: From randomization date to first CNS symptom or lesions
| Intervention | percentage of participants (Number) |
|---|---|
| Neratinib | 9.4 |
| Lapatinib+Capecitabine | 12.9 |
Objective Response Rate, investigator assessment. The ORR was defined as the percentage of participants demonstrating a confirmed objective response, either Complete Response (CR) or Partial Response (PR) during the study per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. (NCT00777101)
Timeframe: From randomization date to progression or last tumor assessment, assessed up to 69 months
| Intervention | percentage of participants (Number) |
|---|---|
| Neratinib | 29.1 |
| Lapatinib+Capecitabine | 40.5 |
Overall Survival (OS) was defined as the time from randomization to death due to any cause. Subjects last known to be alive were censored at the last date of last contact or the data cutoff employed for the analysis, whichever was earlier. (NCT00777101)
Timeframe: From randomization date to death, assessed up to 69 months
| Intervention | months (Median) |
|---|---|
| Neratinib | 19.74 |
| Lapatinib+Capecitabine | 23.62 |
Progression Free Survival, Measured in Months, for Subjects Randomized. Investigator assessment. The time interval from the date of randomization until the earliest date of progression per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) or death due to any cause. For subjects without death or progression, censorship was at the last valid tumor assessment. (NCT00777101)
Timeframe: From randomization date to progression or death, assessed up to 69 months
| Intervention | months (Median) |
|---|---|
| Neratinib | 4.53 |
| Lapatinib+Capecitabine | 6.83 |
Time to symptomatic or progressive Central nervous system (CNS) lesions. Time to symptomatic or progressive CNS lesions was the time from the date of randomization until the date of progressive disease (PD) considering CNS lesions only (ie, appearance of newly diagnosed CNS lesions or progressive CNS lesions). (NCT00777101)
Timeframe: From randomization date to first CNS symptom or lesions
| Intervention | months (Median) |
|---|---|
| Neratinib | 19.68 |
| Lapatinib+Capecitabine | NA |
The number of participants who discontinued neratinib earlier than expected during the course of study therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 1 |
The number of participants who experienced a dose hold of neratinib during the course of study therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 0 |
The number of participants whose dose was reduced at any time during the course of therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 5 |
Percentage of participants with clinically assessed grade 3 or greater diarrhea reported within the first 2 cycles (each cycle is 21 days) of neratinib while using anti-diarrheal strategies. Reports of diarrhea will be graded according to NCI CTCAE version 4.0. (NCT03094052)
Timeframe: Up to 6 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment (Neratinib) | 36.3 |
Percentage of patients requiring multiple anti-diarrheal medications will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 7 |
Percentage of participants with reported serious adverse events and adverse events of interest of any grade that have been determined to be related to the anti-diarrhea treatment will be reported by worst grade and associated toxicity. (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment (Neratinib) | 100 |
"The overall ORR was the percentage of evaluable participants who achieved complete response [CR] or partial response [PR] according to RECIST criteria version 1.0.~CR reflected the disappearance of all tumor lesions (with no new tumors)~PR reflected a pre-defined reduction in tumor burden~Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo/FOLFIRI | 11.1 |
| Aflibercept/FOLFIRI | 19.8 |
"Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011).~OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 12.06 |
| Aflibercept/FOLFIRI | 13.50 |
"PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC.~PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.~The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred." (NCT00561470)
Timeframe: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)
| Intervention | months (Median) |
|---|---|
| Placebo/FOLFIRI | 4.67 |
| Aflibercept/FOLFIRI | 6.90 |
Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay. (NCT00561470)
Timeframe: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo
| Intervention | participants (Number) | |
|---|---|---|
| At least one positive sample in the ADA assay | At least one positive sample in the NAb assay | |
| Aflibercept/FOLFIRI | 8 | 1 |
| Placebo/FOLFIRI | 18 | 2 |
"All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization.~The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported." (NCT00561470)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Treatment-Emergent Adverse Event (TEAE) | Serious TEAE | TEAE leading to Death | TEAE causing permanent treatment discontinuation | |
| Aflibercept/FOLFIRI | 606 | 294 | 37 | 164 |
| Placebo/FOLFIRI | 592 | 198 | 29 | 73 |
Quality of life (QoL) is evaluated using FACIT-D scale. FACIT-D is composed of 38 items, whose responses range from 0 to 4. The total FACIT-D score may range from 0 to 152. The 38 items compose five subscales, each evaluating a different component of the (QOL). For calculating the subscale score, some items are computed in a reverse fashion, so that higher FACIT-D scores indicate a better (QoL). Descriptive statistics (mean, standard deviation, median, minimum and maximum) are used to summarize FACIT-D scores (total and subscales) by study group at each time point. (NCT00582426)
Timeframe: Baseline to Day 168
| Intervention | Units on a scale (Mean) |
|---|---|
| Octreotide Long Acting Release | 0.5 |
| Standard Treatment | 3.4 |
Number of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Episodes/patients/day (Mean) |
|---|---|
| Octreotide Long Acting Release | 21.6 |
| Standard Treatment | 20.4 |
The percentage of patients developing diarrhea (incidence of grade 1 to 4) during treatment, considering only the worst grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0=None, 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 month overall
| Intervention | Percentage of Participants (Number) |
|---|---|
| Octreotide Long Acting Release | 76.1 |
| Standard Treatment | 78.9 |
For patient, chemotherapy dose reduction due to diarrhea as counted each time it occurred. Chemotherapy dose reduction because of other adverse events related to chemotherapy was not considered. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of participants (Number) |
|---|---|
| Octreotide Long Acting Release | 26.9 |
| Standard Treatment | 11.3 |
(NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Participants (Number) |
|---|---|
| Octreotide Long Acting Release | 4.5 |
| Standard Treatment | 7.0 |
(NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Participants (Number) |
|---|---|
| Octreotide Long Acting Release | 1.5 |
| Standard Treatment | 1.4 |
(NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of patients (Number) |
|---|---|
| Octreotide Long Acting Release | 6 |
| Standard Treatment | 4.2 |
Mean number of episodes of diarrhea is evaluated by patient diaries recorded by cycle. (cycle 1 to cycle 7.) (NCT00582426)
Timeframe: at each cycle (28 days per cycle)
| Intervention | Episodes/patient/cycle (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 (n=20, 18) | Cycle 2 (n=36,38) | Cycle 3 (n=33,39) | Cycle 4 (n=24, 27) | Cycle 5 (n=20,29) | Cycle 6 (n=22, 22) | Cycle 7 (n= 16, 20) | |
| Octreotide Long Acting Release | 2.6 | 8.2 | 6.9 | 8.6 | 8.1 | 6.1 | 4.8 |
| Standard Treatment | 2.2 | 5.9 | 6.7 | 7.1 | 7 | 5.8 | 6.6 |
Grade (severity)of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence;or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Episodes (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Octreotide Long Acting Release | 65.4 | 23.3 | 11.3 | 0 |
| Standard Treatment | 66.9 | 27.2 | 5.9 | 0 |
Lesions that can be accurately measured in at least one dimension (longest diameter (LD) to be recorded) as > 20 mm with conventional techniques (CT, MRI) or as > 10 mm with spiral CT scan. All measurable lesions up to maximum of 5 lesions per organ and 10 lesions in total representative of all involved organs should be identified as target lesions and recorded and measured at baseline. Complete Response is defined as Disappearance of all target lesions. Partial Response is defined at least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum LD. (NCT00582426)
Timeframe: Day 56, Day 84, Day 112, Day 140, Day 168
| Intervention | Percentage of Participants (Number) | ||||
|---|---|---|---|---|---|
| Day 56 (N=11,2) | Day 84 (N=5,3) | Day 112 (N=1,1) | Day 140 (N=9,1) | Day 168 (N=2,1) | |
| Octreotide Long Acting Release | 45.5 | 60.0 | 100 | 44.4 | 100 |
| Standard Treatment | 0.0 | 100 | 0.0 | 100 | 100 |
Grade (severity) of episodes of diarrhea is evaluated by patient diaries recorded on a daily basis by considering only worse grade of diarrhea for each patient. Diarrhea was graded according to Common Toxicity Criteria where Grade 0 = None, 1 = Increase of <4 stools/day over pretreatment, Grade 2 = Increase of 4-6 stools/day, or nocturnal stools, Grade 3 = Increase of ≥7 stools/day or incontinence; or need for parenteral support for dehydration and Grade 4= Physiologic consequences requiring intensive care; or hemodynamic collapse. (NCT00582426)
Timeframe: 6 months overall
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Octreotide Long Acting Release | 41.2 | 25.5 | 33.3 | 0 |
| Standard Treatment | 26.8 | 51.8 | 21.4 | 0 |
The percentage of subjects with Complete Response, Partial Response, or Stable Disease at least 24 weeks per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.
| Intervention | percentage of participants (Number) |
|---|---|
| Prior Lapatinib Subjects | 71.4 |
| Lapatinib Naive Subjects P1 | 72.1 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 73.0 |
Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00741260)
Timeframe: From start date of response to first PD/death, up to three years.
| Intervention | weeks (Median) |
|---|---|
| Prior Lapatinib Subjects | 48.3 |
| Lapatinib Naive Subjects P1 | 46.3 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 46.3 |
MTD reflects the highest dose of capecitabine in combination with neratinib that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.
| Intervention | mg/m^2 (Number) |
|---|---|
| Capecitabine in Combination With Neratinib | 1500 |
MTD reflects the highest dose of neratinib plus capeciteabine that did not cause a selected Grade 3 toxicity in >= 2 participants, which is any of 1) Grade 3 or 4 non-hematologic toxicity (Grade 3 asthenia was not considered a DLT unless lasting >3 days, 2) Grade 3 diarrhea lasting >2 days on optimal medical therapy or associated with fever or dehydration. 3) Grade 4 neutropenia lasting ≥ 3 days or Grade 4 febrile neutropenia, 4) Grade 4 thrombocytopenia lasting ≥3 days or associated with bleeding or requiring platelet transfusion, 5) Delayed recovery [to ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline] from one of the above listed toxicities that were related to neratinib and/or capecitabine that delayed the initiation of the next dose by more than 3 weeks. (NCT00741260)
Timeframe: From first dose date to day 21.
| Intervention | mg (Number) |
|---|---|
| Neratinib in Combination With Capecitabine | 240 |
Number of participants reporting Adverse Events Causing Dose Limiting Toxicities (DLT). (NCT00741260)
Timeframe: From first dose date to day 21
| Intervention | Participants (Count of Participants) |
|---|---|
| N160 + C1500 | 0 |
| N160 + C2000 | 2 |
| N200 + C2000 | 2 |
| N240 + C1500 | 0 |
| N240 + C2000 | 2 |
| N + C MTD - No Prior Lap | 0 |
| N + C MTD - Prior Lap | 0 |
Number of Subjects with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. (NCT00741260)
Timeframe: From first dose date to progression or last tumor assessment, up to three years.
| Intervention | percentage of participants (Number) |
|---|---|
| Prior Lapatinib Subjects | 57.1 |
| Lapatinib Naive Subjects P1 | 63.9 |
| Lapatinib Naive Subjects Part 2 + Part 1 | 63.5 |
The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.
| Intervention | percentage with confirmed response (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 3.31 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 0.67 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 7.69 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 0.84 |
"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 4.9 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 4.2 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 6.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 4.2 |
"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months
| Intervention | percentage of participants with CBR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 14 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 13 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 14 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 |
Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of participants with TMR (Number) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 23.6 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 28.9 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 8.6 |
"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 2.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.6 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 3.1 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.5 |
Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months
| Intervention | months (Median) |
|---|---|
| MM-398 Arm A (Mono Therapy Comparison) | 1.7 |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 1.4 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2.3 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 1.4 |
This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months
| Intervention | percent of patients in category (Number) | ||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Health Status: Improved | Global Health Status: Stable | Global Health Status: Worsened | Physical Functioning: Improved | Physical Functioning: Stable | Physical Functioning: Worsened | Role Functioning: Improved | Role Functioning: Stable | Role Functioning: Worsened | Emotional Functioning:Improved | Emotional Functioning:Stable | Emotional Functioning:Worsened | Cognitive Functioning:Improved | Cognitive Functioning:Stable | Cognitive Functioning:Worsened | Social Functioning:Improved | Social Functioning:Stable | Social Functioning:Worsened | Fatigue:Improved | Fatigue:Stable | Fatigue:Worsened | Nausea and Vomiting:Improved | Nausea and Vomiting:Stable | Nausea and Vomiting:Worsened | Pain:Improved | Pain:Stable | Pain:Worsened | Dyspnoea:Improved | Dyspnoea:Stable | Dyspnoea:Worsoned | Insomnia:Improved | Insomnia:Stable | Insomnia:Worsened | Appetite Loss:Improved | Appetite Loss:Stable | Appetite Loss:Worsened | Constipation:Improved | Constipation:Stable | Constipation:Worsened | Diarrhoea:Improved | Diarrhoea: Stable | Diarrhoea: Worsened | Financial Difficulties: Improved | Financial Difficulties: Stable | Financial Difficulties: Worsened | |
| 5-FU + Leucovorin (Arm B) (Mono Therapy Comparison) | 11 | 41 | 48 | 11 | 37 | 52 | 10 | 39 | 52 | 8 | 59 | 33 | 6 | 42 | 52 | 11 | 43 | 46 | 11 | 30 | 59 | 6 | 42 | 52 | 10 | 37 | 53 | 6 | 69 | 24 | 4 | 49 | 47 | 6 | 42 | 52 | 4 | 63 | 34 | 4 | 58 | 39 | 1 | 67 | 31 |
| 5-FU + Leucovorin (Combo Therapy Comparison) | 12 | 44 | 44 | 11 | 40 | 49 | 11 | 37 | 53 | 9 | 58 | 33 | 7 | 44 | 49 | 11 | 47 | 42 | 12 | 33 | 54 | 4 | 46 | 51 | 11 | 40 | 49 | 5 | 68 | 25 | 5 | 49 | 46 | 5 | 46 | 49 | 4 | 67 | 30 | 4 | 58 | 39 | 0 | 74 | 26 |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 17 | 38 | 45 | 10 | 41 | 49 | 15 | 32 | 52 | 20 | 46 | 34 | 11 | 48 | 41 | 13 | 34 | 54 | 14 | 20 | 66 | 13 | 32 | 55 | 27 | 34 | 39 | 7 | 51 | 42 | 18 | 34 | 48 | 11 | 45 | 44 | 13 | 56 | 31 | 6 | 39 | 55 | 8 | 51 | 41 |
| MM-398 Arm A (Mono Therapy Comparison) | 10 | 31 | 57 | 10 | 29 | 61 | 6 | 29 | 66 | 10 | 32 | 56 | 12 | 32 | 54 | 11 | 26 | 62 | 13 | 18 | 69 | 5 | 37 | 58 | 20 | 30 | 50 | 10 | 47 | 44 | 9 | 43 | 48 | 9 | 38 | 53 | 13 | 47 | 39 | 4 | 35 | 59 | 6 | 51 | 42 |
Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration
| Intervention | Total irinotecan = ug/L; SN38= ug/L (Geometric Mean) | |||
|---|---|---|---|---|
| Total Irinotecan-Cavg | Total Irinotecan-Cmax | Total SN38-Cavg | Total SN38-Cmax | |
| MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison | 2120.00 | 28460.00 | 0.68 | 2.58 |
| MM-398 Arm A (Mono Therapy Comparison) | 2550.00 | 40550.00 | 0.82 | 3.93 |
"CBR is defined by the percentage of participants achieving either a confirmed tumor response of complete response (CR) or partial response (PR) or stable disease (SD) for at least 24 weeks. Response Criteria in Solid Tumors (RECIST) is a system for measuring tumor shrinkage or progression in terms of the longest dimensions of the tumor on imaging scans such as computerized tomography (CT). A partial response requires a decrease of 30% or more, complete response requires all target lesions disappear, Progression requires an increase of at least 20%, and Stable disease falls in between these two. All responses have a repeat assessment to confirm the response." (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 90 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Lapatinib + Capecitabine | 57.7 |
Duration of response (complete response, partial response or stable disease) is defined as the time of first documentation of disease response until the date of disease progression or death due to breast cancer, whichever occurs first. DOR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for duration of response. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 88.80 months.
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 8.18 |
PFS is defined as the time from first dose date until the date of disease progression or death due to any reason, whichever occurs first. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90.38 months.
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 6.34 |
Six Months Progression-Free Survival is defined as the percentage of surviving participants who are progression-free longer than six months (greather than 180 days) after the first start date of study treatment. (NCT00508274)
Timeframe: at Baseline and every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed up to 90.38 months, with 6 months PFS reported.
| Intervention | Percentage of participants (Number) |
|---|---|
| Lapatinib + Capecitabine | 53.55 |
Time to response is defined as the time from first dose date until first documentation of disease response. TTR only applied to participants for whom best overall response was complete response (CR), partial response (PR) or stable disease (SD). Participants who had not had a partial response, complete response or stable disease at the cut-off date for this endpoint analysis were censored for time to response. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was approx. 14.78 months
| Intervention | Months (Median) |
|---|---|
| Lapatinib + Capecitabine | 4.07 |
On treatment deaths were collected from the start of treatment up to 30 days after study drug discontinuation, for a maximum duration of 4276 days (treatment duration ranged from 13 - 4246 days) for Lapatinib and 3384 days (treatment duration ranged form 8 - 3354 days) for Capecitabine. Total deaths was collected from study start to study end (LPLV). (NCT00508274)
Timeframe: up to 4276 days for Lapatinib/up to 3384 days for Capecitabine (on-treatment), approx. 12 years (all collected deaths)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Total Deaths | On-treatment Deaths | |
| Lapatinib + Capecitabine | 11 | 2 |
Number of participants who had Central Nervous System metastasis as the first site of relapse. CT, Magnetic Resonance Imaging, etc. were used for the assessment. (NCT00508274)
Timeframe: Baseline; every 6 weeks for the first 36 weeks and then every 12 weeks until disease progression. The maximum time participants were followed was 90 months
| Intervention | participants (Number) | |
|---|---|---|
| Participants with any site of relapse | Participants with CNS disease as first site of relapse | |
| Lapatinib + Capecitabine | 17 | 2 |
The three year rate of Disease-Free Survival (NCT00216086)
Timeframe: 36 months
| Intervention | percentage (Number) |
|---|---|
| Single Group Assignment | 75.5 |
To determine the rates of local and distant disease recurrence after treatment. (NCT00216086)
Timeframe: 36 months
| Intervention | percentage of particpants (Number) | |
|---|---|---|
| metastatic disease recurrence | locally recurrence | |
| Single Group Assignment | 22 | 0 |
"· To determine the pathological response rate of preoperative chemotherapy with capecitabine and irinotecan followed by combined modality chemoradiation with capecitabine in patients with locally advanced rectal cancer.~Pathological response was defined in the protocol as the proportion of complete (pCR) and non-complete pathological response (pNCR) among all evaluable patients." (NCT00216086)
Timeframe: 36 months
| Intervention | percentage of patients (Number) | |
|---|---|---|
| pCR | pNCR | |
| Single Group Assignment | 33 | 56 |
DR was defined as the time from the first objective documentation of CR or PR that was subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 30.1 |
| FOLFIRI + Placebo | 39.0 |
Objective disease response: participants with a confirmed complete response (CR) or partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST). CR was defined as the disappearance of all target lesions. PR was defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00457691)
Timeframe: Day 28 of Cycle 1 up to 30 months
| Intervention | Participants (Number) |
|---|---|
| FOLFIRI + Sunitinib | 124 |
| FOLFIRI + Placebo | 128 |
OS was defined as the time from randomization to the date of death due to any cause. OS data were censored on the day following the date of the last contact at which the patient was known to be alive. (NCT00457691)
Timeframe: Baseline up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 87.9 |
| FOLFIRI + Placebo | 85.9 |
PFS defined as time from date of randomization to date of first documentation of objective tumour progression or death due to any cause, whichever occurred first. (NCT00457691)
Timeframe: First dose of study treatment up to 30 months
| Intervention | Weeks (Median) |
|---|---|
| FOLFIRI + Sunitinib | 33.6 |
| FOLFIRI + Placebo | 36.6 |
"EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problem); 3 indicates worst health state (eg, confined to bed). Scoring formula developed by EuroQol Group assigns a utility value for each domain. Score is transformed and results in total score range -1.11 to 1.000; higher score indicates better health state." (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 0.04 | 0.04 | 0.03 | 0.05 | 0.05 | 0.09 |
| FOLFIRI + Sunitinib | 0.02 | 0.02 | 0.02 | 0.03 | 0.00 | 0.01 |
EQ-5D: participant-rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 3.3 | 4.3 | 6.6 | 4.3 | 4.0 | 9.0 |
| FOLFIRI + Sunitinib | 1.0 | 1.7 | 1.8 | 3.8 | -0.9 | -1.6 |
Symptom Interference score is comprised of the sum 6 function items from MDASI core (general activity, walking, work, mood, relations with other people, and enjoyment of life). Participant asked to rate how much symptoms have interfered in past 24 hours; each item rated from 0 to 10, with 0=did not interfere and 10=interfered completely; lower scores indicated better outcome (range: 0 to 60). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until EOT/withdrawal
| Intervention | scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | -1.3 | -1.7 | -1.2 | -0.2 | -1.7 | -1.0 |
| FOLFIRI + Sunitinib | 0.0 | -0.1 | 0.2 | -0.5 | 2.1 | 3.1 |
Symptom Intensity score is comprised of the sum of 13 MDASI core items (ie, pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsiness, dry mouth, sadness, vomiting, numbness or tingling). Participant asked to rate severity of each symptom at their worst in past 24 hours; each item rated from 0 to 10, with 0=symptom not present and 10=as bad as you can imagine; lower scores indicated better outcome (range: 0 to 130). (NCT00457691)
Timeframe: Day 1 of Cycles 1-3 and Day 1 of every odd-numbered cycle thereafter until end of treatment (EOT)/withdrawal
| Intervention | Scores on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 5, Day 1 | Cycle 7, Day 1 | Cycle 9, Day 1 | Cycle 11, Day 1 | |
| FOLFIRI + Placebo | 0.4 | 0.9 | 1.8 | 2.7 | 1.2 | -2.7 |
| FOLFIRI + Sunitinib | 1.7 | 0.8 | 1.0 | 0.7 | 0.8 | 5.0 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module. (NCT00005908)
Timeframe: 6 years
| Intervention | Participants (Number) |
|---|---|
| Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine | 9 |
| Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine | 20 |
Patients were classified as responders or non-responders based on change in tumor size by clinical exam and pathologic response.For instance, patients with a pathological complete response, micro-invasive disease at surgery, or clinical complete response after four cycles of treatment were considered responders. Changes in gene expression associated with treatment was assessed before/after chemotherapy. All gene expression summary intensities below 50 were thresholded to the value of 50 and genes showing variability significantly smaller than the median gene variability were screened out. (NCT00005908)
Timeframe: 6 years
| Intervention | Participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine | 8 | 2 |
| Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine | 7 | 13 |
Patients were classified as responders or non-responders based on change in tumor size by clinical exam and pathologic response.For instance, patients with a pathological complete response, micro-invasive disease at surgery, or clinical complete response after four cycles of treatment were considered responders. Changes in gene expression associated with treatment was assessed before/after chemotherapy. All gene expression summary intensities below 50 were thresholded to the value of 50 and genes showing variability significantly smaller than the median gene variability were screened out. (NCT00005908)
Timeframe: 6 years
| Intervention | Participants (Number) | |
|---|---|---|
| Responders | Non-responders | |
| Dose A & B-Cohort 1 & 2-Arm 1 & 2-Docetaxel & Capecitabine | 8 | 13 |
Overall response rate is defined as the percentage of participants with a CR (complete disappearance of all target lesions), PR (a 30% decrease in the sum of the longest diameter of target lesions) determined by clinical measurements per the Response Evaluation Criteria in Solid Tumors (RECIST) and/or a complete pathologic response (disappearance of all invasive tumor pathologically or presence of ductal carcinoma in situ) per the Chevallier criteria. For details about the RECIST or Chevallier criteria see the protocol link module. (NCT00005908)
Timeframe: 6 years
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| Complete Response | Partial Response | Complete pathologic response | |
| Dose A & B-Cohort 1 & 2-Arm 1& 2-Docetaxel & Capecitabine | 31 | 59 | 10 |
The duration of overall complete response was assessed from the time that measurement criteria were met for complete response until the first date that recurrent or progressive disease was objectively documented. Participants without observed progressive disease after an objective complete response were censored at the date of the last tumor assessment. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Number) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 12.45 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 12.68 |
Duration of overall response was assessed from the time that measurement criteria were first met for CR/PR (whichever is first recorded) until the first date that recurrent or progressive disease was documented. It was analyzed for responders only. Participants without observed progressive disease after an objective response were censored at the date of the last tumor assessment. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 7.0 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.7 |
Overall Survival is defined as the time from start of treatment to the date of death. Participants who did not die were censored at the last date the participant was known to be alive. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 22.9 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 20.5 |
Survival was measured as the time from start of treatment to the date of death or till one year whichever occurred first. (NCT00022698)
Timeframe: Up to Month 12
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 67 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 71 |
Time to disease progression was assessed as the time from start of treatment to the time the participant was first recorded as having disease progression or died due to causes other than disease progression. If a participant never progressed while being followed, he/she was censored at the date of the last tumor assessment or the date of the last dose if no post-baseline tumor measurement was available. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 6.1 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.6 |
The time to objective response is defined as the time from start of treatment to the date of first objective response. Participants who never responded during study were censored at the last tumor assessment or the date of last dose, whichever was later, or at the date of death if occurring prior to response. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 5.5 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 4.3 |
Time to treatment failure was assessed as the time from start of treatment to the time the participant was withdrawn due to any of the reasons such as adverse events, progressive disease, insufficient therapeutic response, death, failure to return, or refused treatment, did not cooperate or withdrew consent. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | months (Median) |
|---|---|
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 5.8 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 7.3 |
An adverse event (AEs) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. A serious adverse event is defined as any event which was fatal (resulted in death), life-threatening (with immediate risk of death), resulted in a new or prolongation of a current hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, considered medically significant by the investigator, required intervention to prevent one or more of the outcomes listed above. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | Number of participants (Number) | |||
|---|---|---|---|---|
| Any AEs | SAEs | Deaths During Study | Deaths During Follow-up | |
| Cohort 1, Initial Regimen: (Capecitabine + Irinotecan) | 15 | 10 | 0 | 13 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 52 | 25 | 3 | 23 |
| Total Participants (Cohort 1 + Cohort 2) | 67 | 35 | 3 | 36 |
Objective Response Rate (ORR) is defined as the percentage of participants with complete response (CR) or partial response (PR) according to response evaluation criteria in solid tumors (RECIST 1.0). CR is defined as the disappearance of all target and non-target lesions and normalization of tumor marker level. PR is defined as a greater than or equal to (>/=) 30% decrease in the sum of the longest diameter (LD) of the target lesions, taking as reference the baseline sum of LD. Participants who did not have a post-baseline tumor measurement were considered non-responders in the assessment of ORR. (NCT00022698)
Timeframe: Approximately 43 Months
| Intervention | percentage of participants (Number) | |
|---|---|---|
| CR | PR | |
| Cohort 1, Initial Regimen:(Capecitabine + Irinotecan) | 7 | 40 |
| Cohort 2, Amended Regimen: (Capecitabine + Irinotecan) | 2 | 42 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
37 reviews available for fluorouracil and Diarrhea
| Article | Year |
|---|---|
A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing.
Topics: Capecitabine; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Pharmacogenetics; | 2022 |
[Acute Kidney Injury in a Patient with Diarrhea and Vomiting Undergoing Chemotherapy for Colorectal Cancer].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Diarrhea; Fluoroura | 2016 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Death; Colorectal Neoplas | 2014 |
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla | 2014 |
Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Fluorouracil; Humans; Incide | 2014 |
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Combinations; Fluorouracil; Humans; I | 2016 |
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combine | 2016 |
Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; D | 2016 |
Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2008 |
Unanticipated toxicity to capecitabine.
Topics: Antimetabolites, Antineoplastic; Black or African American; Breast Neoplasms; Capecitabine; Deoxycyt | 2009 |
Current combination chemotherapy regimens for metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineop | 2009 |
Oral uracil-tegafur plus leucovorin vs fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans | 2011 |
[Lapatinib treatment-option in trastuzumab-resistant breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2009 |
Update on capecitabine alone and in combination regimens in colorectal cancer patients.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, An | 2010 |
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2011 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2011 |
Systemic toxicity from occlusive therapy with topical 5-fluorouracil: a case report and review of the literature.
Topics: Abdominal Pain; Administration, Cutaneous; Antimetabolites, Antineoplastic; Chills; Diarrhea; Drug E | 2012 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Current status of capecitabine in the treatment of colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherap | 2002 |
Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
Topics: Antimetabolites, Antineoplastic; Dermatitis; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; D | 2003 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials a | 2003 |
Overview of chemotherapy-induced diarrhea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluorouracil; Humans; Irinot | 2003 |
Adjuvant therapy for rectal cancer in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cli | 2004 |
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
Topics: Alopecia; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic | 2004 |
Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Clin | 2004 |
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biotransformation; Deoxyuracil Nucleotides; Diarrhea; Di | 2004 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt | 2005 |
Capecitabine: a new adjuvant option for colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Cause of Death; Colorectal Neop | 2006 |
[Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
Topics: Agranulocytosis; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; | 2006 |
[Zollinger-Ellison syndrome].
Topics: Benzimidazoles; Calcium; Cimetidine; Diarrhea; Duodenal Ulcer; Female; Fluorouracil; Gastrectomy; Ga | 1984 |
Metastatic colorectal cancer: advances in biochemical modulation and new drug development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neoplasms; Diar | 1995 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Diarrhea; Dogs; Drug Combinations; Female; Fluor | 1998 |
Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colorec | 1998 |
Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Fluor | 1998 |
[Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 1998 |
[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorou | 1991 |
255 trials available for fluorouracil and Diarrhea
| Article | Year |
|---|---|
Ameliorative Potential of L-Alanyl L-Glutamine Dipeptide in Colon Cancer Patients Receiving Modified FOLFOX-6 Regarding the Incidence of Diarrhea, the Treatment Response, and Patients' Survival: A Randomized Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Dipeptides; Fluorouraci | 2022 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluoroura | 2023 |
A randomized controlled, open-label early phase II trial comparing incidence of FOLFIRI.3-induced diarrhoea between Hangeshashinto and oral alkalization in Japanese patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Campto | 2019 |
Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Diet Records; Diet, Ca | 2020 |
Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy.
Topics: Abdominal Pain; Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Ne | 2020 |
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2021 |
Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arylamine | 2017 |
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Cohort Studies; Colore | 2018 |
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacologica | 2018 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Femal | 2017 |
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2019 |
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2014 |
Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 2013 |
A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colo
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2013 |
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
[Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2013 |
[Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; | 2013 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2014 |
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2014 |
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine | 2014 |
Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.
Topics: Adult; Aged; Antidiarrheals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2014 |
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Cohort Studies; De | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemo | 2014 |
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
Development of prediction tools for diarrhea and rash in breast cancer patients receiving lapatinib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast N | 2014 |
Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; China; Colorectal Neoplas | 2014 |
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2014 |
A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia | 2014 |
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2014 |
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Topics: Acetamides; Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic | 2014 |
Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Area Under Curve; Carcinoma, | 2016 |
NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2015 |
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; | 2016 |
Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer-biweekly versus standard triweekly XELOX (The ORION Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; De | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineo | 2016 |
Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycy | 2008 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2008 |
Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2009 |
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Diseas | 2009 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Dige | 2009 |
Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplas | 2009 |
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2009 |
Phase II, randomized, double-blind, placebo-controlled study of recombinant human intestinal trefoil factor oral spray for prevention of oral mucositis in patients with colorectal cancer who are receiving fluorouracil-based chemotherapy.
Topics: Abdominal Pain; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea | 2009 |
Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Administration, Oral; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; B | 2010 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2010 |
A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2010 |
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplas | 2011 |
Efficacy and safety of capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated pancreatic, gallbladder, and bile duct carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Ne | 2010 |
Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2010 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2010 |
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas | 2012 |
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclon | 2010 |
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dia | 2011 |
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve | 2011 |
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2012 |
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Capecit | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Campto | 2011 |
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
Topics: Administration, Metronomic; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy | 2012 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal | 2012 |
Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2011 |
Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemical Phenomena; Chemoradiotherapy, Adjuvant | 2011 |
Phase I study of irinotecan by 24-h intravenous infusion in combination with 5-fluorouracil in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2012 |
Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2011 |
Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2012 |
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2012 |
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diabe | 2012 |
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiot | 2012 |
Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under C | 2012 |
Colonic methane production modifies gastrointestinal toxicity associated with adjuvant 5-fluorouracil chemotherapy for colorectal cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breath Tests; Carcinoma; Chemotherapy, Adj | 2013 |
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem | 2013 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capeci | 2012 |
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; | 2012 |
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizu
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2013 |
The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemoth | 2013 |
Phase I study of sequential administration of topotecan and 5-fluorouracil in patients with advanced malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dose-Response Rel | 2002 |
Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fluorouracil; Humans; Infus | 2002 |
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2002 |
Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Col | 2002 |
A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrh | 2002 |
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2002 |
A phase I toxicity and feasibility trial of sequential dose-dense induction chemotherapy with doxorubicin, paclitaxel, and 5-fluorouracil followed by high dose consolidation for high-risk primary breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Diarrhea; | 2002 |
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp | 2002 |
Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2003 |
A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fatigu | 2004 |
Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; | 2003 |
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal | 2003 |
A phase II study with CPT-11 plus leucovorin and bolus IV 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2003 |
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2004 |
Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Combined Modality Therapy; Diarrhea; Di | 2004 |
[An institution-randomized trial of 5-fluorouracil and l-leucovorin therapy given monthly versus every two months to patients with advanced colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Case-Control Studies; Colo | 2004 |
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; | 2004 |
Phase II trial of capecitabine/irinotecan and capecitabine/oxaliplatin in advanced gastrointestinal cancers.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2004 |
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Cap | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2004 |
Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Doxorubici | 2004 |
Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Female; Fluoro | 2003 |
A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 2004 |
Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2004 |
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2005 |
A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyc | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl | 2005 |
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Respo | 2005 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2005 |
A randomized trial between two neoadjuvant chemotherapy protocols: CDDP + 5-FU versus CDDP + VP16 in advanced cancer of the head and neck.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; Etoposid | 2005 |
A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Colorectal Neo | 2005 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2005 |
[The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2005 |
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemot | 2005 |
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2005 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2005 |
Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chronotherapy; Diarrhe | 2006 |
Irinotecan, oxaliplatin plus bolus 5-fluorouracil and low dose folinic acid every 2 weeks: a feasibility study in metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2006 |
Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease Progression; Female; | 2006 |
Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2006 |
A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytid | 2006 |
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2006 |
A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy | 2006 |
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administr | 2006 |
[Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2006 |
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2007 |
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 2007 |
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2007 |
Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2007 |
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Diseases; Colonic Neop | 2007 |
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2006 |
Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Diarrhea; Dose-Response Re | 2006 |
Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2007 |
A clinical pharmacokinetic analysis of tegafur-uracil (UFT) plus leucovorin given in a new twice-daily oral administration schedule.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2007 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemot | 2008 |
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci | 2008 |
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Topics: Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); DNA Methylation; Fema | 2008 |
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2008 |
Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diarrhea; Dru | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus | 2008 |
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1984 |
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical Tria | 1983 |
Prospective randomized reappraisal of 5-fluorouracil in metastatic colorectal carcinoma. A comparative trial with 6-thioguanine.
Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Female; Fluorour | 1984 |
Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Evalu | 1983 |
Use of methotrexate and 5-FU for recurrent head and neck cancer.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Diarrhea; Drug Therapy, Combination | 1982 |
Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Diarrhea; Drug Therap | 1980 |
Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Drug Therapy, C | 1980 |
[Early phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Administr | 1995 |
[Treatment of acute chemically induced diarrhea by inhibition of enkephalinase. Results of a pilot study].
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Diarrhe | 1995 |
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
[A cooperative late phase II trial of l-leucovorin and 5-fluorouracil in the treatment of advanced gastric cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
Topics: Adult; Aged; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intrav | 1995 |
[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
Topics: Adult; Aged; Anorexia; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorou | 1995 |
Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea.
Topics: Adult; Aged; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged | 1995 |
Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; F | 1995 |
Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspart | 1995 |
Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1995 |
[A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration | 1995 |
Phase II trial of 5-fluorouracil and folinic acid in the treatment of advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Diarrhea; Female; Fluor | 1994 |
A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Doxorubicin | 1994 |
5-fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fluorouracil; Humans; Leucovorin; Ma | 1994 |
Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colonic Neoplasms | 1994 |
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; | 1994 |
Double modulation of 5-fluorouracil in the treatment of advanced colorectal carcinoma: report of a trial with sequential methotrexate, intravenous (loading dose) folinic acid, 5-fluorouracil, and a literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorecta | 1994 |
Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Diarrhea; Female; Fluorouracil; Humans; Leucovorin; | 1993 |
Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Feasibi | 1993 |
Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.
Topics: Adult; Aged; Diarrhea; Female; Fluorouracil; Humans; Loperamide; Male; Middle Aged; Octreotide | 1993 |
Low-dose, continuous infusion 5-fluorouracil and oral etoposide for the treatment of advanced sarcomas.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration | 1995 |
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anemia; Antidotes; Antimetabolites, Antineoplast | 1996 |
Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: results of a randomized multicenter trial. Study Group for Palliative Treatment of Metastatic Colorectal Cancer Study Protocol 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms | 1996 |
A phase II study of oral fluorouracil for gastrointestinal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diarrhea; Drug Administrati | 1996 |
A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Colorectal Neopl | 1996 |
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Topics: Adult; Aged; Antidotes; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Prot | 1996 |
Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colon | 1997 |
A phase I study of 5-fluorouracil, leucovorin and levamisole.
Topics: Adjuvants, Immunologic; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; | 1997 |
Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antidotes; Antimetabolites, An | 1997 |
The Spanish experience with high-dose infusional 5-fluorouracil (5-FU) in colorectal cancer. The Spanish Cooperative Group For Gastrointestinal Tumor Therapy (TTD).
Topics: Administration, Oral; Adult; Aged; Anemia; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Co | 1996 |
Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chi-Square Distribution; Colorectal | 1997 |
Metastatic breast cancer: treatment with fluorouracil-based combinations.
Topics: Adult; Aged; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Di | 1997 |
Neoadjuvant therapy with cisplatin/fluorouracil vs cisplatin/UFT in locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 1997 |
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Female | 1998 |
Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Diarrhea; Fluorouracil; Huma | 1998 |
Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas.
Topics: Aged; Anorexia; Antidotes; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Bone Marrow; Di | 1998 |
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over | 1998 |
Phase II study of the modified regimen of etoposide, leucovorin and 5-fluorouracil for patients with advanced gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admini | 1998 |
Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1998 |
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cohor | 1996 |
Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 1999 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 1999 |
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biliru | 1999 |
Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhea and failure of loperamide treatment.
Topics: Administration, Oral; Administration, Topical; Aged; Anti-Inflammatory Agents; Antineoplastic Agents | 1999 |
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Topics: Acetates; Adult; Antimetabolites, Antineoplastic; Cytoprotection; Diarrhea; Dose-Response Relationsh | 2000 |
High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients.
Topics: Administration, Oral; Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic C | 2000 |
A phase I and pharmacokinetic study of docetaxel administered in combination with continuous intravenous infusion of 5-fluorouracil in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Diar | 2000 |
Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineo | 2000 |
Randomized comparison of prophylactic antidiarrheal treatment versus no prophylactic antidiarrheal treatment in patients receiving CPT-11 (irinotecan) for advanced 5-FU-resistant colorectal cancer: an open-label multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Drug R | 2000 |
Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal | 2000 |
Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
Topics: Adult; Aged; Antidiarrheals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam | 2000 |
Phase II trial of cisplatin, etoposide, and 5-fluorouracil in advanced non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study (PB586).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2000 |
Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: a potential role for growth factor as mucosal protectant.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Cohort Studies; Diarr | 1999 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemother | 2000 |
Oral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Diarrhea; Dou | 2001 |
Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2000 |
A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies.
Topics: Abdominal Pain; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dinoprost; Do | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D | 2001 |
Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Dose-Response | 2001 |
Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined | 2001 |
Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2001 |
Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2001 |
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; D | 2002 |
Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chr | 2001 |
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta | 2001 |
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2002 |
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; DNA, Antise | 2002 |
Physical performance, toxicity, and quality of life as assessed by the physician and the patient.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2002 |
Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carci | 2002 |
Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2002 |
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2002 |
Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr | 1992 |
Phase II trial of 5-fluorouracil and recombinant interferon alfa-2B in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Drug Ev | 1992 |
Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 1992 |
Randomised comparison of weekly bolus 5-fluorouracil with or without leucovorin in metastatic colorectal carcinoma.
Topics: Adult; Aged; Colorectal Neoplasms; Conjunctivitis; Diarrhea; Drug Administration Schedule; Female; F | 1992 |
[5-Fluorouracil (5-FU)/leucovorin in comparison to other current chemotherapy protocols in metastasizing colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Fluorou | 1991 |
5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Allopurinol; Anorexia; Antineoplastic Combined Chemotherapy Protocols; | 1990 |
The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal | 1988 |
Severe life-threatening toxicities observed in study using leucovorin with 5-fluorouracil.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; D | 1987 |
Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cytarabine; Diabetic Ketoacidosis; Diar | 1972 |
A clinical study of fluorouracil.
Topics: Adult; Aged; Clinical Trials as Topic; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Humans; Le | 1968 |
Phase I study of a combination of azotomycin (NSC-56654) and 5-fluorouracil (NSC-19893) in malignant disease.
Topics: Antibiotics, Antineoplastic; Azo Compounds; Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; D | 1970 |
Corticosteroids and fluorouracil toxicity.
Topics: Bone Marrow; Clinical Trials as Topic; Diarrhea; Digestive System; Fluorouracil; Humans; Injections, | 1966 |
229 other studies available for fluorouracil and Diarrhea
| Article | Year |
|---|---|
2'-Fucosyllactose Ameliorates Chemotherapy-Induced Intestinal Mucositis by Protecting Intestinal Epithelial Cells Against Apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Diarrhea; Fluorouracil; Goblet Cells; Mice; Muc | 2022 |
TBHQ attenuates ferroptosis against 5-fluorouracil-induced intestinal epithelial cell injury and intestinal mucositis via activation of Nrf2.
Topics: Animals; Cell Death; Cell Line; Cytokines; Diarrhea; Disease Models, Animal; Epithelial Cells; Ferro | 2021 |
Oral administration of cystine and theanine attenuates 5-fluorouracil-induced intestinal mucositis and diarrhea by suppressing both glutathione level decrease and ROS production in the small intestine of mucositis mouse model.
Topics: Animals; Cystine; Diarrhea; Disease Models, Animal; Drug Therapy, Combination; Fluorouracil; Glutama | 2021 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; | 2022 |
Protective effect of polysaccharides isolated from the seeds of Cuscuta chinensis Lam. on 5-fluorouracil-induced intestinal mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; bcl-2-Associated X Protein; Body Weight; Caspase 3; Cuscut | 2022 |
Evaluation and validation of chemotherapy-specific diarrhoea and histopathology in rats.
Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; Diarrhea; Doxorubicin; Fluorouracil; Idarubici | 2022 |
Wumei pills attenuates 5-fluorouracil-induced intestinal mucositis through Toll-like receptor 4/myeloid differentiation factor 88/nuclear factor-κB pathway and microbiota regulation.
Topics: Animals; Antineoplastic Agents; Body Weight; Butyrates; Cadherins; Claudin-1; Diarrhea; Drugs, Chine | 2022 |
Mouse organoids as an in vitro tool to study the in vivo intestinal response to cytotoxicants.
Topics: Animals; Apoptosis; Caspase 3; Diarrhea; Fluorouracil; Humans; Intestinal Mucosa; Mice; Organoids | 2023 |
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile.
Topics: Capecitabine; Diarrhea; Enterocolitis; Fluorouracil; Humans; Pharmacogenetics | 2022 |
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile.
Topics: Capecitabine; Diarrhea; Enterocolitis; Fluorouracil; Humans; Pharmacogenetics | 2022 |
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile.
Topics: Capecitabine; Diarrhea; Enterocolitis; Fluorouracil; Humans; Pharmacogenetics | 2022 |
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile.
Topics: Capecitabine; Diarrhea; Enterocolitis; Fluorouracil; Humans; Pharmacogenetics | 2022 |
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile.
Topics: Capecitabine; Diarrhea; Enterocolitis; Fluorouracil; Humans; Pharmacogenetics | 2022 |
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile.
Topics: Capecitabine; Diarrhea; Enterocolitis; Fluorouracil; Humans; Pharmacogenetics | 2022 |
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile.
Topics: Capecitabine; Diarrhea; Enterocolitis; Fluorouracil; Humans; Pharmacogenetics | 2022 |
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile.
Topics: Capecitabine; Diarrhea; Enterocolitis; Fluorouracil; Humans; Pharmacogenetics | 2022 |
Capecitabine-induced enterocolitis: a case report and pharmacogenetic profile.
Topics: Capecitabine; Diarrhea; Enterocolitis; Fluorouracil; Humans; Pharmacogenetics | 2022 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoradiotherapy; Dermatitis; Diarr | 2023 |
Characterization of a novel dual murine model of chemotherapy-induced oral and intestinal mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Diarrhea; Disease Models, Animal; Fluorouracil; Intestinal | 2023 |
Anakinra and dexamethasone treatment of idarubicin-induced mucositis and diarrhoea in rats.
Topics: Animals; Antineoplastic Agents; Dexamethasone; Diarrhea; Fluorouracil; Idarubicin; Interleukin 1 Rec | 2023 |
Probiotic Supplementation Attenuates Chemotherapy-Induced Intestinal Mucositis in an Experimental Colorectal Cancer Liver Metastasis Rat Model.
Topics: Animals; Antineoplastic Agents; Colorectal Neoplasms; Diarrhea; Fluorouracil; Male; Mucositis; Probi | 2023 |
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapy.
Topics: Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Australia; Bayes Theorem; Diarrhea; | 2023 |
[Bletilla striata polysaccharide improves toxic and side effects induced by 5-FU: an untargeted metabolomics study].
Topics: Animals; Colonic Neoplasms; Diarrhea; Fluorouracil; Hormones; Male; Metabolomics; Mice; Mice, Inbred | 2023 |
A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug-induced toxicity.
Topics: Animals; Citrulline; Diarrhea; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Fluorou | 2023 |
Topics: Alpinia; Animals; Diarrhea; Dinoprostone; Fluorouracil; Gastrointestinal Microbiome; Mice; Mucositis | 2023 |
Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat.
Topics: Animals; Benzoxazines; Cannabinoid Receptor Agonists; Cannabinoids; Diarrhea; Fluorouracil; Humans; | 2023 |
Mucoprotective effects of Saikosaponin-A in 5-fluorouracil-induced intestinal mucositis in mice model.
Topics: Animals; Antimetabolites, Antineoplastic; Antioxidants; Apoptosis; Cytokines; Diarrhea; Disease Mode | 2019 |
Pharmacokinetics-based Dose Management of 5-Fluorouracil Clinical Research in Advanced Colorectal Cancer Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Dose-Response | 2020 |
Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Body Weight; Diarrhea; Dipeptidyl Pe | 2019 |
Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2019 |
Systems biology analysis identifies molecular determinants of chemotherapy-induced diarrhoea.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2020 |
Patchouli oil ameliorates 5-fluorouracil-induced intestinal mucositis in rats via protecting intestinal barrier and regulating water transport.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cytokines; Diarrhea; Dose-Response Relationship | 2020 |
Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Disease-Fr | 2020 |
Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; | 2020 |
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecit | 2021 |
Effects of 10.6-μm laser moxibustion and electroacupuncture at ST36 in a 5-Fu-induced diarrhea rat model.
Topics: Acupuncture Points; Animals; Diarrhea; Electroacupuncture; Fluorouracil; Humans; Lasers; Male; Moxib | 2021 |
Babao Dan Alleviates 5-Fluorouracil-Induced Intestinal Damage via Wnt/β-Catenin Pathway.
Topics: Animals; Antineoplastic Agents; beta Catenin; Diarrhea; Fluorouracil; Intestinal Mucosa; Male; Mice; | 2022 |
Lactobacillus Kefiri LKF01 (Kefibios
Topics: Aged; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Diarrhea; Endpoint Determination; F | 2021 |
Anti-inflammatory effects of Radix Aucklandiae herbal preparation ameliorate intestinal mucositis induced by 5-fluorouracil in mice.
Topics: Animals; Anti-Inflammatory Agents; Asteraceae; Body Weight; Cytokines; Diarrhea; Disease Models, Ani | 2021 |
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Color | 2021 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diar | 2021 |
Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine; Cohort Studies; Deox | 2021 |
Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice.
Topics: Animals; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Cyto | 2017 |
Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons.
Topics: Acetamides; Animals; Antimetabolites, Antineoplastic; Diarrhea; Famotidine; Fluorouracil; Histamine | 2017 |
PET-CT guided SIB-IMRT combined with concurrent 5-FU/MMC for the treatment of anal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Chem | 2017 |
Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses.
Topics: Animals; Apoptosis; Bifidobacterium bifidum; Body Weight; Diarrhea; Dysbiosis; Fluorouracil; Inflamm | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model.
Topics: Animals; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Carnosine; Cell Proliferation; Colorect | 2017 |
Bifidobacterium Infantis Ameliorates Chemotherapy-Induced Intestinal Mucositis Via Regulating T Cell Immunity in Colorectal Cancer Rats.
Topics: Animals; Antineoplastic Agents; Bifidobacterium longum subspecies infantis; Cell Line; Colorectal Ne | 2017 |
TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Breast; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, B | 2018 |
Active Ingredients of Hange-shashin-to, Baicalelin and 6-Gingerol, Inhibit 5-Fluorouracil-Induced Upregulation of CXCL1 in the Colon to Attenuate Diarrhea Development.
Topics: Animals; Antimetabolites, Antineoplastic; Catechols; Chemokine CXCL1; Colon; Diarrhea; Disease Model | 2017 |
Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bloo | 2018 |
Folate-producing lactic acid bacteria reduce inflammation in mice with induced intestinal mucositis.
Topics: Animals; Caco-2 Cells; Cytokines; Diarrhea; Fluorouracil; Folic Acid; Humans; Inflammation; Intestin | 2018 |
Intensity-modulated Radiotherapy for Anal Cancer: Dose-Volume Relationship of Acute Gastrointestinal Toxicity and Disease Outcomes.
Topics: Abdominal Cavity; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; An | 2018 |
Assessment of dose-response relationship of 5-fluorouracil to murine intestinal injury.
Topics: Amine Oxidase (Copper-Containing); Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associ | 2018 |
The protective effects of Aquilariae Lignum Resinatum extract on 5-Fuorouracil-induced intestinal mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Diarrhea; Fluorouracil; Intestinal Diseases; Male; Medicin | 2019 |
Fluoropyrimidine-induced intestinal mucosal injury is associated with the severity of chemotherapy-related diarrhea.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antineoplastic Agents; Capsule Endoscopy; | 2019 |
Ameliorative effect of Atractylodes macrocephala essential oil combined with Panax ginseng total saponins on 5-fluorouracil induced diarrhea is associated with gut microbial modulation.
Topics: Animals; Atractylodes; Diarrhea; Fluorouracil; Ginsenosides; Mice; Oils, Volatile; Panax; Plant Oils | 2019 |
Impact of protocol change on individual factors related to course of adverse reactions to chemotherapy for breast cancer.
Topics: Abdominal Pain; Adult; Aged; Alcohol Oxidoreductases; Antineoplastic Combined Chemotherapy Protocols | 2020 |
Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2019 |
Prediction of irinotecan toxicity in metastatic colorectal cancer patients based on machine learning models with pharmacokinetic parameters.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; | 2019 |
Gut microbial modulation in the treatment of chemotherapy-induced diarrhea with Shenzhu Capsule.
Topics: Animals; Antimetabolites, Antineoplastic; Atractylodes; Diarrhea; Drug Evaluation, Preclinical; Drug | 2019 |
Qingjie Fuzheng Granule attenuates 5-fluorouracil-induced intestinal mucosal damage.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Body Weight; Cell Proliferation; Diarrhea; Drugs, Ch | 2019 |
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxyc | 2013 |
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Diamine oxidase as a marker of intestinal mucosal injury and the effect of soluble dietary fiber on gastrointestinal tract toxicity after intravenous 5-fluorouracil treatment in rats.
Topics: Administration, Intravenous; Amine Oxidase (Copper-Containing); Animals; Biomarkers; Diarrhea; Dieta | 2014 |
Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Diarrhea; Disease- | 2013 |
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Campto | 2013 |
Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Anxiety; Carcinoma; Chemoradiotherapy; Cispl | 2013 |
Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; China; | 2014 |
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Colonic N | 2014 |
Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Biopsy | 2014 |
Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil.
Topics: Animals; Antibodies, Neutralizing; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Pr | 2014 |
Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; b | 2014 |
Neutrophil recruitment is critical for 5-fluorouracil-induced diarrhea and the decrease in aquaporins in the colon.
Topics: Animals; Antimetabolites, Antineoplastic; Aquaporin 4; Aquaporins; Chemokine CXCL1; Chemokine CXCL2; | 2014 |
Exogenous IL-1Ra attenuates intestinal mucositis induced by oxaliplatin and 5-fluorouracil through suppression of p53-dependent apoptosis.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2015 |
Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austr | 2014 |
Irinophore C™, a lipid nanoparticle formulation of irinotecan, abrogates the gastrointestinal effects of irinotecan in a rat model of clinical toxicities.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cholester | 2014 |
Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycy | 2014 |
Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2017 |
Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiothera | 2017 |
Long Survival and Severe Toxicity Under 5-Fluorouracil-Based Therapy in a Patient With Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Gene Frequency; Genet | 2015 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptotheci | 2017 |
Influence of an elemental diet on 5-fluorouracil-induced morphological changes in the mouse salivary gland and colon.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Colon; Diarrhea; Disease Models, Anim | 2016 |
Amelioration of Chemotherapy-Induced Intestinal Mucositis by Orally Administered Probiotics in a Mouse Model.
Topics: Administration, Oral; Animals; Bifidobacterium; Cytokines; Diarrhea; Disease Models, Animal; Fluorou | 2015 |
A nanomedicine-promising approach to provide an appropriate colon-targeted drug delivery system for 5-fluorouracil.
Topics: Animals; Body Weight; Cecum; Colon; Diarrhea; Drug Delivery Systems; Drug Liberation; Female; Fluoro | 2015 |
A new animal model of intestinal mucositis induced by the combination of irinotecan and 5-fluorouracil in mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Admin | 2016 |
Curcumin Inhibits 5-Fluorouracil-induced Up-regulation of CXCL1 and CXCL2 of the Colon Associated with Attenuation of Diarrhoea Development.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antioxidants; Che | 2016 |
Protective effect and potential mechanisms of Wei-Chang-An pill on high-dose 5-fluorouracil-induced intestinal mucositis in mice.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Biomarkers; Cell Proliferation; Chromatogra | 2016 |
Intestinal permeability to iohexol as an in vivo marker of chemotherapy-induced gastrointestinal toxicity in Sprague-Dawley rats.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; | 2016 |
Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer-a real-world outcome study.
Topics: Age Factors; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Diarrhea; Disease-Free Surviv | 2016 |
May cannabinoids prevent the development of chemotherapy-induced diarrhea and intestinal mucositis? Experimental study in the rat.
Topics: Animals; Antineoplastic Agents; Cannabinoids; Diarrhea; Fluorouracil; Gastrointestinal Motility; Int | 2017 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth | 2016 |
A prospective study of nutritional supplementation for preventing oral mucositis in cancer patients receiving chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Esophageal Neoplasms; Fe | 2017 |
Combined cetuximab, capecitabine, oxaliplatin, and radiotherapy in rectal cancer: Dr. Jekyll or Mr. Hyde? In regard to Rödel et al. (Int J Radiat Oncol Biol Phys 2008;70:1081-1086.).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
[The prevention of diarrhea while under capecitabine therapy].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Fluoro | 2008 |
[Preparation of a brochure for patients undergoing FOLFIRI chemotherapy based on survey of adverse reactions].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Con | 2008 |
Single and combined supplementation of glutamine and n-3 polyunsaturated fatty acids on host tolerance and tumour response to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11)/5-fluorouracil chemotherapy in rats bearing Ward colo
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Camptothecin; Colonic Neoplasms; Combined M | 2009 |
Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability model.
Topics: Antimetabolites, Antineoplastic; Diarrhea; Dose-Response Relationship, Radiation; Fluorouracil; Huma | 2010 |
Chemotherapy: Optimizing irinotecan regimens for colorectal cancer.
Topics: Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineopl | 2009 |
Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice.
Topics: Amidines; Animals; Antimetabolites, Antineoplastic; Cytokines; Diarrhea; Dose-Response Relationship, | 2010 |
Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Diarrhea; Feasibility Studies | 2010 |
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemot | 2010 |
Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2011 |
Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; | 2010 |
New recommendation of doses in an ongoing phase II study of docetaxel, oxaliplatin and capecitabine as first line therapy in advanced gastro-oesophageal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; De | 2011 |
Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzimidazoles; Diarrhea; Disease Models, Anima | 2011 |
Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Body Weight; Diarrhea; Disease M | 2010 |
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2011 |
[Taxan induction chemotherapy and concomitant chemoradiotherapy with cisplatin in patients with locally advanced head and neck cancer--early results].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplat | 2010 |
Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Colorectal | 2011 |
[Diamine oxidase as blood biomarker in rats and humans to GI tract toxicity of fluorouracil anti-cancer drugs].
Topics: Aged; Amine Oxidase (Copper-Containing); Animals; Antimetabolites, Antineoplastic; Biomarkers; Diarr | 2011 |
Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Fema | 2011 |
Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-Fluorouracil in a mouse mucositis model.
Topics: Animals; Body Weight; Diarrhea; Disease Models, Animal; Drug Interactions; Female; Fluorouracil; Gen | 2011 |
CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Chemokine CXCL9; Diarrhea; | 2011 |
Prevention of acute radiation enteritis: efficacy and tolerance of glutamine.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Diarrhe | 2011 |
Pretherapeutic uracil and dihydrouracil levels of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Topics: Adverse Drug Reaction Reporting Systems; Capecitabine; Data Mining; Deoxycytidine; Diarrhea; Fluorou | 2012 |
[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
Topics: Adult; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2011 |
Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer.
Topics: Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Defecation; Deoxycytidine; Diarrhea; F | 2012 |
Dose-modified XELIRI chemotherapy for metastatic colorectal cancer--a retrospective study of 78 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; De | 2012 |
[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2012 |
Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2013 |
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
Topics: Aged; Biomarkers; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Huma | 2012 |
In regard to Samuelian et Al.
Topics: Antineoplastic Agents; Data Interpretation, Statistical; Diarrhea; Fluorouracil; Humans; Postoperati | 2012 |
5-HT₃ receptor antagonists ameliorate 5-fluorouracil-induced intestinal mucositis by suppression of apoptosis in murine intestinal crypt cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Benzimidazoles; | 2013 |
[Severe diarrhea].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Camptothecin; Diarrhea; Fluorouracil; Gastrointestinal | 2012 |
5-Fluorouracil induces diarrhea with changes in the expression of inflammatory cytokines and aquaporins in mouse intestines.
Topics: Animals; Antimetabolites, Antineoplastic; Aquaporins; Body Weight; Cytokines; Diarrhea; Etanercept; | 2013 |
Long-term results of reirradiation for patients with recurrent rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; D | 2002 |
Severe 5-fluorouracil toxicity associated with a marked alteration of pharmacokinetics of 5-fluorouracil and its catabolite 5-fluoro-5,6-dihydrouracil: a case report.
Topics: Alopecia; Antimetabolites, Antineoplastic; Area Under Curve; Diarrhea; Drug Eruptions; Female; Fever | 2002 |
Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.
Topics: Antidiarrheals; Antineoplastic Agents; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Tri | 2003 |
Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bacitracin; Camptothecin; Colo | 2003 |
Primary chemoradiation as definitive treatment for unresectable cancer of the trachea.
Topics: Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2003 |
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Databases, Factual; Diarrhea; Drug | 2003 |
Oral and intestinal microflora in 5-fluorouracil treated rats, translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria.
Topics: Animals; Antimetabolites, Antineoplastic; Bacteria, Anaerobic; Bacterial Translocation; Body Weight; | 2003 |
Amifostine, in a reduced dose, protects against severe diarrhea associated with weekly fluorouracil and folinic acid chemotherapy in advanced colorectal cancer: a pilot study.
Topics: Aged; Aged, 80 and over; Amifostine; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea | 2003 |
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne | 1963 |
COMPARISON OF HIGH-DOSAGE AND LOW-DOSAGE-MAINTENANCE THERAPY WITH 5-FLUOROURACIL IN SOLID TUMORS.
Topics: Diarrhea; Fluorouracil; Humans; Nausea; Neoplasms; Stomatitis; Toxicology; Vomiting | 1964 |
CURRENT STATUS OF 5-FLUOROURACIL THERAPY IN FAR-ADVANCED NEOPLASTIC DISEASE.
Topics: Alopecia; Chlorpromazine; Diarrhea; Erythema; Fluorouracil; Leukopenia; Nausea; Neoplasms; Thrombocy | 1964 |
TREATMENT OF ADVANCED CANCER WITH 5-FLUOROURACIL.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Humans; Leuko | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo | 1964 |
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2003 |
[Management of chemotherapy induced diarrhea].
Topics: Antidiarrheals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2004 |
Neomycin as secondary prophylaxis for irinotecan-induced diarrhea.
Topics: Administration, Oral; Anti-Bacterial Agents; Antidiarrheals; Antineoplastic Agents, Phytogenic; Anti | 2004 |
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neo | 2004 |
Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Drug Administra | 2004 |
[Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Dihydroura | 2005 |
[Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 2005 |
[Method of levofolinate.5-FU administration by hepatic arterial infusion therapy for hepatic metastasis from colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarr | 2006 |
Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diarrhea; Fe | 2006 |
[Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Dihydrouracil Dehydrogenase ( | 2006 |
Severe diarrhea in patients with advanced-stage colorectal cancer receiving FOLFOX or FOLFIRI chemotherapy: the development of a risk prediction tool.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2007 |
[Chemotherapy for elderly patients with colorectal cancer].
Topics: Age Factors; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine | 2007 |
Chemotherapy-induced mucositis: focusing on diarrhea.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Budesonide; Camptothecin; Dehydration; Diar | 2007 |
Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2007 |
[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2007 |
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2007 |
The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diarrhea; Female; Fluorou | 2008 |
[Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2007 |
Pooled analysis of diarrhea events in patients with cancer treated with lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinic | 2008 |
Predicting fluorouracil toxicity: can we finally do it?
Topics: Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Genetic | 2008 |
Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2008 |
[Polymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patients].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian Peop | 2007 |
Reevaluation of 5-fluorouracil as a single therapeutic agent for gestational trophoblastic neoplasms.
Topics: Choriocarcinoma; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Humans; Hydatidiform Mole, Invas | 1984 |
Weekly large fraction radiotherapy and 5 fluorouracil as a palliative treatment for large bowel carcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Diarrhea; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Large; | 1982 |
Use of arterial devascularization and cytotoxic drugs in 30 patients with the carcinoid syndrome.
Topics: Adult; Aged; Carcinoid Tumor; Cyclophosphamide; Diarrhea; Doxorubicin; Embolization, Therapeutic; Fe | 1982 |
Phase I study of continuous-infusion PALA and 5-FU.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltransferase; Asparti | 1984 |
[Non-hematologic adverse effects of cytostatic drugs].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Diarrhea; Drug Eruptions; Female; | 1984 |
Phase I evaluation of oral tegafur.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio | 1983 |
[Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)].
Topics: Adenocarcinoma; Alopecia; Candidiasis, Oral; Diarrhea; Female; Fluorouracil; Hepatomegaly; Humans; M | 1982 |
Diurnal variation in the intestinal toxicity of 5-fluorouracil in the rat.
Topics: Animals; Circadian Rhythm; Diarrhea; DNA; Fluorouracil; Intestinal Absorption; Intestinal Mucosa; In | 1981 |
Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Drug Evalua | 1993 |
Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Circadian Rhythm; Diarrhea; Dose-Response Relationship, Drug; Female; F | 1993 |
Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diar | 1993 |
Uridine allows dose escalation of 5-fluorouracil when given with N-phosphonacetyl-L-aspartate, methotrexate, and leucovorin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Diarrhea; Drug Synergism | 1993 |
Have enteric infections a role in 5-fluorouracil-associated diarrhea?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bacterial Infections; Colorectal Neoplasms; Diarrhea; | 1995 |
Influence of inflammatory bowel disease on the ability of patients to tolerate systemic fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Diarrhea; Female; Fluorouracil; Gastrointestinal Neopl | 1996 |
Octreotide treatment of chemotherapy-induced diarrhoea.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Diarrhea; Female; Fluorouracil; Gastrointestinal Agent | 1996 |
Suppository delivery of 5-fluorouracil in rectal cancer.
Topics: Administration, Rectal; Animals; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liqu | 1996 |
Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer.
Topics: Adenocarcinoma; Administration, Rectal; Animals; Antibiotics, Antineoplastic; Chromatography, High P | 1997 |
Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; Flu | 1998 |
A risk-benefit assessment of irinotecan in solid tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 1998 |
Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Di | 1998 |
Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Basal Cell; Diarrhea; Dihydrour | 1999 |
Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Catheterization, Central Venous; Cohort Studies; Colonic | 1999 |
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Female | 1999 |
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopla | 1999 |
Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diarrhea | 2000 |
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Intestinal Di | 2000 |
Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Colon; Diarrhea; Digestive System; Drug Combi | 2000 |
Moving beyond fluorouracil for colorectal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2000 |
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrh | 2001 |
Adjuvant postoperative 5-fluorouracil chemotherapy combined with pelvic radiation for rectal cancer: results from an Asian population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Agranulocytosis; Antimetabolites, Antineoplastic; Ch | 2001 |
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Topics: Adult; Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neopla | 2001 |
The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer.
Topics: Acute Disease; Adenocarcinoma; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Modal | 2002 |
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls
Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Diarrhea; Dihydrouracil Dehydrogenase (NADP); | 2002 |
Zollinger-Ellison syndrome: special considerations.
Topics: Adolescent; Adult; Aged; Child; Diarrhea; Female; Fluorouracil; Gastrectomy; Gastric Juice; Gastrins | 1977 |
The adverse effects of elemental diets on tolerance for 5-FU toxicity in the rat.
Topics: Amino Acids, Essential; Animals; Blood; Blood Proteins; Body Weight; Colon; Diarrhea; Diet; Dietary | 1977 |
The clinical results of 5-fluorouracil intrahepatic arterial infusion in 528 patients with metastatic cancer to the liver.
Topics: Diarrhea; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; | 1978 |
[Life-threatening gastrointestinal toxicity during 5-fluorouracil therapy].
Topics: Diarrhea; Drug Hypersensitivity; Fluorouracil; Humans | 1977 |
Basal-cell carcinoma. A case unmasked by systemic fluorouracil therapy.
Topics: Administration, Topical; Carcinoma, Basal Cell; Diarrhea; Fluorouracil; Humans; Injections, Intraven | 1976 |
Adenocarcinoma of the bile ducts. Relationship of anatomic location to clinical features.
Topics: Adenocarcinoma; Adult; Aged; Alkaline Phosphatase; Bile Duct Neoplasms; Bile Ducts; Bile Ducts, Intr | 1975 |
The role of schedule dependency of 5-fluorouracil/leucovorin combinations in advanced colorectal cancer.
Topics: Clinical Trials as Topic; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Fluorouracil | 1992 |
Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Female; Fluorouracil; Humans; Interf | 1992 |
[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Diarrhea; Dru | 1991 |
Protein intake and 5-fluorouracil toxicity in tumor-bearing animals.
Topics: Animals; Body Weight; Diarrhea; Dietary Proteins; Female; Fluorouracil; Leukopenia; Mammary Neoplasm | 1990 |
A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. Demonstration of biochemical modulation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Admin | 1989 |
Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314.
Topics: Anal Canal; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cobalt Radioisot | 1989 |
Watery diarrhea-hypokalemia-achlorhydria syndrome and carcinoma of the esophagus.
Topics: Achlorhydria; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; | 1985 |
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1986 |
Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Colonic Neoplasms; Diarrhea; D | 1988 |
Reevaluation of the maximum tolerated dose of continuous venous infusion of 5-fluorouracil with pharmacokinetics.
Topics: Diarrhea; Fluorouracil; Humans; Infusions, Intravenous; Skin | 1988 |
A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma.
Topics: Adenocarcinoma; Bone Marrow Diseases; Diarrhea; Drug Evaluation; Erythema; Fluorouracil; Humans; Inj | 1987 |
Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea | 1987 |
High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Female; Fl | 1987 |
5-Fluorouracil and high-dose folic acid treatment for metastatic colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Female; Fluorouracil; F | 1987 |
[Therapeutic effect of sequential doses of methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced gastric cancer: comparison of intermediate-dose MTX with high-dose MTX].
Topics: Adult; Aged; Alopecia; Diarrhea; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusio | 1985 |
Elemental diet in the management of the intestinal lesion produced by 5-fluorouracil in man.
Topics: Aged; Amino Acids; Animals; Biopsy; Diarrhea; Diet Therapy; Dietary Proteins; Female; Fluorouracil; | 1971 |
The value of fluorinated pyrimidines in advanced malignancy.
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Female; Floxuridine; Fluorouracil; Humans; Leu | 1968 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
Proceedings: Islets of Langerhans.
Topics: Adenoma, Islet Cell; Diarrhea; Fluorouracil; Follow-Up Studies; Gastrectomy; Gastrins; Glucagon; Hum | 1972 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
Cytotoxic perfusion of the liver via the umbilical vein for liver metastases in carcinoma of the colon.
Topics: Aged; Blood Sedimentation; Cholestasis; Colonic Neoplasms; Diarrhea; Fluorouracil; Humans; Leukocyte | 1973 |
[Preoperative treatment of the carcinoma of the urinary bladder (author's transl)].
Topics: Bone Marrow; Cystitis; Diarrhea; Fluorouracil; Humans; Precancerous Conditions; Preoperative Care; R | 1974 |
[Comparative evaluation of the efficacy of fluorofur (Ftorafur) and 5-fluorouracil (5-ftouracil) in the treatment of breast cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Diarrhea; Drug Evaluation; Female; Fluorouracil; Furans; Hu | 1974 |
Toxicity studies of fluorouracil used with adrenalectomy in breast cancer.
Topics: Adrenalectomy; Adult; Aged; Alopecia; Ataxia; Blood Platelet Disorders; Breast Neoplasms; Diarrhea; | 1972 |
5-fluorouracil intravenous infusion for 48 hours, repeated every two weeks.
Topics: Adult; Aged; Breast Neoplasms; Diarrhea; Evaluation Studies as Topic; Female; Fluorouracil; Gastroin | 1972 |
Experience with ftorafur treatment in breast cancer.
Topics: Breast Neoplasms; Diarrhea; Female; Fluorouracil; Furans; Humans; Injections, Intravenous; Leukopeni | 1972 |
The effect of 5-fluorouracil on small bowel mucosa.
Topics: Adult; Aged; Biopsy; Diarrhea; Duodenum; Female; Fluorouracil; Humans; Intestinal Mucosa; Intestine, | 1971 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |